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SCIENTIFIC OPINION 
Scientific Opinion on VTEC-seropathotype and scientific criteria regarding 
pathogenicity assessment
1
 
EFSA Panel on Biological Hazards (BIOHAZ)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
During 2007-2010, 13 545 confirmed human VTEC infections and 777 haemolytic uraemic syndrome (HUS) 
cases were reported in the EU; isolates from 85 % of cases were not fully serotyped and therefore could not be 
classified using the Karmali seropathotype concept. Seropathotype group D covered 5 % of isolates from fully 
serotyped cases; 14 cases (0.7 %) belonged to seropathotype group E, defined by Karmali et al. (2003) as non-
human only. Isolates from around 27 % of cases could not be assigned. There were no HUS cases reported for 
the serotypes in groups D and E but 17 HUS cases could not be assigned. The health outcome was reported for 
only a fraction of confirmed cases. About 64 % of patients presented with only diarrhoea; VTEC infection 
resulted in HUS in around 10 % of cases. The new ISO/TS 13136:2012 standard improves the detection of 
VTEC in food. An alternative concept based on the detection of verocytotoxins alone or genes encoding such 
verocytotoxins does not provide a sound scientific basis on which to assess risk to the consumer because there is 
no single or combination of marker(s) that fully define a „pathogenic‟ VTEC. Strains positive for verocytotoxin 2 
gene (vtx2)- and eae (intimin production)- or [aaiC (secreted protein of EAEC) plus aggR (plasmid-encoded 
regulator)] genes are associated with higher risk of more severe illness than other virulence gene combinations. 
The 2011 O104:H4 outbreak demonstrated the difficulty of predicting the emergence of „new‟ pathogenic VTEC 
types by screening only for the eae gene or by focusing on a restricted panel of serogroups. A molecular 
approach utilising genes encoding virulence characteristics additional to the presence of vtx genes has been 
proposed.  
© European Food Safety Authority, 2013. 
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SUMMARY 
Following a request from the Austrian Federal Ministry of Health, the Panel on Biological Hazards 
(BIOHAZ) was asked by the European Food Safety Authority to deliver a scientific Opinion on 
VTEC-seropathotype and scientific criteria regarding pathogenicity assessment. Specifically, EFSA 
was asked to review the „seropathotype‟ concept of Karmali and colleagues (2003) – the limitation to 
“relevant” serotypes O157, O26, O103, O111, O145, O121, O91, O104, O113 and assess whether the 
pathogenicity can be excluded for defined VTEC serotypes, to justify the statement: „seropathotypes D 
and E are not HUS-associated and are uncommon in man or only found in non-human sources’ and to 
assess an alternative concept based on detection of verocytotoxins or genes encoding for 
verocytotoxins in isolates. EFSA was also asked to assess the contribution by VTEC to diarrhoeal 
cases and to more severe outcomes in the EU, based on hazard identification and characterisation, and 
under-reporting in EU and the public health risk associated with the contamination of ready-to-eat 
(RTE) foods with VTEC, considering either the seropathotype concept or the detection of 
verocytotoxins or genes encoding the production of such toxins in isolates. 
The 2003 Karmali seropathotype model classifies verocytotoxin-producing Escherichia coli (VTEC) 
into seropathotypes. Serotypes responsible for haemorrhagic colitis (HC) and haemolytic uraemic 
syndrome (HUS), O157:H7 and O157:NM, were assigned to seropathotype A. Seropathotype B strains 
have been associated with outbreaks and HUS, but less commonly than those of seropathotype A and 
included O26:H11, O103:H2, O111:NM, O121:H19 and O145:NM. Seropathotype C serotypes were 
associated with sporadic HUS cases but not epidemics. The serotypes in group C were O91:H21, 
O104:H21, O113:H21, O5:NM, O121:NM and O165:H25. Seropathotype D serotypes have been 
associated with diarrhoea but not with outbreaks or HUS cases; seropathotype E serotypes comprised 
VTEC serotypes that had never been associated with human disease and had been isolated only from 
animals. Seropathotypes D and E included multiple serotypes, 12 serotypes for seropathotype D and 
14 for seropathotype E. 
The approach adopted entailed a summary of the types of pathogenic E. coli which have been 
associated with cases of human disease, and the putative virulence factors therein; the use of data from 
the European Surveillance System (TESSy data) as provided by the ECDC (European Centre for 
Disease Prevention and Control) and data available in the EU Summary Report on Trends and Sources 
of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2011 for assessing the current situation 
regarding human infections with VTEC in the EU; a review of methods for the isolation and 
identification of VTEC, including detection of virulence factors and characterisation and typing of 
VTEC strains and virulence genes therein; hazard characterisation, including illnesses associated with 
VTEC and identification of predictive factors for VTEC that may contribute to human disease; 
evaluation of the seropathotype concept using the Karmali approach, a modification of the Karmali 
approach based on the health outcome of reported confirmed human VTEC cases in the EU during 
2007-2010, and a molecular approach based on the identification of known or putative colonization 
genes and additional toxins; and finally exposure assessment, including EU monitoring data on 
occurrence of VTEC in RTE food. 
The BIOHAZ Panel concluded that the Karmali seropathotype classification does not define 
pathogenic VTEC nor does it provide an exhaustive list of pathogenic serotypes. Instead it classifies 
VTEC based on their reported frequency in human disease, their known association with outbreaks 
and their severity of the outcome including HUS and HC. During 2007-2010, 13 545 confirmed 
human VTEC infections were reported in Europe; isolates from 85 % of these cases were not fully 
serotyped and could therefore not be classified using the seropathotype concept. The D group covered 
5 % of human cases that were fully serotyped. Fourteen cases (0.7 %) were assigned to seropathotype 
group E, defined by Karmali et al. (2003) as non-human only. Around 27 % of the cases could not be 
assigned to a seropathotype group as these were not listed in the 2003 Karmali paper. There were no 
HUS cases reported for the serotypes included in groups D and E, but there were 17 HUS cases 
reported that could not be assigned to a group. The health outcome has been reported for only a 
fraction (for diarrhoea: 53 % of cases; and for HUS: 59 % of cases) of the reported confirmed VTEC 
VTEC-seropathotype and scientific criteria regarding pathogenicity assessment  
 
EFSA Journal 2013;11(4):3138 3 
cases in the EU between 2007 and 2010. Most patients (ca. 64 %) presented with only diarrhoea. 
VTEC infection resulted in HUS in around 10 % of cases. Thus pathogenicity can neither be excluded 
nor confirmed for a given VTEC serogroup or serotype based on the seropathotype concept or analysis 
of the public health surveillance data. 
Detection of VTEC is highly dependent on the methods applied to clinical specimens and these vary 
between different Member States (MSs). The degree of under-estimation (including under-
ascertainment and under-reporting) of VTEC O157 infections has been estimated in seven EU MSs. 
Disease-multipliers differ widely between EU countries, ranging from 13 to 87. The 2011 O104:H4 
German outbreak has clearly demonstrated the difficulty of predicting the emergence of „new‟ 
pathogenic VTEC types by only looking at the presence of the eae gene or by focusing on a restricted 
panel of serogroups. The new ISO/TS 13136:2012 standard improves the strategy for detecting VTEC 
in the food by enlarging the scope of the previous standard to all VTEC. 
The BIOHAZ Panel further concluded that it is not possible to fully define human pathogenic VTEC 
or to identify factors for VTEC that absolutely predict the potential to cause human disease. The 
detection of verocytotoxins alone, or of genes encoding for such verocytotoxins is not a sound 
scientific basis for assessing the disease risk to the consumer. There is no single or combination of 
marker(s) that defines a „pathogenic‟ VTEC. Strains positive for verocytotoxin 2 gene (vtx2)- and eae 
(intimin production)- or [aaiC (secreted protein of EAEC) plus aggR (plasmid-encoded regulator)] 
genes are associated with a higher risk of more severe illness than other virulence gene combinations. 
Other virulence gene combinations and/or serotypes may also be associated with severe disease in 
humans, including HUS.  
A modification of the Karmali seropathotype model was proposed based on the health outcome of 
reported confirmed human VTEC cases in the EU during 2007-2010. In cases when full serotyping has 
been undertaken all serotypes associated with severe disease (HUS) could be categorised as 
seropathotype group „haemolytic uraemic syndrome (HUS)-associated serotype(s)‟ or HAS. By this 
modified approach, in cases when full serotyping has been undertaken all serotypes associated with 
severe disease are automatically categorised in the HAS group. 
A molecular approach, utilising genes encoding virulence characteristics additional to the presence of 
vtx genes, is proposed. This molecular approach must be regarded as provisional because screening 
VTEC for the presence of eae, aaiC or aggR genes is not routinely undertaken. This scheme has the 
advantage of overcoming problems associated with the lack of flagella „H‟ antigen typing. The 
performance of this proposed approach needs to be verified with well-characterised isolates from cases 
of human infection and from food-producing animals and foods. 
VTEC has been recovered from a range of different animal species and food categories. The most 
widely used analytical method only aims at detecting VTEC O157, whereas fewer investigations have 
been conducted with analytical methods aiming at detecting all or selected serotypes of VTEC.  
On the basis of the proposed provisional molecular classification scheme, any RTE product 
contaminated with an isolate of one of the VTEC serogroups of group I (O157, O26, O103, O145, 
O111, O104) in combination with vtx and [1] eae or [2] aaiC and aggR genes should be considered as 
presenting a potentially high risk for diarrhoea and HUS. For any other serogroups in combination 
with the same genes, the potential risk is regarded as high for diarrhoea, but currently unknown for 
HUS. In the absence of these genes, current available data do not allow any inference regarding 
potential risks. 
The BIOHAZ Panel made a series of recommendations relating to public health investigation of 
VTEC infection, verification and periodic revision of the proposed molecular approach for the 
categorisation of VTEC strains. The inclusion of aaiC and aggR genes in this approach is due to the 
2011 outbreak, which was caused by a highly virulent strain. This was an exceptional event and future 
surveillance will provide data that may be used to review the inclusion of these virulence factors. Thus 
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screening VTEC for the presence of aaiC and aggR genes should be performed on isolates from 
human, food and animal sources, to address this question. Finally, international harmonisation of 
nomenclature of VTEC and its virulence factors was suggested.  
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BACKGROUND AS PROVIDED BY THE AUSTRIAN FEDERAL MINISTRY OF HEALTH  
Verocytotoxin-producing Escherichia (E.) coli (VTEC) are an important cause of cases of acute 
gastroenteritis in Austria and around the world. These bacteria are strongly associated with severe 
forms of infection including haemorrhagic colitis (bloody diarrhoea, haemorrhagic colitis (HC)) and 
haemolytic uraemic syndrome (HUS). 
Previously routine diagnostics were lacking in the detection of the major pathogenic factor: the 
production of verocytotoxins. When serotype O157 has been identified as the major cause of HUS in 
children, as a consequence test systems (sorbitol agar) were implemented in routine clinical 
microbiology to identify VTEC O157 in stool samples. Following the availability of test kits for 
verocytotoxins in food, outbreaks and sporadic cases of VTEC infections have been found to be 
associated with a growing number of different VTEC serotypes. 
“Simple methods for identification of VTEC O157 strains and improved techniques for O26, O103, 
O111 and O145 may have led to a degree of overestimation of the prevalence and importance of these 
serotypes”.4 
“The concept of seropathotype classifies VTEC into groups based on the incidence of serotypes in 
human disease, associations with outbreaks versus sporadic infections, their capacity to cause HUS or 
HC, and the presence of virulence markers”.4 
Austrian experts think that this concept is not adequate to support food safety considerations: 
 Outbreaks versus sporadic infections: the dimension of a food-borne outbreak and the number 
of infected persons depends on the kind of food involved (ready-to-eat, RTE, food supporting 
growth, distribution …) and not only on the pathogenicity of the microorganism. 
 The capacity to cause HUS or HC: HUS or HC are severe complications, but in connection 
with VTEC not the primary food safety criterion. Bacteria that cause solely diarrhoea already 
constitute a food safety concern. 
 Serotypes are phenotypes, useful for epidemiological purposes, whereas pathogenicity of 
VTEC is characterised by the ability to produce verocytotoxins and other virulence factors. 
 The incidence of serotypes in human disease is questionable: massive underreporting - due to 
routine use of test systems designed to find only VTEC O157 and generally scarce testing in 
clinical microbiology - leads to an invalid database. Therefore plausible incidences of 
serotypes in human disease cannot be calculated on the basis of historical data only, without 
considering underreporting. 
Data from Austrian and German reference laboratories as well as results reported by EFSA and ECDC 
(Annex) demonstrate an unacceptable high level (10 – 50 %) of VTEC “others” than the serotypes 
mentioned in the “seropathotype concept” causing diarrhoea, severe illness and HUS. 
In December 2011 Austrian experts were involved in intensive discussions. VTEC O27:H30 VT2 pos., 
culture-positive, were detected in RTE food and an identical serotype, VT2 pos. strain occurred in a 
sick child in 2010. The pathogenicity of the bacteria was doubted, based on a seropathotype concept
5
:  
“A restricted range of serotypes (i.e. O157, followed by O26, O103, O91, O145 and O111) are 
associated with public health risks, however isolates of these serotypes are not necessarily pathogenic 
when recovered from food or live animals”. 
                                                     
4 EFSA Journal 2011;9(11):2424. 
5 EFSA Journal 2007;579:1-31. 
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At the time of the outbreak caused by VTEC in Germany, VTEC O104 was not covered by the 
“seropathotype concept”5. Fenugreek seeds tested positive for VTEC O104 before May 2011 would 
not have been considered a “public health risk” on the basis of the relevant EFSA Opinion. 
Nevertheless this concept and a pathogenicity concept based on detection of verocytotoxins were 
discussed equally by EFSA
4
. 
Based on a seropathotype concept only a few serotypes are considered in a recent discussion paper 
distributed by the European Commission and in the relevant method (amending Regulation (EC) No. 
2073/2005
6
 on microbiological criteria for foodstuffs as regards of microbiological criteria for 
sprouted seeds): 
1.29 Sprouted 
seeds (ready to 
eat) 
Shiga toxin producing E. coli 
(STEC) O157, O26, O111, 
O103, O145 and O104 
5 0 Absence in 
25 grams 
CEN ISO 
13136
7
 
Products placed on 
the market during 
their shelf-life 
 
Most likely the limitation to a small number of serotypes will be the basis for future problems in 
the EU when another serotype will be identified as the cause of a food-borne outbreak. Food 
business operators might feel encouraged to place RTE food (sprouted seeds and other) on the market, 
contaminated with VTEC “other than the relevant serotypes”. 
The Austrian Federal Ministry of Health cannot accept an approach resulting in the next outbreak 
(which will be only a matter of time given the intensified and improved diagnostic methods in the 
human health area) being the cause for simply adding another serotype to the list, while waiting for the 
next outbreak.
8
 
Furthermore, if the method (CEN ISO 13136 – an ISS paper/EU ref. laboratory in Rome + O104 
amendment) will be implemented in EU Member States laboratories, other VTEC than the six types 
mentioned (European Commission) will not be isolated from food samples any longer. According 
to this method isolation of VTEC will only be performed if the PCR for the six types is positive, 
causing severe consequences for outbreak investigations and monitoring
7
. 
                                                     
6
  Commission Regulation (EC) No 2073/2005 of 15 November 2005 on microbiological criteria for foodstuffs. OJ L 338, 
22.12.2005, p. 1-26. The amendment was introduced by Commission Regulation (EU) No 209/2013 of 11 March 2013 
amending Regulation (EC) No 2073/2005 as regards microbiological criteria for sprouts and sampling rules for poultry 
carcases and fresh poultry meat. (OJ L 68, 12.3.2013, p. 19-23). 
7
  ISO/PRF TS 13136. Microbiology of food and animal feeding stuffs – Real-time polymerase chain reaction (PCR)-based 
method for the detection of food-borne pathogens -- Horizontal method for the detection of Shiga toxin-producing 
Escherichia coli (STEC) belonging to O157, O111, O26, O103 and O145 serogroups. International Organization for 
Standardization. This standard has been amended since receipt of the request on 4 May 2012 and has been published as 
ISO/TS 13136 “Microbiology of food and animal feed – Real-time polymerase chain reaction (PCR)-based method for 
the detection of food-borne pathogens – Horizontal method for the detection of Shiga toxin-producing Escherichia coli 
(STEC) and the determination of O157, O111, O26, O103 and O145 serogroups”. 
8  Recital 12 of Regulation (EU) 209/2013 of 11 March 2013 clarifies the basis for the decision to limit to six serogroups in 
the proposal which received the support of the Member States. Recital 12 of the Regulation states that “Certain STEC 
serogroups (namely O157, O26, O103, O111, O145 and O104:H4) are recognized to be those causing the most of the 
Haemolytic Uremic Syndrome (HUS) cases occurring in the EU. Furthermore serotype O104:H4 caused the outbreak in 
May 2011 in the Union. Therefore microbiological criteria should be considered for these six serogroups. It cannot be 
excluded that other STEC serogroups may be pathogenic to humans as well. In fact, such STEC may cause less severe 
forms of disease such as diarrhoea and or bloody diarrhoea or may also cause HUS and therefore represent a hazard for 
the consumer's health.” 
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TERMS OF REFERENCE AS PROVIDED BY THE AUSTRIAN FEDERAL MINISTRY OF HEALTH 
The Austrian Federal Ministry of Health requests that EFSA provides a scientific opinion on: 
 a discussion on the scientific evidence of the following concepts, based on valid data and 
recent literature: 
- the “seropathotype concept” – the limitation to “relevant” serotypes O157, O26, O103, 
O111, O145, O121, O91, O104, O113
4
. The database and literature justifying the 
statement: “seropathotypes D and E are not HUS-associated and are uncommon in man 
or only found in non-human sources”4 
- versus a concept based on detection of verocytotoxins (relevant pathogenicity factor) in 
isolates; 
- and the consequences for food safety: is it acceptable to concentrate on most severe 
complications and VTEC causing the predominant number of these complications, 
ignoring VTEC causing HUS or HC in fewer cases and neglect considering the clinical 
picture of diarrhea? 
 including a statement concerning the assessment of pathogenicity of all types of VTEC found 
in RTE food. Can pathogenicity be excluded for defined serotypes? Are VTEC (including vtx-
pos., eae-neg., all serotypes) on RTE food generally a risk for consumers? If this is confirmed: 
is a seropathotype concept
4
 sufficient for food safety issues? 
Revision of the Terms of Reference 
Following discussion with the Austrian Federal Ministry of Health services, the Terms of Reference of 
the mandate have been revised and confirmed by the Austrian Federal Ministry of Health in an e-mail 
dated 23/11/2012.  
The Austrian Federal Ministry of Health requests that, based on valid data and recent literature, EFSA 
provides a Scientific Opinion on: 
1. The „seropathotype‟ concept – the limitation to “relevant” serotypes O157, O26, O103, O111, 
O145, O121, O91, O104, O113
4
 i.e., can pathogenicity be excluded for defined VTEC 
serotypes?; 
2. justification of the statement: „seropathotypes D and E are not HUS-associated and are 
uncommon in man or only found in non-human sources’4; 
3. an alternative concept based on detection of verocytotoxins, or genes encoding for 
verocytotoxins, in isolates; 
4. the contribution by VTEC to diarrhoeal cases and to more severe outcomes in the EU, based 
on hazard identification and characterisation, and under-reporting in EU; 
5. the public health risk associated with the contamination of RTE foods with VTEC, 
considering either the seropathotype concept or the detection of verocytotoxins or genes 
encoding the production of such toxins in isolates. 
VTEC-seropathotype and scientific criteria regarding pathogenicity assessment  
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APPROACH TAKEN 
 Hazard identification, including a summary of the types of Escherichia coli pathogenic for 
humans and the putative virulence factors therein amongst serotypes from cases of human 
infection; the use of TESSy data (ECDC) for assessing the current situation regarding human 
infections with verocytotoxin-producing E. coli (VTEC) in the EU; 
 Review of methods for the isolation and identification of VTEC, including detection of 
virulence factors and characterisation and typing of VTEC strains and virulence genes therein; 
 Hazard characterisation, including illnesses associated with VTEC and identification of 
predictive factors for VTEC that may contribute to human disease; 
 Evaluation of the seropathotype concept using the Karmali approach, a modification of the 
Karmali approach based on the health outcome of reported confirmed VTEC cases in the EU 
during 2007-2010, and a new approach based on serogroup information and utilising 
molecular virulence characteristics additional to the presence of vtx genes; 
 Exposure assessment, including EU monitoring data on occurrence of VTEC in ready-to-eat 
(RTE) food. 
VTEC-seropathotype and scientific criteria regarding pathogenicity assessment  
 
EFSA Journal 2013;11(4):3138 11 
ASSESSMENT 
1. Introduction 
Illnesses associated with verocytotoxin-producing Escherichia coli (VTEC
9
) range from mild to 
bloody diarrhoea through to haemorrhagic colitis (HC), haemolytic uraemic syndrome (HUS), and 
thrombocytopenia. Such symptoms are common to VTEC infections worldwide. 
To assist in assessing the clinical and public health risks associated with different VTEC strains an 
empirical VTEC seropathotype classification, based on their reported frequency in human disease, 
their known association with outbreaks and the severity of the outcome including HUS and HC was 
proposed by Karmali and colleagues in 2003 (Karmali et al., 2003). This classification system, 
presented in Table 1, utilises a gradient ranging from seropathotype A – high risk – to seropathotypes 
D and E – minimal risk. This approach has been of considerable value in defining pathogenic VTEC 
serotypes of importance in cases of human infection (Caprioli et al., 1997; Coombes et al., 2011; 
EFSA, 2007) and also for VTEC isolates from ruminants (for review, see Gyles (2007)). 
Table 1:  Classification of VTEC serotypes into seropathotypes (Karmali et al., 2003) 
Seropathotype Relative 
incidence
(a)
 
Frequency of 
involvement in 
outbreaks 
Association 
with severe 
disease
(b)
 
Serotypes 
A High Common Yes O157:H7, O157:NM
(c)
 
B Moderate Uncommon Yes O26:H11, O103:H2, O111:NM
(c)
, 
O121:H19, O145:NM
(c)
 
C Low Rare Yes O91:H21, O104:H21, O113:H21, 
other
(d)
 
D Low Rare No Multiple
(e)
 
E Non-human only NA
(f)
 NA
(f)
 Multiple
(g)
 
(a): Reported frequency in human disease. 
(b): Haemolytic uraemic syndrome (HUS) or haemorrhagic colitis (HC). 
(c): NM = non-motile. 
(d): Includes O5:NM, O121:NM, O165:H25. 
(e): Includes O7:H4, O69:H11, O103:H25, O113:H4, O117:H7, O119:H25, O132:NM, O146:H21, O171:H2, O172:NM, 
O174:H8, Orough:H2. 
(f): NA = not applicable. 
(g): Includes O6:H34, O8:H19, O39:H49, O46:H38, O76:H7, O84:NM, O88:H25, O98:H25, O113:NM, O136:H12, 
O136:NM, O153:H31, O156:NM, O163:NM. 
 
The most common serotype worldwide associated with both outbreaks and sporadic cases has 
undoubtedly been E. coli O157:H7. Recent developments, and in particular the increasing number of 
reports of non-O157 VTEC outbreaks and cases, and the major outbreak of the serotype O104:H4, 
first identified in northern Germany in May 2011 (see section 2.2.2.1.), has focused attention on the 
applicability or otherwise of the Karmali seropathotype concept. 
In response to a request from the Austrian Federal Ministry of Health, this Opinion presents an 
assessment of the validity of the Karmali seropathotype concept in relation to food safety, for the most 
part based on the use of data from the European Surveillance System (TESSy data) as provided by the 
ECDC
10
 (European Centre for Disease Prevention and Control) for assessing human infections with 
VTEC in the EU from 2007 to 2010. TESSy data for 2011 were not available for use in this Opinion. 
                                                     
9  Verocytotoxin-producing Escherichia coli is also known as verotoxigenic E. coli, verocytotoxigenic E. coli, verotoxin 
producing E. coli and Shiga toxin-producing Escherichia coli (STEC). 
10  ECDC, TESSy Release on 01/11/2012. ECDC has no responsibility for the results and conclusions when disseminating 
the results of the work employing TESSy data supplied by ECDC. 
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Reference to human VTEC data for 2011 was therefore based on the information available in the EU 
Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 
2011 (EFSA and ECDC, 2013). 
2. Hazard identification 
2.1. Pathogenic Escherichia coli, including VTEC 
Escherichia coli strains, which form part of the flora of the intestine, can cause enteric/diarrhoegenic 
or extra-intestinal (ExPEC) infections in humans. ExPEC infections are primarily urinary tract (caused 
by uropathogenic E. coli – UPEC) and sepsis/meningitis (particularly neonatal meningitis). Only the 
enteric E. coli will be covered in this Opinion. 
Traditionally enteric E. coli that cause disease have been divided into six pathotypes (for review, see 
Clements et al. (2012)): (i) verocytotoxigenic E. coli (VTEC), which is synonymous with the term 
„STEC‟ (Shiga toxin-producing E. coli), and also includes the enterohaemorrhagic E. coli (EHEC) 
category; (ii) enteropathogenic E. coli (EPEC); (iii) enterotoxigenic E. coli (ETEC); (iv) 
enteroaggregative E. coli (EAEC); (v) enteroinvasive E. coli (EIEC) and (vi) diffuse adherent E. coli 
(DAEC) (Table 2). Of these, isolates belonging to VTEC pathotypes and one EAEC pathotype (EAEC 
O104:H4) are of particular importance in the context of food safety. 
VTEC are characterised by the production of verocytoxins (Vtx) (because of their cytotoxicity to Vero 
cells), and are also known as Shiga toxins (Stx), because of their similarity with the toxin produced by 
Shigella dysenteriae.  
EHEC are a subset of VTEC, that in addition to the vtx-encoding genes, usually carry the attaching 
and effacing gene (eae, intimin-coding) and thereby have the ability to cause attaching and effacing 
(A/E) lesions in infected cells. The ability to cause A/E lesion is mediated by the locus of enterocyte 
effacement (LEE) pathogenicity island (PAI). EHEC strains are typically isolated from cases of severe 
disease. 
EPEC carry the eae gene but do not produce Vtx. They are subdivided into typical and atypical strains 
based on the presence (or absence) of the EPEC Adherence Factor (EAF) plasmid. Typical EPEC 
carry this plasmid, which includes the bundle forming pili (bfp) operon encoding the pili required for 
localised adherence on epithelial cells. ETEC are associated with traveller‟s diarrhoea. ETEC adhere 
to the epithelium of the small intestine using one or more colonisation factor antigens (CFA), and 
produce heat-stable (ST) and/or heat-labile (LT) enterotoxins. 
EAEC are characterised by their ability to aggregatively adhere to tissue culture cells in a distinct 
„stacked and brick-like‟ manner which is mediated by aggregative adherence fimbriae (AAF). They 
usually produce an enteroaggregative heat-stable toxin (EAST1) encoded by the plasmid-borne astA 
genes. 
EIEC invade gut epithelial cells in a process mediated by invasion plasmid antigens (Ipa) encoded in 
the ipa operon that is carried on a 220 kilobase (kb) virulence plasmid. Illness is characterised by the 
appearance of blood and mucus in the faeces. 
DAEC are comprised of a heterogenous group of E. coli with variable virulence. They are identified 
by their adherence to HEp-2 cells in a diffuse pattern. 
Different E. coli serogroups or serotypes may belong to more than one pathotype group. For example 
O26 may be an EPEC or a VTEC and the major 2011 outbreak E. coli O104:H4 strain had 
characteristics of both the VTEC and EAEC categories. 
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Table 2:  Summary of virulence factors expressed by the human enteric E. coli pathotypes (adapted from Clements et al. (2012)) 
Pathotype Adhesin Toxin T3SS(a) SPATE(b) Symptomology/Illness/Dise
ase 
VTEC 
 
Aggregative adherence fimbriae (AAF) 
IrgA homologue adhesin (Iha) 
STEC autoagglutinating adhesion (Saa) 
Verocytotoxin (Vtx)(c) - 
 
Pic 
Pet 
Mild to severe bloody 
diarrhoea through to HC, 
HUS, and thrombocytopenia 
 Including 
EHEC(d) 
Intimin 
Paa 
Toxin B (ToxB) 
E. coli factor for adherence (Efa)-1 
LPF 
Saa 
E. coli immunoglobulin-binding protein 
(EibG) 
EHEC autotransporter encoding gene A 
(EhaA) 
Outer membrane protein A (OmpA) 
Iha 
Vtx(c) LEE 
encoded 
EspP As above 
DAEC  Afimbrial (Afa) or fimbrial (Dr) adhesins - - Sat Acute diarrhoea (<5 years 
old) 
EPEC Intimin 
Bundle forming pili (BFP) 
Paa 
LPF 
Iha 
EhaA 
- LEE 
encoded 
EspC Infant diarrhoea 
ETEC Colonization factors (CF) 
Porcine A/E associated adhesin (Paa) 
Heat-labile enterotoxin (LT) 
Heat-stable enterotoxin (ST) 
Cytolysin A (ClyA) 
- ETEC autotransporter A (EatA) Acute watery diarrhoea (<5 
years old) 
Travellers‟ diarrhoea 
EAEC AAF (I, II, III, Hda) 
Toxigenic invasion loci A (Tia) 
EAEC heat-stable enterotoxin 
1 (EAST1) 
Shigella enterotoxin (ShET)1 
Haemolysin E (HlyE) 
+/-(e) Plasmid-encoded toxin (Pet) 
Protein involved in intestinal colonization (Pic) 
Secreted autotransporter toxin (Sat)  
Shigella IgA-like protease homology (SigA) 
E. coli-secreted protein (Esp)P 
Travellers‟ diarrhoea 
Infant diarrhoea 
EIEC 
(Shigella) 
- ShET1/2 
 
pINV 
encoded 
Shigella extracellular protein (Sep)A 
SigA 
Shigellosis 
(a): Type three secretion system. 
(b): SPATE = serine protease autotransporter of Enterobacteriaceae. 
(c): Verocytotoxin (Vtx) is also known as Shiga toxin (Stx). 
(d): EHEC may also be subgroup of EAEC.  
(e): One potentially functional but as yet uncharacterised T3SS (ETT2) was found in the genome sequence of EAEC O42 (and remnants of a second). 
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Infections with E. coli occur through consumption of contaminated food products (e.g. undercooked 
meat, or fresh produce such as salad leaves), drinking water contaminated with animal or human 
waste, contact with animals, the environment, or through direct person-to-person or animal-to-person 
spread. In the developing world ETEC, EPEC and EAEC appear to be major causes of infantile 
diarrhoea with potentially fatal consequences when untreated. In contrast, in the developed world such 
infections are mild and self-limiting and VTEC are the main E. coli pathogens associated with food-
poisoning outbreaks (Pennington, 2000; Whittaker et al., 2009; Willshaw et al., 2001a), with 
institutional outbreaks involving person-to-person transmission (Devakumar et al., 2013), and with 
outbreaks associated with open farms (Underwood et al., 2013). 
Various factors and toxins contribute to the virulence of VTEC. Verocytotoxin type 2 (Vtx2) is more 
often associated with cases of human disease, and those strains producing this toxin are more 
frequently associated with severe illness. Strains that produce Vtx2 and more specifically Vtx2 
subtype c (Vtx2c), have been suggested to be more likely to cause HUS than those that produce Vtx1 
alone (Bosilevac and Koohmaraie, 2011; Friedrich et al., 2002). Except for the intimin protein 
encoded by the LEE PAI and the AAF encoded by the EAEC plasmid (for review see Kaper et al. 
(2004)), to our knowledge there are no other adherence factors that have been consistently associated 
with the virulence of EHEC and VTEC respectively (Nataro and Kaper, 1998; Nataro et al., 1998). 
2.2. EU monitoring data on VTEC in humans 
2.2.1. Sporadic human cases 
The case classification of a confirmed case of STEC/VTEC is defined in Decision (EC) No 
2012/506/EU
11
 as „any person meeting the clinical criteria (for STEC/VTEC diarrhoea: any person 
with at least the following two: diarrhoea or abdominal pain; and for HUS: any person with acute 
renal failure and at least one of the following two: microangiopatic haemolytic anaemia or 
thrombocytopenia) and at least one of the four laboratory criteria: (1) isolation of an Escherichia coli 
strain that produces Shigatoxin (Stx) or harbours stx1 or stx2 gene(s); (2) isolation of non-sorbitol-
fermenting (NSF) Escherichia coli O157 (without Stx or stx gene testing); (3) direct detection of stx1 
or stx2 gene(s) nucleic acid (without strain isolation); (4) direct detection of free Stx in faeces 
(without strain isolation)’. In the Annex of this Decision, it is explained that a confirmed case means a 
case classified as confirmed for reporting purposes. Confirmed cases are laboratory-confirmed and 
may or may not fulfil the clinical criteria as described in the case definition. 
Detection of VTEC is highly dependent on the methods applied to clinical specimens. Such methods 
vary markedly between different EU Member States (MSs) and, VTEC O157 is more readily detected 
than non-O157 VTEC. Thus data relating to non-O157 VTEC probably represent a substantive under-
estimation of its true incidence, both for the EU as a whole and particularly for those MSs where 
molecular detection methods are not as yet fully utilised. 
A total of 4 000 confirmed human VTEC cases were reported from 25 EU MSs in 2010 through 
TESSy; the EU notification rate being 0.83 cases per 100 000 population (EFSA and ECDC, 2012). In 
2011, due to the O104:H4 outbreak (see section 2.2.2.1.), a large increase was observed and 9 485 
confirmed VTEC cases were reported from 23 MSs (EFSA and ECDC, 2013).  
Full serotype data on VTEC isolates were reported for 1 288 and 686 (32 % and 7.2 %) of confirmed 
infections whereas data on the „O‟ (lipopolysaccharide) antigen were reported for 68 % and 55.9 % of 
such infections in 2010 and 2011 respectively. In 2010 almost half of the reported „O‟ serogroups 
were O157 (41.1 %) (Table 3). In 2011, the most commonly reported „O‟ serogroups were O157 
(41.2 %) followed by O104 (20.1 %). The latter was due to the O104:H4 outbreak. Only two cases of 
serogroup O104 were reported in 2010. 
                                                     
11  Commission Implementing Decision (EC) No 2012/506/EU of 8 August 2012 amending Decision 2002/253/EC laying 
down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of 
the European Parliament and of the Council. OJ L 262, 27.09.2012, p. 1-57. 
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Table 3:  Reported confirmed VTEC cases in humans in the EU(a) by serogroup, 2007-2011, EFSA and ECDC (2010, 2011, 2012, 2013) 
2011  2010  2009  2008  2007 
Serogroup n %
(d)
  Serogroup n %
(d)
  Serogroup n %
(d)
  Serogroup n %
(d)
  Serogroup n %
(d)
 
Total typed 4 499 85.0  Total typed 2 413 66.1  Total typed 2 553 71.5  Total typed 2 340 74.1  Total typed 2 062 71.0 
O157 2 185 48.5  O157 1 501 62.2  O157 1 848 72.4  O157 1673 71.5  O157 1 571 76.2 
O104 1 064 23.6  O26 257 10.7  O26 192 7.5  O26 166 7.1  O26 136 6.6 
O26 287 6.4  O103 90 3.7  O103 82 3.2  O103 88 3.8  O103 77 3.7 
O103 141 3.1  O145 61 2.5  O91 48 1.9  O145 49 2.1  O91 43 2.1 
O91 116 2.6  O91 57 2.4  O145 47 1.8  O91 50 2.1  O145 31 1.5 
O145 76 1.7  O63 42 1.7  O146 31 1.2  O111 43 1.8  O111 23 1.1 
O128 53 1.2  O111 41 1.7  O128 26 1.0  O128 28 1.2  O128 21 1.0 
O111 52 1.2  O128 29 1.2  O111 25 1.0  O146 25 1.1  O113 16 0.8 
O146 48 1.1  O146 28 1.2  O113 22 0.9  O117 20 0.9  O146 14 0.7 
Other
(b)
 484 10.7  Other
b
 307 12.7  Other
b
 232 9.1  Other
b
 198 8.5  Other
b
 130 6.3 
NT
(c)
 795 15.0  NT
c
 1 238 33.9  NT
c
 1 020 28.5  NT
c
 819 25.9  NT
c
 842 29.0 
Grand total 5 301   Grand total 3 651   Grand total 3 573   Grand total 3 159   Grand total 2 904  
(a): Austria, Belgium, Czech Republic (only 2011), Cyprus (only 2008), Denmark, Estonia, Finland (not 2011), France, Germany, Greece (only 2011 and 2010), Hungary (not 2008), Ireland, 
Italy, Luxembourg, Malta, Poland (not 2009), Romania (only 2011, 2010 and 2008), Slovakia, Slovenia, Spain, Sweden, the Netherlands and the UK. 
(b): Other is other than top nine. 
(c): NT = untyped/untypeable and cases where „O‟ antigen was reported as unknown. 
(d): The percentage for the serogroups is using the total typed as denominator. 
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The clinical outcome of the confirmed VTEC cases in the EU in 2007-2010 by serotype, based on the 
data as provided by the ECDC
10
, is presented in Appendix A, Table 1. In the period 2007-2010, 13 545 
confirmed VTEC infections were reported to ECDC. For the majority of these cases, the clinical 
outcome was not reported: the case fatality was not reported for 52 % of these cases, hospitalisation 
was not reported for 90 % and HUS status was unknown for 41 %. Data on hospitalisation have only 
been collected for the last two years (2009 and 2010). The clinical manifestation (expressed as bloody 
diarrhoea, diarrhoea or asymptomatic) was not reported for 47 % of cases. 
The virulence characteristics of the reported confirmed VTEC serogroups, in terms of presence of the 
eae gene as well as vtx1 and vtx2 genes, are listed in Table 4. These virulence characteristics were 
reported for isolates from 7 278 (54 %) out of 13 545 cases. Most cases (around 60 %), for which 
information was reported on virulence factors, were eae,vtx2-positive and this was particularly 
common for serogroup O157 (71 % of cases; 3 833 out of 5 412 cases) (Table 4). For VTEC O157, 
eae in combination with both verocytotoxin genes was also common (28 % of cases). Most isolates 
from cases associated with serogroups O26, O103 and O111 were eae- and vtx1-positive. 
Approximately 11 % of serogroups did not carry the eae gene (770 out of 7 278 cases). All but two 
reported cases caused by serogroup O91 – for which information was provided on virulence and 
virulence-associated factors – were eae-negative. The majority of reported cases by O117 and O146 
serogroups were also eae-negative. The 2011 O104 outbreak strain was eae-negative and vtx2-positive 
(EFSA and ECDC, 2013). 
Table 4:  Virulence characteristics of reported confirmed VTEC serogroups from cases of human 
infection from 2007-2010 (based on TESSy data as provided by ECDC) 
Serogroup Total 
Virulence
(a)
 characteristics 
eae,vtx1 eae,vtx2 eae,vtx1,vtx2 vtx1 vtx2 vtx1,vtx2 
O157 5 412 31 3 833 1 530 1 13 4 
O26 309 205 63 30 9 2 0 
O103 176 168 4 2 1 1 0 
O145 108 25 81 1 0 1 0 
O91 69 0 1 1 35 5 27 
O111 67 37 13 13 1 2 1 
O117 64 2 0 1 60 1 0 
O146 62 0 1 1 3 30 27 
O128 61 1 7 5 7 19 22 
O121 49 1 45 1 1 1 0 
O113 35 0 5 0 2 18 10 
O63 29 0 25 4 0 0 0 
O174 23 0 0 0 1 12 10 
O156 21 6 0 0 13 0 2 
O76 21 2 0 0 15 1 3 
O5 18 9 0 1 4 1 3 
O55 14 3 4 0 7 0 0 
O8 11 0 2 1 0 7 1 
O153 11 0 7 0 1 2 1 
O84 10 8 0 0 0 2 0 
O181 10 0 0 0 4 0 6 
Other
(b)
 231 26 51 10 42 80 22 
NT
(c)
 467 88 112 41 88 89 49 
Total 7 278 
612 
(8.4 %) 
4 254 
(58.5 %) 
1 642 
(22.6 %) 
295 
(4.1 %) 
287 
(3.9 %) 
188 
(2.6 %) 
(a): eae = intimin-coding gene; vtx1 = verocytotoxin 1 gene; vtx2 = verocytotoxin 2 gene. 
(b): Includes other serogroups than already listed. This group includes 83 serogroups. 
(c): NT = untyped/untypeable and cases where „O‟ antigen was reported as unknown. 
 
VTEC-seropathotype and scientific criteria regarding pathogenicity assessment  
 
EFSA Journal 2013;11(4):3138 17 
During 2007-2010 the most commonly reported serotype was O157:H7 (774 out of 2 140 fully 
serotyped cases) followed by O157:H- (273) and O103:H2 (131). In 2011 the most commonly 
reported serotype was O104:H4 (118 out of 686 fully serotyped isolates), followed by O157:H- (117) 
and O157:H7 (114) (Table 5). 
Table 5:  VTEC O:H serotypes most commonly reported and confirmed in cases of human 
infection from 2007-2010 (based on TESSy data as provided by ECDC) and in 2011 (based on EFSA 
and ECDC (2013)) 
 2007-2010    2011  
Serotype No. of cases % of cases  Serotype No. of cases % of cases 
O157:H7 774 36.2  O104:H4
(a)
 118 17.2 
O157: H-
(b)
 273 12.8  O157: H- 117 17.1 
O103:H2 131 6.1  O157:H7 114 16.6 
O26:H11 107 5.0  O26:H11 39 5.7 
O117:H7 55 2.6  O103:H2 30 4.4 
O91:H- 44 2.1  O146:H21 16 2.3 
O145:H- 33 1.5  O111:H- 14 2.0 
O63:H6 31 1.4  O26: H- 13 1.9 
O128:H2 30 1.4  O145:H- 9 1.3 
O111:H- 29 1.4  O145:H34 8 1.2 
O146:H21 27 1.3  O128:H2 7 1.0 
O121:H19 23 1.1  O91:H14 5 0.7 
O26:H- 20 0.9     
Other 563 26.3  Other 196 28.6 
Total 2 140 100  Total 686 100 
(a): This serotype O104:H4 was common in 2011 due to the extensive 2011 O104:H4 outbreak. 
(b): H- = the flagellar or „H‟ antigen was analysed but was absent. 
2.2.2. EU food-borne outbreaks 
EFSA coordinates the annual reporting of zoonoses, zoonotic agents, antimicrobial resistance, food-
borne outbreaks and animal populations in the EU under the Directive 2003/99/EC,
12
 as well as 
analysing and summarising the data collected. 
The zoonoses reports also include data on food-borne outbreaks and has been mandatory for EU MSs 
since 2005. Starting in 2007, harmonised specifications on the reporting of these outbreaks at the EU 
level have been applied
13
. Since 2010, revised reporting specifications for food-borne outbreaks were 
implemented and the distinction between „verified‟ and „possible‟ food-borne outbreaks was changed 
to „strong‟ or „weak‟ based on the strength of evidence implicating a suspect food vehicle. 
Food-borne outbreak investigation systems at the national level are not harmonised between MSs. 
Consequently, the differences in the numbers and types of reported outbreaks, as well as the causative 
agents, may not reflect differences in food safety between MSs but may be more indicative of 
differences in the efficiency and sensitivity of the national monitoring systems for identifying and 
investigating food-borne outbreaks. Nevertheless this zoonosis reporting represents the most 
comprehensive set of data for the EU. 
                                                     
12  Directive 2003/99/EC of the European Parliament and of the Council of 17 November 2003 on the monitoring of zoonoses 
and zoonotic agents, amending Council Decision 90/424/EEC and repealing Council Directive 92/117/EEC. OJ L 325, 
12.12.2003, p. 31–40. 
13 EFSA (European Food Safety Authority), 2007. Report of the Task Force on Zoonoses Data Collection on harmonising the 
reporting of foodborne outbreaks through Community reporting system in accordance with Directive 2003/99/EC. EFSA 
Journal,123, 1-16. 
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Food-borne outbreak data from 2007 to 2011 have been extracted and used for this Opinion. In this 
period, 306 food-borne outbreaks caused by human pathogenic E. coli were reported in the EU 
(Table 6). Most outbreaks (n = 197) were „weak evidence‟ outbreaks (or possible outbreaks). Seventy-
three outbreaks were supported by „strong evidence‟ (or verified outbreaks) and involved 5 212 
confirmed cases, of which 4 250 were reported in 2011. In 2011, twelve MSs reported a total of 60 
food-borne outbreaks caused by pathogenic E. coli. This represents 1.1 % of the total number of 
reported food-borne outbreaks in the EU. Fourteen E. coli outbreaks (23.3 %) were supported by 
„strong evidence‟. The term „pathogenic E. coli’ is used here since consolidated data on all E. coli 
types causing food-borne outbreaks (including VTEC) are only collected as part of the zoonoses 
monitoring process. 
Table 6:  „Strong‟ and „weak evidence‟ food-borne outbreaks caused by pathogenic E. coli 
(excluding „strong evidence‟ waterborne outbreaks) in the EU, 2007-2011. Based on EFSA and ECDC 
(EFSA and ECDC, 2010, 2011, 2012, 2013) 
Year Total outbreaks  „Strong evidence‟ outbreaks(a)  „Weak evidence‟ outbreaks(b) 
   n Cases Hospitalised Deaths  n Cases Hospitalised Deaths 
2007 65  29 541 24 0  - - - - 
2008 75  10 135 8 0  65 204 40 0 
2009 75  18 228 62 0  57 367 33 0 
2010 31  2 58 2 0  29 131 28 0 
2011 60  14 4 250 2 495 54  46 226 29 0 
Total 306  73 5 212 2 591 54  197 928 130 0 
(a): Reported as verified outbreaks in 2007-2009. 
(b): Reported as possible outbreaks in 2008-2009, not reported in 2007. 
 
The clinical outcome of cases was also different in the last year of reporting. In the period 2007-2010, 
96 cases out of the 962 (10.0 %) cases were hospitalised with no case fatalities. In contrast in 2011, 
2 495 cases were hospitalised and 54 fatal cases occurred. The 2011 O104:H4 outbreak was 
responsible of 89.2 % of cases, 94.3 % of hospitalisations and 98.1 % of deaths related to „strong 
evidence‟ outbreaks due to pathogenic E. coli. 
Detailed information (i.e. the number of cases, hospitalisations and deaths) on the „strong evidence‟ 
outbreaks in the EU in 2007-2011 is provided in Appendix B, Table 1. 
Twelve of the 14 „strong evidence‟ pathogenic E. coli outbreaks reported in 2011 were due to VTEC. 
Different serogroups/types were reported: VTEC O157 in seven outbreaks, VTEC O27:H30 in one, 
and E. coli O104:H4 in four outbreaks, all of which were related to the original outbreak reported by 
Germany (see section 2.2.2.1.). „Vegetables, juices and other products thereof‟ were involved in seven 
outbreaks (50.0 %) and three of those seven were caused by the consumption of sprouted imported 
fenugreek seeds (i.e. the 2011 O104:H4 outbreak in Germany and related outbreaks in Denmark and 
the Netherlands). The remaining three were linked to imported sugar peas, mixed salad, raw leeks and 
raw potatoes. France reported an outbreak associated to „vegetables and juices and other products 
thereof‟ without any additional foodstuff information. 
In 2010 a „strong evidence‟ outbreak of VTEC O26 with contaminated cheese the implicated food was 
reported by Germany. In an outbreak in Spain in 2010 the implicated food vehicles were crustaceans, 
shellfish, molluscs and products thereof. In previous years the reported outbreak strains were VTEC 
O157:H7 (German outbreak in 2008 with raw milk as implicated food), VTEC O157 (Irish outbreak in 
2007 with well-water implicated), VTEC O76 (Swedish outbreak in 2007 with cheese as the 
implicated food), and VTEC O26:H- (outbreak in Denmark in 2007 with organic sausage as the 
implicated food). 
Within the O26 serogroup isolates of O26:H11 are classified as seropathotype B. Only the O76:H7 
serotype was included in Karmali et al. (2003), and was assigned to seropathotype E. Full serotyping 
information was reported in only six VTEC outbreaks during the period of 2007-2011; this was the 
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case for one outbreak by VTEC O27:H30, one by O157:H7, one by O26:H- and in 2011 four by 
VTEC O104:H4. Of these, only O157:H7 was included in Karmali et al. (2003) and was assigned to 
seropathotype group A. 
Although undoubtedly caused by pathogenic VTEC, the lack of reporting the „O‟ antigen in outbreaks, 
and the lack of reporting the „H‟ antigen in the outbreaks described above (several by O157, one by 
O26, one by O76), exemplifies a critical weakness of classifying all human VTEC outbreak isolates 
using the seropathotype concept. 
2.2.2.1. The 2011 E. coli O104:H4 outbreak 
The most recent example of a major outbreak caused by a non-O157 VTEC was the O104:H4 
outbreak, first identified in northern Germany in May 2011 (Frank et al., 2011a). This outbreak 
resulted in 4 321 confirmed of VTEC infection and 852 of HUS, with 54 deaths reported in 14 EU 
countries, the USA and Canada when the epidemic was declared to be over at the end of July 2011 
(Buchholz et al., 2011; Karch et al., 2012). The outbreak was unusual because of the high proportion 
of adult patients (ca. 25 %) presenting with HUS, plus the frequent development of neurological 
symptoms in these patients (Frank et al., 2011b). These clinical characteristics were thought to be due 
to the unique combination of traits carried by the pathogen, which included features typical of EAEC, 
together with the capacity to produce Vtx (Frank et al., 2011b). The strain also has a distinct set of 
additional virulence and antibiotic resistance genes (Rasko et al., 2011). Whole genome sequence 
analysis has suggested that the clinical characteristics of the outbreak strain were due to the unique 
combination of virulence factors carried by the pathogen and acquired by horizontal gene transfer 
(Frank et al., 2011a; Frank et al., 2011b). 
2.2.3. Under-estimation considerations 
The above monitoring data should be interpreted with care. Such data are largely based on passive 
surveillance and as such underestimate the true incidence of human VTEC infections. In line with 
ECDC (ECDC, 2011) under-ascertainment refers specifically to cases or exposure in the community 
which are not recorded by a notification or surveillance system, because health care advice may not 
have been sought. Under-reporting refers more specifically to cases where healthcare advice is sought 
but the infection status is misdiagnosed, misclassified, miscounted or the information summarised, 
meaning that full details are not passed on to national monitoring. In short, under-ascertainment occurs 
within the community and under-reporting occurs within institutes and involves physicians, hospitals, 
laboratories, governmental organisations and networks. Furthermore, detection will be highly 
dependent on the methods applied to clinical specimens. Such methods vary markedly between 
different MSs, and consequently VTEC O157 is more readily detected than non-O157 VTEC. 
There have been attempts to more accurately estimate the true prevalence of VTEC infection in both 
the EU and the USA. To estimate the true number of illnesses due to VTEC in the EU, the notified 
number of cases can be multiplied with a „disease-multiplier‟, which is a hazard-specific value that 
expresses the degree of under-reporting and under-ascertainment. Haagsma et al. (2012) have 
developed a transparent model to reconstruct the surveillance pyramid for seven pathogens that cause 
gastroenteritis, including VTEC O157, in seven EU MSs (see Table 7). Furthermore, they estimated 
differences in the proportions of patients within the community, consulting a General Practitioner (GP) 
and becoming hospitalised. Disease-multipliers for VTEC O157, including both under-ascertainment 
and under-reporting, differed widely between countries, and ranged from 13 to 87 (Table 7). The 
authors considered that the substantive differences in disease-multipliers were mainly due to the 
differences in the proportion of patients visiting a GP and in the proportion of patients submitting a 
stool sample. 
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Table 7:  Median values of disease-multipliers, incidence rates and annual numbers of VTEC O157 
infections (Haagsma et al., 2012) 
 Germany Denmark the Netherlands Sweden UK 
Disease-multiplier
(a)
 23 33 87 13 34 
Population
(b)
 2.2 (2 400) 85 (4 600) 76 (12 000) 15 (1 360) 50 (25 000) 
GP
(b),(c)
 1.1 (890) 37 (2 000) 19 (3 000) 5.1 (450) 6.8 (3 400) 
Hospital
(b)
 0.2 (180) 0.9 (50) 0.3 (40) 1.6 (140) 3.1 (1 500) 
(a): Includes both under-ascertainment and under-reporting. 
(b): Incidence rate per 100 000 person-years (median annual number of infections). 
(c): GP = General Practitioner. 
 
In the USA, disease-multipliers are available for both VTEC O157 and non-O157 VTEC (Scallan et 
al., 2011). For VTEC O157, the disease-multiplier is 26.1, while for non-O157 VTEC it is 106.8. This 
multiplier is only composed of under-ascertainment as it is stated that there is no under-reporting for 
these pathogens in the USA, in the Food-borne Diseases Active Surveillance Network (Food-Net). 
Based on the USA figures the disease-multipliers for the EU as a whole are estimated as 51.2 for 
VTEC O157 and 209.6 for non-O157 VTEC. This approach used to calculate these multipliers 
assumes that the relative degree of under-reporting between hazards is the same in the USA and EU. 
Detailed information can be found in a previous EFSA Opinion (EFSA Panel on Biological Hazards, 
2013). 
The estimated disease-multipliers are presented in Table 8 and the estimated true number of illnesses 
is calculated by the product of the disease-multiplier and the notified number of cases of VTEC O157, 
non-O157 VTEC and „untyped/untypeable‟ VTEC. The yearly true number of VTEC cases (based on 
data from 2007-2010) is therefore estimated as 446 101 of which 85 222 (19.1 %) are due to VTEC 
O157 and 149 445 (33.5 %) to non-O157 VTEC (the remainder due to „untyped/untypeable‟ VTEC). 
When the estimation is based on data that also includes 2011, the yearly true number of VTEC cases is 
somewhat higher (509 680 cases) as a result of a higher incidence of non-O157 VTEC. It should be 
noted that in 2011 the multipliers, in particular for non-O157 VTEC, may have been overestimated 
because of active case seeking due to the O104 outbreak. For comparison, the yearly true number of 
cases of salmonellosis and campylobacteriosis in the EU were estimated at around 6 and 9 million, 
respectively (EFSA Panel on Biological Hazards, 2012b, 2012c; Havelaar et al., 2013). VTEC 
infections are more severe. Havelaar et al. (2012) estimated that the burden per case (in Disability 
Adjusted Life Years (DALY)) was approximately 3-fold higher for VTEC compared to salmonellosis 
and campylobacteriosis. 
Table 8:  Estimated true number of illnesses per year in the EU by VTEC, VTEC O157 and non-
O157 VTEC based on the application of disease-multipliers 
Serotype Estimated disease-
multipliers in EU
(a)
 
Notification per year
(b)
, 
average 2007-2010 
(average 2007-2011) 
Estimated true incidence 
data at the EU level
(c)
, 
average 2007-2010 
(average 2007-2011) 
VTEC O157 51.2 1 665 (1 768) 85 222 (90 522) 
non-O157
 
VTEC 209.6 713 (1 034) 149 445 (216 684) 
VTEC NT
(d)
 209.6 1 009 (966) 211 434 (202 474) 
Total VTEC  3 386 (3 768) 446 101 (509 680) 
(a): Disease-multipliers for each pathogen based on the estimates published by Scallan et al. (2011) and anchored to the 
Salmonella disease-multiplier estimated at the EU level by Havelaar et al. (2012). 
(b): Reported confirmed VTEC cases in humans in EU. 
(c): Estimated true number of illnesses in the EU per year calculated by the product of the Salmonella based disease-
multiplier and the notified number of cases as reported to ECDC database TESSy (The European Surveillance System). 
(d): VTEC NT group (untyped/untypeable and cases where „O‟ antigen was reported as unknown). It is assumed that the 
disease-multiplier for this group is the same as the one for non-O157 VTEC. 
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Cohort studies have provided insight in the degree of under-reporting and under-diagnosis of diseases 
caused by gastrointestinal pathogens. Amongst 395 patients with diarrhoea-associated HUS in the UK 
and Ireland who were ill between 1985-1988 and 1997-2001, VTEC was detected in 330 (84 %), of 
which there was evidence for E. coli O157 in 329; the remaining patient was infected with E. coli O26 
(Lynn et al., 2005). Of the remaining 65 patients, no infective agent was detected in 59 and a range of 
other pathogens were detected in the remaining six. In this study presumptive E. coli O157 isolates 
were confirmed biochemically as E. coli and as O157 by serotyping. Confirmed O157 isolates were 
tested for vtx genes by DNA hybridisation or PCR; serum samples were tested for antibodies to E. coli 
O157 lipopolysaccharide (LPS). 
The number of asymptomatic cases is extremely difficult to estimate since healthy people rarely have 
samples of faeces examined for VTEC. In a study in Scotland between 1999 and 2008 (Locking et al., 
2011), of the 2 228 individuals where VTEC O157 had been isolated (including contacts of cases), 202 
(9.1 %) individuals were asymptomatic. 
Two large prospective, population-based studies of infectious intestinal disease (IID) incidence and 
aetiology have been conducted in the UK in 1993–1996 (IID1) and in 2008–2009 (IID2). Both 
culturing for VTEC O157 as well as PCR-based procedures for the detection of vtx genes were applied 
(Tam et al., 2012; Tompkins et al., 1999). In the latter study, within patients with diarrhoea VTEC 
O157 was detected by culture in one out of 866 patients and non-O157 VTEC in seven out of 866 
patients. The IID1 study isolated non-O157 VTEC more frequently from asymptomatic controls than 
from cases. VTEC O157 was isolated from a small number of cases, but not from asymptomatic 
controls (Tompkins et al., 1999). Both the IID 1 and IID 2 studies have allowed an estimate of the 
degree of under-reporting and under-diagnosis in the UK.  
Because of phenotypic diversity, there are no simple, generally applicable culture-based tests for the 
detection of non-O157 VTEC in faecal specimens. The UK Health Protection Agency National 
Standard Methods,
14
 that are widely used in clinical microbiology laboratories in England and Wales 
for diagnosis and identification of E. coli O157, are not effective for the detection of VTEC generally. 
A small number (<15) of isolates of non-O157 VTEC are identified annually in England and Wales by 
diagnostic testing using a combination of PCR and culture of bacteria from faeces associated with 
cases of HUS and bloody diarrhoea but their true incidence is unknown. In a recent evaluation of the 
European Union Reference Laboratory (EU-RL-VTEC) guidelines, a real-time PCR for the detection 
of VTEC in faeces (Jenkins et al., 2012) was applied to 500 stool samples from patients with 
diarrhoea. PCR detected vtx genes in 62 samples, of which VTEC was recovered by culture in 36, 23 
were O157, and 13 were other „O‟ types (O26, O103, O104, O111, O117 and O186). 
In other countries, non-O157 VTEC has been identified as a significant cause of infectious intestinal 
disease, including HUS (Mellmann et al., 2008; Tozzi et al., 2003), and its incidence has been found to 
exceed that of VTEC O157. This may reflect both actual prevalence and differences in testing 
methods. Recent advice for the USA (Gould et al., 2009) has recommended that all stools submitted 
for routine testing from patients with acute community-acquired diarrhoea (regardless of patient age, 
season of the year, or presence or absence of blood in the stool) be simultaneously cultured for E. coli 
O157:H7 and tested with an assay that detects verocytotoxins or toxin genes to detect non-O157 
VTEC. 
VTEC infections and HUS occur in persons of all ages, but the incidence of VTEC infection is highest 
in children aged <5 years, as is the risk of HUS (Lynn et al., 2005). The true incidence of non-O157 
VTEC infections is probably underestimated because standard stool culture methods routinely used in 
many clinical laboratories do not detect these bacteria. Surveillance of paediatric HUS provides 
valuable information on human infection with VTEC. In a prospective survey of paediatric HUS from 
1985 to 1988 in the British Isles, the average annual incidence was 79 per 100 000 children under 16 
years of age (Lynn et al., 2005). In the intervening years, the number of laboratory-confirmed cases of 
                                                     
14  http://www.hpa-standardmethods.org.uk/ 
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VTEC O157 in England and Wales increased from 50 in 1985 to 1 087 in 1997 (Lynn et al., 2005). 
Similar increases were seen in Scotland and Ireland. Some of the increase in VTEC O157 might 
reflect improved laboratory techniques, improved detection or reporting of milder cases, and a greater 
awareness of the need to investigate diarrhoeal disease for VTEC O157 and VTEC O111, which have 
a high likelihood of infection at low infectious exposures (<100 organisms) (EC, 2003). The 
pathogenic potential of other serogroups in England and Wales is not known. 
2.3. Conclusions 
The Karmali seropathotype model does not define pathogenic VTEC or provide an exhaustive list of 
pathogenic serotypes. Instead it classifies VTEC based on their reported frequency in human disease, 
their known association with outbreaks and their severity of the outcome including HUS and HC. 
EHEC are a subset of VTEC that, in addition to the verocytotoxin-encoding genes, usually carry the 
attaching and effacing intimin-coding (or eae gene) and thereby have the ability to cause attaching and 
effacing lesions governed by the LEE PAI. Such strains are typically isolated from cases of severe 
disease. 
In the period 2007-2010, for the majority of the 13 545 confirmed VTEC cases, the clinical outcome 
was not reported: the case fatality was not reported for 52 % of these cases, hospitalisation was not 
reported for 90 % and HUS status was unknown for 41 %. The clinical manifestation (expressed as 
bloody diarrhoea, diarrhoea or asymptomatic) was not reported for 47 % of the cases. 
Full serotyping information was reported for only six VTEC outbreaks (period 2007-2011). Of these, 
only O157:H7 could be assigned to a seropathotype group using the Karmali classification, as the 
other strains were not included in the study by Karmali et al. (2003). 
The degree of under-estimation (including under-ascertainment and under-reporting) of VTEC O157 
infections has been estimated in seven EU MSs. Disease-multipliers differ widely between countries, 
ranging from 13 to 87. Assuming that the relative degree of under-reporting between hazards is the 
same in the USA and EU, the disease-multipliers for the EU as a whole are estimated as 51.2 for 
VTEC O157 and 209.6 for non-O157 VTEC. 
3. Microbiological methods for VTEC 
Methods for the isolation and identification of VTEC (both O157 and non-O157) from food, water and 
environmental (FW&E) samples, the detection of virulence factors and the characterisation and typing 
of VTEC strains and virulence genes therein are discussed below. Of note are changes in detection 
strategy and of identification of the factors contributing to virulence following the 2011 outbreak of 
E. coli O104:H4. 
3.1. Methods for isolation and identification of VTEC 
Detection of VTEC in complex matrices represents a challenge, and may be affected by different types 
of clinical specimens or FW&E samples. 
Analysis of clinical specimens for the detection of VTEC is in principle less problematic than their 
detection in FW&E samples. In cases of VTEC disease, the pathogen often constitutes the principal 
bacterial population in the specimen and the identification of the presence of the vtx-encoding genes or 
the Vtx is enough to come to a correct diagnosis. Moreover, selection of the specimens to be included 
in the screening for such pathogens may be operated according to the symptoms shown by the patient. 
Nevertheless, VTEC can cause diseases characterised by a broad range of symptoms many of which 
can be also ascribed to infections caused by a number of other enteric pathogens. Incorrect differential 
diagnosis may therefore occur, and together with the general lack of scientific and technical skills 
required for managing DNA- or toxin-based assays, may contribute to the low application of routine 
screening programmes for VTEC in clinical microbiology laboratories. 
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The screening of FW&E samples for the presence of bacterial pathogens is intended to be proactive in 
protecting people from acquiring the infections. This implies the availability of markers with a high 
predictive value associated with pathogenicity. While for some bacterial pathogens the identification 
of the presence of microorganisms belonging to a given species is regarded as a risk for the consumer 
in its own right (e.g. Salmonella spp.), this is not applicable to E. coli. 
VTEC differ from commensal E. coli by the presence of the vtx genes and, in addition, by a complex 
array of accessory genetic determinants associated with virulence, including those encoding factors 
involved in colonization, other toxins and immunomodulators (Imamovic et al., 2010; Morabito et al., 
2003; Tozzoli et al., 2005). The virulence genes are heterogeneously distributed among VTEC strains 
but only a sub-population of strains have been associated with the most severe forms of infections and 
contain a complete set of virulence genes. Other strains contain only part of the virulome, are 
infrequently or never associated with severe forms of infection, but still possess the vtx genes. 
The 2011 O104:H4 outbreak (see section 2.2.2.1.) raised questions on the efficacy of using a strategy 
for the detection of VTEC in food based on the identification of the virulence and serogroup-
associated genes for characterising VTEC considered as pathogenic according to the previous 
definitions (EFSA, 2007, 2009). The outbreak strain did not fit in this scheme and yet was possibly the 
most pathogenic VTEC ever described. The 2011 O104:H4 outbreak strain had unusual genetic 
features, e.g. the lack of the eae gene and presence of enteroaggregative adhesion determinants, and as 
such did not belong to the typical VTEC serogroups associated with HUS. Its appearance determined a 
shift in the perception of the hazard represented by VTEC and made the definition of pathogenic 
strains problematic, thereby leading to changes in the methodologies proposed for testing food. 
3.1.1. Isolation of VTEC O157 
The methodology for the detection and isolation of E. coli O157 in food and feedstuffs is the subject 
of the international standard ISO 16654:2001
15
. The protocol is based on the selective enrichment of 
the food samples in a standard culture medium. Part of the enrichment culture is then treated with an 
O157-specific immuno-magnetic separation (IMS) reagent based on paramagnetic beads coated with 
antibodies against the LPS antigen of this E. coli serogroup and plated onto a solid medium containing 
sorbitol instead of lactose. 
The method described above is very effective in isolating E. coli O157 from complex matrices and is 
highly sensitive. Nevertheless there are some concerns. For example, isolated colonies have still to be 
confirmed as VTEC by demonstrating the presence of vtx genes or the production of verocytotoxins. 
Moreover, sorbitol-fermenting E. coli O157 has recently emerged as a public health problem. 
3.1.2. Isolation of non-O157 VTEC 
The isolation of non-O157 VTEC is hampered by the lack of the differential selection offered by the 
Sorbitol-MacConkey (CT-SMAC) medium as these are generally more susceptible to inhibition from 
the antimicrobials used in the ISO 16654 method than the typical VTEC O157. The metabolic and 
antimicrobial resistance features of „typical‟ E. coli O157 are not always present in non-O157 VTEC, 
which are phenotypically indistinguishable from the other commensal E. coli. This has hindered the 
development of specific media for the detection of non-O157 VTEC strains. 
VTEC belonging to the O26 serogroup exhibit, as a common feature, the inability to ferment 
rhamnose. This characteristic may be useful to distinguish this VTEC serogroup from the other E. coli, 
being infrequent in the latter strains. Although useful, this feature is not linked, in VTEC O26, to 
antimicrobial resistance characteristics that can be exploited for their selection onto a specific agar 
medium. 
                                                     
15  ISO 16654:2001. Microbiology of food and animal feeding stuffs – Horizontal method for the detection of Escherichia 
coli O157. International Organization for Standardization. 
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One promising strategy is based on a two-step method and involves the use of a solid medium with 
selective and differential properties, followed by plating of the presumptive VTEC colonies on a 
second confirmation medium (Possé et al., 2008). This medium showed some discrimination between 
non-O157 VTEC and other microflora and to be effective in the exclusivity testing against a panel of 
Enterobacteriaceae, Pseudomonas and Gram-positive bacteria, but showed high false-positive ratios 
for the different VTEC serogroups. 
In order to reduce the number of false positive results, Possé et al. (2008) have proposed the use of a 
second passage onto a second agar medium where the suspected colonies from the first plates are 
streaked. Despite the good outcome in the exclusivity testing and the decrease in the false positive 
results, the proposed strategy remains time-consuming, bringing to three to four days the time needed 
for isolating the suspected colonies, which still have to be confirmed by molecular methods for the 
presence of the main virulence genes. Moreover, the study of Possé et al. (2008) reported the 
performances of the proposed media based on their use with pure cultures of VTEC or mixed cultures 
from pure strains cultured in the laboratory and have not been tested with enrichment cultures from 
complex matrices such as food samples. Finally, the preparation of the media is labour-intensive and 
since such media is not available as pre-assembled commercial formulations, its use is limited in the 
routine clinical or food testing laboratories. 
Immuno-magnetic separation (IMS) can be carried out before plating using either commercially 
available IMS beads, available for the serogroups O26, O45, O103, O111 (Bonardi et al., 2007; OIE 
(World Organisation for Animal Health), 2008) or in-house prepared IMS beads (Fratamico et al., 
2011). A suspension of the recovered beads is then spread on selective or chromogenic agar 
(Kalchayanand et al., 2013) and colonies screened by serum agglutination by serogroup-specific 
antisera. 
3.1.3. Identification of VTEC 
3.1.3.1. Available standard methods 
Until recently ISO 16654:2001
15
 was the only published international standard for the detection of 
E. coli strains belonging to a VTEC serogroup in food or feed. The standard describes a method for the 
isolation of E. coli O157 based on specific features of bacteria belonging to this serogroup, including 
their capability to grow in presence of novobiocin, cefixime and potassium tellurite as well as the 
inability to ferment sorbitol. Despite the attempt to identify features characterising the growth of non-
O157 VTEC, the development of cultural standards for the detection and isolation of strains belonging 
to these other VTEC serogroups has been hampered by the lack of clear-cut metabolic and 
antimicrobial resistance features allowing the specific enrichment and discrimination from the 
ubiquitous and commensal E. coli. 
VTEC are distinguished from the other E. coli mainly on a genetic basis. The choice of virulence 
characteristics to be included as targets for a molecular detection methodology has been based on the 
assumption that pathogenic VTEC were characterised by the presence, in addition to the vtx-encoding 
genes, of the eae gene. Additionally, the serogroups that had been most frequently associated with 
severe human disease in the EU, in particular HUS, belonged to O157, O26, O111, O103, and O145, 
also regarded as the “top five”. Therefore the grid of features identifying VTEC causing severe disease 
in humans was proposed to be made up of a number of targets including the vtx and eae genes as well 
as genes associated with the above-mentioned five serogroups (EFSA, 2007, 2009). 
This scheme represented the core of a detection method developed under the coordination of the EU-
RL VTEC and proposed as an international standard to the working group on microbial contaminants 
(WG6) of the “Food analysis-Horizontal methods” technical committee (TC 275) of the European 
Committee of Standardization (CEN). The proposed detection methodology was based on the 
screening by real-time PCR of enrichment cultures from food samples for the detection of the 
proposed grid of VTEC virulence and serogroup-associated genes. The laboratory procedure has been 
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approved by the CEN TC275 WG6 as a Technical Specification (CEN ISO/TS 13136) entitled 
“Microbiology of food and animal feed – Real-time polymerase chain reaction (PCR)-based method 
for the detection of foodborne pathogens – Horizontal method for the detection of Shiga toxin-
producing Escherichia coli (STEC) belonging to O157, O111, O26, O103 and O145 serogroups”. 
The new standard includes sequential application of the screening for vtx genes followed, in the 
positive samples, by screening for the eae gene. All samples in which the vtx and eae genes have been 
detected are then subjected to screening for serogroup-associated genes. This latter step had the 
purpose of indicating the presence of a VTEC with the potential to cause the more severe forms of 
disease in the food sample and to select the positive samples for the isolation by serogroup-specific 
IMS. 
The 2011 outbreak caused by O104:H4 raised questions on the efficacy of the grid adopted for the 
screening of food samples according to the draft CEN ISO/TS 13136. The appearance of such an 
unusual VTEC in the food chain required the modification of the general approach upon which the 
CEN ISO/TS 13136 was based. 
The previous standard was based on the use of PCR and was sufficiently flexible to be adapted to the 
new scenario. The amended standard has been published as ISO/TS 13136
16
 “Microbiology of food 
and animal feed – Real-time polymerase chain reaction (PCR)-based method for the detection of food-
borne pathogens – Horizontal method for the detection of Shiga toxin-producing Escherichia coli 
(STEC) and the determination of O157, O111, O26, O103 and O145 serogroups”. 
The new ISO/TS 13136:2012 version requires an attempt to isolate VTEC from all samples where vtx 
genes are detected; the former CEN ISO/TS 13136 version recommended proceeding towards 
isolation only after the identification, in vtx-positive samples, of the presence of the eae and the 
serogroup-associated genes. 
The flow charts of the operations of the CEN ISO/TS 13136:2012 standard, including both the 
screening of the enrichment cultures and the VTEC isolation procedure are included as Appendices C 
and D. 
3.1.3.2. Detection of additional virulence factors 
For the detection of additional virulence characteristics, a molecular approach has advantages. 
Primarily it allows a rapid identification of negative test samples. In general the methods based on the 
molecular detection of genetic traits have a rapid implementation and, in particular for VTEC, the 
methodology requires 24-27 hours to complete the screening step. The presence of any VTEC in the 
food sample can be excluded at this stage. In the case of positivity, the sample is suspected to contain 
a VTEC (presumptive positivity). 
The approaches based on the indirect evidence of a pathogen in a food vehicle also have drawbacks. In 
the case of VTEC, since the indirect evidence of the presence of virulence genes presumptively 
determines the presence of the bacteria, the isolation of the strain is needed to confirm the presence of 
vtx genes in addition to relevant virulence factors in the same live cell whilst excluding the presence of 
free DNA or free vtx phages in the enrichment culture. This step can delay identification because of 
difficulties in developing culture media specifically or differentially allowing the growth of VTEC. 
Vtx-producing EAEC can be effectively detected by the ISO/TS 13136:2012 procedure (see section 
3.1.3.1.) since they are positive for the presence of vtx genes. For epidemiological purposes, the 
scheme for strain characterisation should be upgraded by incorporating additional genes beside the eae 
                                                     
16  ISO/TS 13136:2012. Microbiology of food and animal feed – Real-time polymerase chain reaction (PCR)-based method 
for the detection of foodborne pathogens – Horizontal method for the detection of Shiga toxin-producing Escherichia coli 
(STEC) and the determination of O157, O111, O26, O103 and O145 serogroups. International Organization for 
Standardization. 
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gene and serogroup-associated genes specific for this pathotype. Genes associated with 
enteroaggregative adhesion (AA) appear to represent the best choice. The gene encoding the regulator 
AggR (Dudley et al., 2006) is a good target for detecting EAEC and has long been used for this 
purpose since it regulates the AAF PAI, governing the enteroaggregative adhesion along with those 
specifying other AA-associated plasmid-encoded factors (Dudley et al., 2006). Because aagR is 
plasmid-located and may not be detected in the event of plasmid loss, the concomitant detection of the 
chromosomal gene aaiC, encoding a secreted protein of EAEC and harboured by the PAI AAI 
(Taniuchi et al., 2012), has been proposed by the authors to circumvent this possibility. 
The 2011 E. coli O104:H4 outbreak strain forced a change in the procedures developed for the 
identification of VTEC causing severe disease. Vtx-producing EAEC do not possess the LEE PAI 
common to most pathogenic VTEC and have a genetic background typically present in the classical 
EAEC. A PCR procedure for the identification of EAEC has therefore been developed. The procedure 
is based on the detection of two genes typically present in the EAEC strains isolated from human 
disease: aaiC, encoding a secreted protein of EAEC and harboured by the AAI PAI (Taniuchi et al., 
2012), and the gene encoding the AggR activator, which is located on the pAA plasmid and is a 
general regulator influencing the transcription of the genes present on the AAI PAI along with those 
specifying other pAA plasmid-encoded factors (Dudley et al., 2006). 
The use of two targets in a multiplex assay ensures the maximum coverage of EAEC strains, which are 
characterised by a high degree of diversity in respect to the composition of the virulome. The 
procedure can be used in combination with the approach used to detect vtx genes and described in the 
international standard for the detection of VTEC in food, ISO/TS 13136:2012, to efficiently detect the 
Vtx-producing EAEC. 
3.2. Characterisation and typing of VTEC strains 
3.2.1. Serotyping 
Strains of E. coli, including VTEC, are classically identified by a scheme comprising over 180 „O‟ 
types (lipopolysaccharide) and 56 „H‟-types (flagella). The combination of the „O‟ and „H‟ types 
constitute the serotype of an E. coli strain. Both the „O‟ and „H‟ types can be determined by 
immunological methods such as agglutination with antisera. These techniques have been described in 
a previous Opinion (EFSA, 2007). PCR methods for the determination of „O‟ types are being 
continuously developed. Methods for the identification by PCR of the „O‟ types associated with the 
most severe forms of VTEC infections have been collected and published on the EU-RL-VTEC 
website
17
. 
3.2.2. Typing of virulence factors and genes 
A number of different investigations applying meta-analysis of the VTEC O157 genome have 
indicated that at least two different lineages of VTEC O157 have developed, and that one of these 
lineages is more commonly associated with human disease than the other (Yang et al., 2004; Zhang et 
al., 2007b). Studies based on subtyping of vtx from VTEC O157 isolated from human patients and 
healthy cattle have furthermore indicated that there are differences among the relative frequency of the 
seropathotypes that predominate among patients with severe disease (HUS and HC) and pathotypes 
that predominate in the bovine reservoir (Roldgaard et al., 2004). The same observation has been made 
for VTEC O26. Strains of VTEC O26:H11 that cause HUS are usually identified as vtx- and eae-
positive, whereas infections caused by vtx1- and eae-positive VTEC O26:H11 are usually 
characterised by causing relatively mild diarrhoeal symptoms in most patients (Ethelberg et al., 2004). 
Classification of VTEC based on phenotypic differences, biological activity, and hybridisation 
properties has been recommended by O'Brien et al. (1994). These toxin attributes are clinically 
relevant since some subtypes or variants of Vtx2 seem to be associated with serious sequelae, namely 
                                                     
17 http://www.iss.it/vtec/work/cont.php?id=152&lang=2&tipo=3 
VTEC-seropathotype and scientific criteria regarding pathogenicity assessment  
 
EFSA Journal 2013;11(4):3138 27 
HUS (Bielaszewska et al., 2006; Friedrich et al., 2002; Persson et al., 2007), while others are primarily 
associated with a milder course of disease (Bielaszewska et al., 2006; Friedrich et al., 2002; Persson et 
al., 2007). 
Vtx2e is primarily associated with oedema disease in pigs (Marques et al.,1987) and is rarely a cause 
of diarrhoeal disease in humans (Pierard et al., 1991; Scheutz and Ethelberg, 2008; Zweifel et al., 
2006) or HUS (Thomas et al., 1994). The differences in Vtx specificity may be due to variation in the 
genes encoding the B subunits which are responsible for binding of the toxin to the eukaryotic cell 
receptor (Jacewicz et al., 1986; Lindberg et al., 1987). Vtx2 variants associated with human disease 
bind primarily to the receptor globotriosyl ceramide found in human kidney cells. In contrast the 
receptor for Vtx2e is globotetraosyl ceramide, more commonly found in porcine tissues (DeGrandis et 
al., 1989; Samuel et al., 1990). 
Consistent nomenclature and subtyping strategies are thus of primary importance for surveillance and 
for predicting the risks associated with particular VTEC infections. A PCR protocol for the subtyping 
of the vtx-encoding genes has been developed and evaluated by means of a multicenter study (Scheutz 
et al., 2012). The primer sequences and the amplification conditions for Vtx gene subtyping are shown 
in Appendix E, Table 1. 
3.2.3. Phage typing 
VTEC O157 strains can be differentiated into about 90 types, termed phage types, according to their 
resistance to the superinfection by a panel of 16 bacteriophages (Khakhria et al., 1990). The 
methodology has been described in a previous EFSA Opinion (EFSA, 2007), together with the 
significance of the approach for the epidemiology of the infections. 
3.2.4. Subtyping 
Pulsed field gel electrophoresis (PFGE) for the subtyping of VTEC is widely used to compare strains 
for epidemiological purposes and probably still represents the gold standard for the investigation of 
outbreaks and source-tracing (Barrett et al., 1994; Willshaw et al., 2001b). 
Sequence-based typing methods such as the multi-locus variable number of tandem repeat analysis 
(MLVA) have been evaluated as an alternative to PFGE for VTEC O157 (Hyytia-Trees et al., 2006; 
Noller et al., 2003). Although effective for subtyping VTEC O26 (Miko et al., 2010) its use with other 
non-O157 VTEC serogroups has as yet not been evaluated. 
Both methodologies have been discussed in a previous EFSA Opinion (EFSA, 2007). 
Whole genome sequencing (WGS) has recently been used to investigate the phylogeny of non-O157 
VTEC, and in particular the 2011 outbreak strain of enterohaemorrhagic O104:H4 (Mellmann et al., 
2011) and to investigate and characterise human and animal isolates of E. coli O157 associated with a 
major outbreak in the UK associated with an open farm (Underwood et al., 2013). There is little doubt 
that with the increased availability of WGS methodology and equipment, rapid next-generation 
sequencing will be increasingly used for the subtyping of both O157 and non-O157 VTEC. 
3.3. Conclusions 
The definition of the sub-population of VTEC causing severe disease has been challenged by the 2011 
O104:H4 outbreak. The appearance of such an unusual VTEC strain has clearly demonstrated the 
impossibility of predicting the emergence of „new‟ pathogenic VTEC types based on the presence of 
the eae gene, or by focusing on a restricted panel of serogroups. 
Vtx-producing EAEC do not possess the LEE locus common to most pathogenic VTEC and have a 
genetic background typically present in the classical EAEC. A PCR procedure for the identification of 
EAEC based on the detection of two genes typically present in the EAEC strains isolated from human 
disease: aaiC, encoding a secreted protein of EAEC and the gene encoding the AggR activator, which 
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is a general regulator influencing the transcription of the genes present on the AAI PAI is being 
evaluated. The procedure can be used in combination with the approach used to detect vtx genes and 
described in the international standard for the detection of VTEC in food, ISO/TS 13136:2012, to 
efficiently detect the Vtx-producing EAEC. 
The new published ISO/TS 13136:2012 improves the methodology for detecting VTEC in food 
vehicles by enlarging the scope to the detection of all VTEC. 
4. Hazard characterisation 
4.1. Illness associated with VTEC 
Illnesses associated with Vtx-producing E. coli range from mild diarrhoea to bloody diarrhoea to HC, 
HUS, and thrombocytopenia. Some individuals may excrete the organism in the faeces but remain 
asymptomatic. E. coli O157:H7 is the VTEC serotype which has been most often associated with the 
more severe forms of disease, and in the USA is estimated to cause 63 000 illnesses, 2 100 
hospitalisations, and 20 deaths each year (Scallan et al., 2011). At least 80 % of childhood HUS is 
attributable to infection with VTEC – mainly serogroup O157, although other serogroups are 
implicated, with considerable differences between countries (Lynn et al., 2005). The peak incidence of 
HUS is in children under five years of age (Fitzpatrick, 1999). 
Isolates belonging to numerous non-O157 VTEC serogroups have also been linked to illnesses and 
disease outbreaks (Scallan et al., 2011). In the USA non-O157 VTEC have been estimated to cause 
diarrhoea at frequencies similar to those of other important enteric bacterial pathogens, such as 
Salmonella and Shigella (Tillman et al., 2012), and also cause infections resulting in HUS and 
outbreaks (Brooks et al., 2005). 
There is increasing recognition worldwide of over 150 non-O157:H7 serotypes that may cause human 
illness, some of which can cause outbreaks and severe disease such as HUS and HC. For example in a 
outbreak in Norway in 2006, 17 persons were diagnosed as infected with E. coli O103:H25. Ten of the 
patients, all children, developed HUS and one died. MLVA of the patient isolates showed that all had 
identical profiles. Identical profiles were also detected in isolates from several lot-numbers of the 
incriminated dry-cured sausage products made of mutton, and later in sheep flocks (Schimmer et al., 
2008; Sekse et al., 2009). In contrast some VTEC strains have been associated with only mild 
diarrhoea or with no reported human disease (Bettelheim, 2007; Bettelheim, 2012; Blanco et al., 2001; 
Coombes et al., 2011; Coombes et al., 2008; EFSA and ECDC, 2012; Johnson et al., 2006). These 
observations are supported by the clinical outcome of reported VTEC cases in the EU from 2007-2010 
(see section 4.3.). 
4.2. Commonality with isolates from beef cattle and beef products 
To provide a global assessment of the beef cattle role in human infection with VTEC, published 
reports on VTEC from beef and beef cattle from 1984 to 2007 were evaluated by Hussein (2007). The 
prevalence rates of E. coli O157 ranged from 0.1 to 54.2 % in ground beef, from 0.1 to 4.4 % in 
sausage, from 1.1 to 36.0 % in various retail cuts, and from 0.01 to 43.4 % in whole carcasses. The 
corresponding prevalence rates of non-O157 VTEC were 2.4 to 30.0 %, 17.0 to 49.2 %, 11.4 to 
49.6 %, and 1.7 to 58.0 %, respectively. Of the 162 VTEC serotypes isolated from beef products, 43 
were detected in HUS patients and 36 are known to cause other human illnesses. Thus only 79 
(48.8 %) of 162 serotypes had been identified in cases of human infection. With regard to beef cattle, 
the prevalence rates of E. coli O157 ranged from 0.3 to 19.7 % in feedlots and from 0.7 to 27.3 % on 
pasture. The corresponding prevalence rates of non-O157 VTEC were 4.6 to 55.9 % and 4.7 to 
44.8 %, respectively, often depending on the sensitivity of the methods used. Of the 373 VTEC 
serotypes isolated from cattle faeces or hides, 65 were detected in HUS patients and 62 are known to 
cause other human illnesses. Thus only 123 (33.0 %) of 373 VTEC serotypes from faeces or hides had 
been associated with human illness. The author concluded that the prevalence of a large number of 
pathogenic VTEC serotypes in beef and beef cattle emphasised the critical need for control measures 
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to assure beef safety. From these studies it is apparent that the human pathogenic potential of many 
VTEC serotypes is as yet unknown. 
4.3. Clinical outcome of reported human cases 
In the period 2007-2010 the clinical presentation (both HUS and diarrhoea) of the VTEC human cases 
was reported for only 5 405 (39.2 %) of the human cases in the EU. Results, presented in Table 9, and 
illustrate that 65 % (or 3 536 out of 5 405 patients with known clinical presentation) had diarrhoea and 
did not develop HUS. In HUS cases, bloody diarrhoea was also frequently reported. 
Table 9:  Clinical presentation of reported confirmed(a) human VTEC infections in the EU in the 
period 2007-2010. Based on TESSy data as provided by ECDC 
 HUS
(b)
  
Clinical manifestation Yes No Unknown Total 
Bloody diarrhoea 180 1 265 737 2 182 
Diarrhoea 98 3 536 953 4 587 
Asymptomatic 3
(c)
 323 26 352 
Unknown 496 2 019 3 909 6 424 
Total 777 7 143 5 625 13 545 
(a): Confirmed cases are laboratory confirmed and may or may not fulfil the clinical criteria as described in the case 
definition. 
(b): HUS = haemolytic uraemic syndrome. 
(c):  Data as reported to ECDC. 
 
By age group, in the period 2007-2010, provided for 584 HUS cases with known serogroup, 64.2 % of 
the HUS cases were reported in children up to 4 years of age and 26.0 % in the 5-14 years age group. 
Of those groups, VTEC O157 was identified in 65.7 % of cases, followed by VTEC O26 in 18.6 % of 
cases. 
In 2011, a total of 1 006 confirmed cases developed HUS, based on EFSA and ECDC (2013) data. Of 
these cases 318 were reported to be due to the O104:H4 outbreak strain, but the majority of the 411 
HUS cases with unknown serogroup reported from Germany are believed to have been caused by the 
outbreak strain. By age group (provided for 577 HUS cases with known serogroup), 28.1 % of the 
HUS cases were reported in children up to 4 years of age, followed by 20.8 % in the 25-44 age group. 
O157 was the most commonly reported VTEC serogroup in the 0-14 year old age groups while O104 
was the predominant serotype of confirmed cases in the remaining age groups (Figure 1). 
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Figure 1:  Haemolytic uraemic syndrome (HUS) by age and serogroup in reporting MSs. Top: 2007-
2010 (n = 584) (based on TESSy data as provided by ECDC); bottom: 2011 (n = 577) (EFSA and 
ECDC, 2013). 
4.4. Predictive markers for VTEC that may cause human disease 
4.4.1. Classification by seropathotype 
Using the 2003 Karmali seropathotype model, the predominant serotypes responsible for HUS and 
HC, O157:H7 and O157:NM, were assigned to seropathotype A (Table 1). Seropathotype B strains 
have been associated with outbreaks and HUS, but less commonly than those of seropathotype A; 
serotypes within seropathotype B included O26:H11, O103:H2, O111:NM and O145:NM. 
Seropathotype C serotypes were associated with sporadic HUS but not epidemics. The serotypes in 
group C were O91:H21, O104:H21, O113:H21, O5:NM, O121:NM, and O165:H25. Seropathotype D 
serotypes have been associated with diarrhoea but not with outbreaks or HUS; seropathotype E 
serotypes comprised VTEC serotypes that had never been associated with human disease and had been 
isolated only from animals. Seropathotypes D and E included multiple serotypes, 12 serotypes for 
seropathotype D and 14 for seropathotype E. 
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Information about seropathotype and disease based on the clinical outcome of confirmed VTEC cases 
in humans in the EU from 2007-2010 by serotype (TESSy data), as provided by ECDC, has been 
presented in Appendix A, Table 1. 
4.4.1.1. Virulence factors 
The ECDC epidemiological data would appear to broadly fit the Karmali seropathotype model in 
terms of the presence of the vtx2-eae gene combination. The percentage of cases, hospitalisations and 
HUS associated with specific eae-vtx gene combinations is shown in Table 10. Most HUS cases 
(almost 90 %), for which information was reported on virulence factors, were either eae,vtx2-positive 
or eae,vtx1,vtx2-positive. 
Tables 1-3 in Appendix F list the virulence characteristics by sero(patho)type for all reported 
confirmed cases (Appendix F, Table 1), hospitalised cases (Appendix F, Table 2) and HUS cases 
(Appendix F, Table 3). Considering the confirmed VTEC cases, 98.5 % (769/781) of the 
seropathotype A strains carried the vtx2 (and vtx1) gene and 99.2 % (763/769) of these were eae-
positive. 99.0 % (297/300) of seropathotype B strains also behaved as predicted by the Karmali 
concept and were eae-positive. Seropathotype B strains from VTEC cases were mostly vtx1-positive 
(81.0 % or 243/300). 
All seropathotype A strains causing HUS (77 cases) were vtx2-positive and 98.7 % of these were eae-
positive. The 17 HUS cases caused by strains of the seropathotype B group were all eae-positive; 14 
were vtx2-positive, two vtx1,vtx2-positive and one vtx1-positive. None of the 124 reported cases due to 
O103:H2, of which all but one were eae,vtx1-positive, caused HUS. 
Table 10:  Virulence characteristics of reported confirmed VTEC cases in 2007-2010 including all 
cases, hospitalised cases only and haemolytic uraemic syndrome (HUS) cases only (based on TESSy 
data as provided by ECDC) 
Cases 
Virulence
(a)
 characteristics 
eae,vtx1 eae,vtx2 eae,vtx1,vtx2 vtx1 vtx2 vtx1,vtx2 
All
(b)
 (n = 7 278) 
612 
(8.4) 
4 254 
(58.5) 
1 642 
(22.6) 
295 
(4.1) 
287 
(3.9) 
188 
(2.6) 
Hospitalised
(b),(c)
 (n = 313) 
22 
(7.0) 
185 
(59.1) 
85 
(27.2) 
4 
(1.3) 
10 
(3.2) 
7 
(2.2) 
HUS
(b)
 (n = 371) 
10 
(2.7) 
294 
(79.2) 
37 
(10.0) 
2 
(0.5) 
24 
(6.5) 
4 
(1.1) 
(a): eae = intimin-coding gene, vtx1 = verocytotoxin 1 gene, vtx2 = verocytotoxin 2 gene. 
(b): The percentage (between brackets) is calculated using the corresponding total number of cases (either 7 218, 313 or 371) 
as denominator. 
(c): Data on hospitalisation have only been collected for the last two years (2009 and 2010). 
 
The question therefore arises as to whether or not the presence of specific virulence factors or 
combinations thereof are good predictors of the public health significance of a particular VTEC 
serotype. The presence of Vtx is necessary, but is not sufficient to cause HUS. While it is unclear 
precisely which virulence factors make a VTEC pathogenic for humans the presence of multiple 
virulence genes in non-O157 VTEC serotypes suggests that the additive effects of a variable repertoire 
of virulence genes contribute to disease severity (Wickham et al., 2006). Furthermore, vtx gene 
variants have been shown to be expressed by a number of enteric pathogens (Mauro and Koudelka, 
2011). Thus these genes are broadly distributed among bacteria, and Vtx-producing organisms are 
abundant in a variety of terrestrial ecosystems, including farm animals and the farm environment. 
There is no single or combination of marker(s) that defines the potential of a VTEC strain to cause 
human disease. While vtx2- and eae-positive strains are associated with a high risk of more serious 
illness other virulence gene combinations and/or serotypes may also be associated with serious 
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disease, including HUS. Patient-associated (e.g., age, immune status, antibiotic therapy in the pre-
infection period), and dose-related factors are also important (Todd and Dundas, 2001). 
Table 11 presents the virulence markers present in strains from the five different seropathotypes. 
While different virulence factor combinations have been associated with disease and the precise 
genetic composition of a pathogenic VTEC cannot be defined, there are genetic features that are 
commonly associated with pathogenic strains. Thus, in general, clinically important VTEC contain the 
LEE (with eae often used as a marker for this pathogenicity island) and more severe human illness is 
associated the vtx2 and vtx2c toxin subtypes (Persson et al., 2007; Zhang et al., 2007a). In the USA 
over 90 % of VTEC HC cases have been reported to have been caused by strains that are eae- and 
haemolysin A (hlyA)-positive (USDA, 2012). 
Table 11:  Virulence markers in the seropathotype concept as proposed by Karmali et al. (2003) 
Sero-
patho-
type 
Incidence in 
human 
disease
(a)
 
Outbreaks  Association with 
severe disease
(b)
 
Virulence markers Serotypes 
    vtx eae  
A High Common Yes vtx2 (but may in 
addition also 
carry vtx1) 
+ O157:H7, O157:NM 
B Moderate Uncommon Yes vtx1 and/or vtx2 + O26:H11, O103:H2, 
O111:NM, O121:H19, 
O145:NM 
C Low Rare Yes vtx1 and/or vtx2 +/- O91:H21, O104:H21, 
O113:H21, O5:NM, 
O121:NM, O165:H25 
D Low 
 
Rare No vtx1 and/or vtx2 +/- Multiple
(c)
 
E Non-human 
only 
NA
(d)
 NA
(d)
 vtx1 and/or vtx2 +/- Multiple
(c)
 
(a): Reported frequency in human disease. 
(b): Haemolytic uraemic syndrome (HUS) or haemorrhagic colitis (HC). 
(c): See Table 1. 
(d): NA = not applicable. 
4.4.2. Evaluation of the seropathotype model 
For the purposes of this Opinion the seropathotype model of Karmali et al. (2003) has been evaluated 
using data reported to ECDC over the period 2007-2010. Two approaches have been used, the original 
Karmali approach (approach 1), as put forward in the 2003 paper (Karmali et al., 2003), and a 
modification of this approach (approach 2) based on the health outcome of reported confirmed human 
VTEC cases in the EU. In an attempt to move towards a molecular-based categorisation scheme, a 
third approach, based on genes encoding virulence characteristics additional to the presence of vtx 
genes, has been proposed. 
A large number of VTEC serotypes from ruminants and foods have rarely, if ever, been reported in 
human cases, despite being vtx-, eae- and hlyA-positive (Gyles, 2007). This was illustrated in two Irish 
studies conducted on 32 farms over the course of 12 months, which reported no less than 82 different 
serotype-virulence profile combinations (Ennis et al., 2012; Monaghan et al., 2011). Of these 
serotypes O5:H-, O13:H2, O26:H11, O150:H2, O-:H-, O76:H34, O157:H7 and O157:H16 had the 
necessary known virulence factors to cause disease in humans and yet only O157:H7 and O26:H11 are 
most frequently isolated from patients. The reasons for these discrepancies are as yet unknown, but 
could result from a combination of factors such as differences in detection and identification methods 
in different MSs, under-estimation problems (see section 2.2.3.), and lack of full information on 
serotypes. For example isolates from cases reported as O76:HNT (Appendix A, Table 1), and 
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therefore not classified, could have been O76:H19 or O76:H34 and therefore classifiable if full 
serotyping had been undertaken. Futhermore some VTEC strains might not be pathogenic. 
4.4.2.1. Original Karmali seropathotype approach (approach 1) 
During 2007-2010, 13 545 confirmed VTEC infections were reported to ECDC. These cases have 
been assigned to seropathotypes based on the list provided by Karmali et al. (2003) and related to 
outcome. In Table 12 and Figure 2, the clinical outcome of the confirmed VTEC cases during 2007-
2010 is shown and categorised by their classification into seropathotypes using the original Karmali 
seropathotype approach. Of these 13 545 cases, 11 488 (or 85 %) of the implicated strains were not 
fully serotyped and could therefore not be classified into seropathotypes.  
These cases included 1 047 (51 % of fully serotyped cases) where the isolated VTEC belonged to 
seropathotype A; 323 (16 %) belonged to seropathotype B, 24 (1 %) to seropathotype C, 104 (5 %) to 
seropathotype D and 14 (0.7 %) to seropathotype E. For 545 cases (27 %) the serotypes were not 
reported in the Karmali paper and therefore could not be included in the Karmali classification. The 
majority of cases reporting a severe clinical outcome were associated with seropathotypes A and B. 
This included the majority (71 %) of the deaths, 76 % of the hospitalisations, 66 % of the HUS cases 
and 88 % of the cases with bloody diarrhoea. 
Considering only those cases with reported outcome and when comparing the classification into 
seropathotypes, – 1.2 % of the total (five cases) were reported with a fatal outcome for seropathotype 
A and 0.5 % (two cases) for the group fully serotyped but not listed by Karmali et al. (2003) (Not 
Listed by Karmali or NLK group), respectively. The fatal cases reported in this latter group were 
associated with strains typed as O105:H18 and O17:H41. Hospitalisation rates for the different 
seropathotypes were: A, 59 %; B, 37 %; C, 100 % (only two cases); D, 75 % (only three cases); E, 
100 % (only one case); and NLK, 37 %. Similarly HUS and bloody diarrhoea was reported from: 
seropathotype A, 16 % and 52 % respectively; seropathotype B, 6 % and 12 %; seropathotype C, 6 %, 
and 0 %; seropathoytype D, 0 % and 1.4%, seropathotype E, 0 % and 0.3%; and NLK, 4 % developed 
HUS and 11 % reported bloody diarrhoea. 
Of the 777 HUS cases reported, 645 cases (83 %) were not fully serotyped and could therefore not be 
classified. Of the remaining 132 cases, 115 (87 %) belonged to seropathotypes A-C and 17 (13 %) 
were not included in the Karmali paper. The latter included the following serotypes: O145:H28, 
091:H10, O111:H8, O128:H2, O121:H2, O76:H19, O174:H21, O174:H2, O1:H42, O86:H27, 
O80:H2, O123:H2, O105:H18, and O7:H6.  
The ECDC epidemiological data covering 2007-2010 would appear to broadly fit the Karmali 
seropathotype model in terms of incidence and severity. This classification, based on the serotypes 
listed by Karmali et al. (2003), has the drawback that the number of serotypes is limited (only 39 
serotypes listed). As a result, for 545 cases (or 27 % of the confirmed VTEC infections) that were 
reported to ECDC in the period 2007-2010, classification was not feasible. This group caused 26.5 % 
of all cases, 29 % of the fatal cases, 17 % of the hospitalisations, 13 % of the HUS cases and 11 % of 
the cases with bloody diarrhoea. 
In addition there are problems in serotyping (e.g., availability of sera for both „O‟ and „H‟ typing in 
different countries, strains which do not react with available sera, lack of resources, etc.), which 
combine to result in incomplete strain identification such as is required for the Karmali model. In the 
above assessment, incomplete serotype identification has resulted in the exclusion of 85 % of reported 
VTEC cases. Such exclusions could give rise to a biased outcome. For example, about half of the 
isolates with missing „H‟ antigen information are from cases of O157 infection (5 610 cases). 
Assuming that these would have been typed as O157:H7 or O157:H-, many of these cases would have 
been assigned to seropathotype group A, thereby expanding this group to 6 657 cases or 87 % of cases, 
78 % of fatal cases, 91 % of the hospitalisations, 91 % of the HUS cases and 95 % of the cases with 
bloody diarrhoea. 
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In the USA the top seven serogroups are O157, O26, O45, O103, O111, O121 and O145 (USDA, 
2012). While the majority of strains belonging to these serogroups are eae-and hlyA-positive, there are 
exceptions and it is not possible to absolutely and definitively distinguish between pathogenic and 
non-pathogenic VTEC based on either serogroup or virulence factor profile. Thus the original Karmali 
seropathotype approach is not absolute in categorising all serotypes falling into groups other than A, B 
or C as not being associated with severe disease. 
There are also important exceptions reported in the scientific literature. Before the 2011 outbreak, 
O104:H4 had a low incidence in human disease and as such was not outbreak-associated 
(seropathotype D); in the 2011 outbreak 3 816 human cases were reported (including 54 deaths) and of 
those, 845 cases developed HUS (EFSA and ECDC, 2013). In addition, of the six food-borne VTEC 
outbreaks (period 2007-2011) where full serotyping data was reported (Appendix B, Table 1), only 
O157:H7 could be assigned to a seropathotype group (group A), as the other strains were not included 
in the list of Karmali et al. (2003). 
Classification by seropathotype may also be affected by differences in the relative occurrence of some 
serogroups in different countries (Caprioli et al., 1997; EC, 2012). Nevertheless in the USA at least 
70 % of the 940 non-O157 VTEC isolates from persons with sporadic illnesses submitted between 
1983 and 2002 to the US Centers for Disease Control and Prevention (CDC), belonged to one of the 
top six VTEC serogroups, namely O26, O111, O103, O121, O45, and O145 (Brooks et al., 2005). In 
the USA, the seropathotype B group has been extended and currently includes 13 VTEC serotypes 
O26:H11 and NM; O45:H2 and NM; O103:H2, H11, H25, and NM; O111:H8 and NM; O121:H19 
and H7; and O145:NM (Bosilevac and Koohmaraie, 2011). 
4.4.2.2. „Modified‟ Karmali seropathotype approach (approach 2) 
To take into account serotypes other than those specifically mentioned in the Karmali paper of 2003 a 
modified seropathotype approach based on the health outcome of reported confirmed VTEC cases in 
the EU has been developed. This second approach was applied to the data reported to ECDC during 
2007-2010. Published literature and older data have not been considered in this assessment. 
In this „modified‟ approach VTEC serotypes in seropathotype groups A, B and C were combined with 
those associated with HUS in the 2007 to 2010 data and designated „HUS-associated serotypes‟ 
(HAS). In Table 13 and Figure 3, the clinical outcome of the confirmed VTEC cases during 2007-
2010 is shown and categorised by their classification using this „modified‟ Karmali seropathotype 
approach. 
With this „modified‟ approach 1 340 (86 % of fully serotyped cases) VTEC cases have been classified 
as seropathotype group HAS. The majority of infections with the most severe forms of the disease 
were associated with Karmali seropathotypes A/B/C. Under the new scheme, the HAS group now 
include the serotypes causing the majority (86 %) of the deaths, 71 % of the hospitalisations, 100 % of 
the HUS cases (due to the concept design) and 86 % of the cases with bloody diarrhoea.  
By this „modified‟ approach, in cases when full serotyping has been undertaken, all serotypes 
associated with severe disease are automatically categorised in the HAS group. Furthermore, as new 
information becomes available, serotypes may be re-classified and the model updated. 
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Table 12:  Health outcome of reported confirmed(a) human VTEC cases during 2007-2010 as categorised by the seropathotype concept of Karmali et al. 
(2003). Based on TESSy data as provided by ECDC 
Seropathotype Total Death  Hospitalisation  HUS  Clinical manifestation 
  Yes (%) No  Yes (%) No  Yes (%) No  Bloody diarrhoea Diarrhoea Asymptomatic 
A(b) 1 047 
[50.9] 
5 (1.23) 
[71.4] 
400  46 (59.0) 
[55.4] 
32  96 (16.3) 
[72.7] 
493  286 (52.1) 
[79.0] 
236 (43.0) 
[26.3] 
27 (4.9) 
[35.1] 
B(c) 323 
[15.7] 
0 (0) 
[0] 
283  17 (37.0) 
[20.5] 
29  18 (6.2) 
[13.6] 
273  31 (11.7) 
[8.6] 
222 (84.1) 
[24.7] 
11 (4.2) 
[14.3] 
C(d) 24 
[1.2] 
0 (0) 
[0] 
16  2 (100) 
[2.4] 
0  1 (5.6) 
[0.8] 
17  0 (0) 
[0] 
15 (93.8) 
[1.7] 
1 (6.3) 
[1.3] 
D(e) 104 
[5.1] 
0 (0) 
[0] 
80  3 (75.0) 
[3.6] 
1  0 (0) 
[0] 
88  5 (6.3) 
[1.4] 
70 (88.6) 
[7.8] 
4 (5.1) 
[5.2] 
E(f) 14 
[0.7] 
0 (0) 
[0] 
12  1 (100) 
[1.2] 
0  0 (0) 
[0] 
10  1 (9.1) 
[0.3] 
9 (81.8) 
[1.0] 
1 (9.1) 
[1.3] 
NLK(g) 545 
[26.5] 
2 (0.48) 
[28.6] 
414  14 (36.8) 
[16.9] 
24  17 (3.8) 
[12.9] 
430  39 (9.3) 
[10.8] 
346 (82.8) 
[38.5] 
33 (7.9) 
[42.9] 
NFT(h) 11 488 11 (0.21) 5 296  439 (38.3) 707  645 (10.0) 5 832  1 820 (31.5) 3 689 (63.8) 275 (4.8) 
Total 13 545 18 (0.28) 6 501  522 (39.7) 793  777 (9.8) 7 143  2 182 (30.6) 4 587 (64.4) 352 (4.9) 
(a): Confirmed cases are laboratory confirmed and may or may not fulfil the clinical criteria as described in the case definition. For the majority of these confirmed VTEC cases, the clinical 
outcome was not reported: the case fatality was not reported for 52 % of these cases, hospitalisation was not reported for 90 % and HUS (haemolytic uraemic syndrome) status was 
unknown for 41 %. The clinical manifestation (expressed as bloody diarrhoea, diarrhoea or asymptomatic) was not reported for 47 % of the cases. Percentages of cases are given between 
brackets based on rows () and based on columns []. 
(b): Includes O157:H7, O157:NM. 
(c): Includes O26:H11, O103:H2, O111:NM, O121:H19, O145:NM. 
(d): Includes O91:H21, O104:H21, O113:H21, O5:NM, O121:NM, O165:H25. 
(e): Includes O7:H4, O69:H11, O103:H25, O113:H4, O117:H7, O119:H25, O132:NM, O146:H21, O171:H2, O172:NM, O174:H8, Orough:H2. 
(f): Includes O6:H34, O8:H19, O39:H49, O46:H38, O76:H7, O84:NM, O88:H25, O98:H25, O113:NM, O136:H12, O136:NM, O153:H31, O156:NM, O163:NM. 
(g): NLK = serotypes that were fully serotyped but were not listed by Karmali et al. (2003). 
(h): NFT = strains that were not fully serotyped.  
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Figure 2:  Health outcome of reported confirmed human VTEC cases during 2007-2010 as listed by Karmali et al. (2003) and categorised accordingly. NLK 
includes these serotypes that were fully serotyped but not listed by Karmali et al. (2003). Based on TESSy data as provided by ECDC. 
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Table 13:  Health outcome of reported confirmed human VTEC cases during 2007-2010 as categorised based on the reported haemolytic uraemic syndrome 
(HUS) cases of human VTEC in EU in 2007-2010 (grouped as HAS (A/B/C)). Based on TESSy data as provided by ECDC
a
 
Seropathotype Total Death  Hospitalisation  HUS  Clinical manifestation 
  Yes (%) No   Yes (%) No  Yes (%) No  Bloody diarrhoea Diarrhoea Asymptomatic 
A/B/C (HAS)(b) 1 340 
[65.1] 
6 (0.94) 
[85.7] 
631  59 (49.2) 
[71.1] 
32  132 (15.6) 
[100.0] 
717  311 (40.6) 
[85.9] 
413 (53.9) 
[46.0] 
43 (5.6) 
[55.8] 
D(c) 717 
[34.9] 
1 (0.17) 
[14.3] 
574  24 (49.0) 
[28.9] 
0  0 (0) 
[0] 
594  51 (9.0) 
[14.1] 
485 (85.1) 
[54.0] 
34 (6.0) 
[44.2] 
NFT(d) 11 488 11 (0.21) 5 296  439 (38.3) 707  645 (10.0) 5 832  1 820 (31.5) 3 689 (63.8) 275 (4.8) 
Total 13 545 18 (0.28) 6 501  522 (39.7) 793  777 (9.8) 7 143  2 182 (30.6) 4 587 (64.4) 352 (4.9) 
(a): Confirmed cases are laboratory confirmed and may or may not fulfil the clinical criteria as described in the case definition. For the majority of these confirmed VTEC cases, the clinical 
outcome was not reported: the case fatality was not reported for 52 % of these cases, hospitalisation was not reported for 90 % and HUS (haemolytic uraemic syndrome) status was 
unknown for 41 %. The clinical manifestation (expressed as bloody diarrhoea, diarrhoea or asymptomatic) was not reported for 47 % of the cases. Percentages of cases are given between 
brackets based on rows () and based on columns []. 
(b): HAS = HUS-associated serotypes. Includes the serotypes that have been associated with reported confirmed HUS cases of human VTEC in EU in 2007-2010: O157:H7, O157:H-, 
O121:H19, O26:H11, O174:H2, O111:H-, O145:H-, O145:H28, O1:H42, O128:H2, O111:H8, O104:H21, O174:H21, O7:H6, O76:H19, O80:H2, O86:H27, O121:H2, O123:H2, 
O105:H18, O91:H10. 
(c): Includes the serotypes that have been fully serotyped but have not been associated with the reported confirmed HUS cases of human VTEC in EU in 2007-2010. 
(d): NFT = strains that were not fully serotyped.  
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Figure 3:  Health outcome of reported confirmed human VTEC cases during 2007-2010 as categorised based on the reported haemolytic uraemic syndrome 
(HUS) cases of human VTEC in EU in 2007-2010 (grouped as HAS (A/B/C)). Based on TESSy data as provided by ECDC 
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4.4.2.3. Molecular approach (approach 3) 
There is insufficient data to perform a quantitative risk assessment relating the presence of a particular 
combination of virulence genes and/or serogroup to a particular disease outcome. Achieving a balance 
between specificity and sensitivity of virulence prediction is therefore difficult. The „modified‟ 
Karmali approach does not resolve the underlying problem with strains that have not been fully 
serotyped. Furthermore classification based solely on the presence of vtx genes is inadequate. To 
overcome these problems a third approach, utilising genes encoding virulence characteristics 
additional to the presence of vtx genes, is proposed.  
The additional virulence-associated genes suggested for this classification are eae (intimin 
production), aaiC (secreted protein of EAEC) and aggR (plasmid-encoded regulator) genes (see 
section 3.1.3.2.). The intimin protein encoded by the LEE PAI (eae gene) is, to our knowledge, the 
only adherence factor that has been consistently associated with clinical isolates of VTEC, but with 
some notable exceptions such as the O104:H4 outbreak strain in 2011, which was eae-negative. 
In principle this approach delivers a new scheme that describes the categorisation of VTEC according 
to potential risk for consumers‟ health. These „risks‟ have been categorised as group I (high potential 
risk) through to group III (unknown risk) (see Table 14). 
Table 14:  Proposed(a) molecular approach for the categorisation of VTEC (vtx present) 
Group Genes
(b)
 Serogroups Potential risk
(c)
 
   Diarrhoea HUS/HC
(d)
 
I eae-positive or 
(aaiC and aggR)-positive 
 
O157, O26, O103, O145, O111, O104 High High 
II eae-positive or 
(aaiC and aggR)-positive 
 
Any other High Unknown 
III eae-negative and 
(aaiC plus aggR)-negative 
Any other Unknown Unknown 
(a): As yet this proposed molecular approach must be regarded as provisional. This is because screening VTEC for the 
presence of eae, aaiC and aggR genes is not routinely undertaken by all laboratories reporting data to TESSy. 
(b): Additional to the presence of vtx genes. eae = intimin-coding gene, aaiC = chromosomally-encoded gene encoding 
secreted protein of EAEC, aggR = plasmid-encoded regulator gene. 
(c): Needs epidemiological studies for confirmation. 
(d): HUS = haemolytic uraemic syndrome, HC = haemorrhagic colitis. 
 
The listed serogroups under group I reflect the top-5 (O157, O26, O103, O145, O111) generally 
recognised as most frequently associated with human clinical cases, with the addition of O104. The 
proposal for the inclusion of aaiC and aggR genes is due to the 2011 outbreak, which was caused by a 
highly virulent strain. This was an exceptional event and future surveillance will provide data that may 
be used to review the inclusion of these virulence factors in this molecular approach. 
VTEC strains falling under group I should be regarded as representing a higher risk. For VTEC that 
would fall under group II there is still uncertainty whether of not they are able to cause HUS due to as 
yet unknown additional virulence mechanisms. For VTEC that would fall under group III there is 
uncertainty whether of not they are able to cause disease and we are unable to make a scientific 
judgement based on current knowledge of virulence characteristics. Routine surveillance that includes 
molecular testing for known/new virulence genes together with accurate reporting of clinical 
presentation will help to classify VTEC strains according to risk. 
PCR-based methods for the identification and detection of the relevant genes in serogroups assigned to 
the three risk groups are already available as well as methods to detect the serogroups listed under 
group I (see section 3.1.3.2.). 
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This molecular approach must be regarded as provisional. This is because screening VTEC for the 
presence of aaiC and aggR genes is not routinely undertaken by all laboratories reporting data to 
TESSy. As such the relevant aaiC and aggR gene data are not fully available for all isolates (see 
Tables 4 and 10). Similarly information on the presence of eae-vtx genes is not always available. For 
example, during 2007-2010 such data were available for only 371 out of 777 (47.7 %) of reported 
HUS cases. Additionally information on serogroup has not always been reported. For example, for the 
remaining 371 cases serogroup information was not available for 56 cases. 
This proposed molecular approach has the advantage of overcoming problems associated with the lack 
of flagella „H‟ antigen typing. The model needs to be periodically revised in light of new 
epidemiological information. The performance of this proposed approach needs to be verified with 
well-characterised isolates from cases of human infection and from food-producing animals and foods, 
thus accommodating all cases with information on the infecting strain.  
4.5. Conclusions 
In the period 2007-2010, 13 545 confirmed human VTEC infections were reported to ECDC. 85 % of 
these cases were not fully serotyped and could therefore not be classified using the seropathotype 
concept of Karmali et al. (2003). 
The human pathogenic potential of many VTEC serogroups is at yet unknown. 
The seropathotype D group of the Karmali seropathotype approach covered 5 % of cases that were 
fully serotyped. Fourteen cases (0.7 %) belonged to the seropathotype E, a group formerly considered 
to be only found in animals. Twenty-seven percent of the cases could not be assigned to a 
seropathotype group as these were not listed in Karmali‟s 2003 paper. There were no HUS cases 
reported for the serotypes included in seropathotype groups D and E. There were 17 HUS cases 
reported that could not be assigned to a seropathotype group. 
Various virulence factors and toxins contribute to the pathogenesis of VTEC. Vtx2 is the more potent 
toxin in cases of human disease, and those strains producing this toxin are generally associated with 
more acute illness. Strains that produce Vtx2 and more specifically, Vtx2 subtype c (Vtx2c) have been 
suggested to be more likely to cause HUS than those that produce Vtx1 alone. A further important 
virulence gene is the eae gene, which encodes a protein involved in the intimate attachment of E. coli 
to the gut mucosa and is typically found in strains causing serious illness. 
There is no single or combination of marker(s) that defines the potential of a VTEC strain to cause 
human disease. While vtx2- and eae-positive strains are associated with a high risk of more serious 
illness other virulence gene combinations and/or serotypes may also be associated with serious 
disease, including HUS. Patient-associated (e.g., age, immune status, antibiotic therapy in the pre-
infection period), and dose-related factors may also be of importance. Alternative concepts based on 
the detection of verocytotoxins alone or genes encoding such verocytotoxins do not provide a sound 
scientific basis on which to assess risk to the consumer. 
The intimin protein encoded by the LEE PAI (eae gene) and the AAF encoded by the EAEC plasmid 
(aaiC) gene are, to our knowledge, the only adherence factors that have been consistently associated 
with the virulence of EHEC and VTEC respectively. Therefore, any VTEC strains that carry at least 
one of the genes encoding such products should be regarded as higher risk. 
Pathogenicity can neither be excluded nor confirmed for a given VTEC serogroup or serotype based 
on the Karmali seropathotype concept or analysis of the public health surveillance data. 
Using a modification of the Karmali et al. (2003) approach based on the health outcome of reported 
confirmed human VTEC cases in the EU during 2007-2010, in cases when full serotyping has been 
undertaken all serotypes associated with severe disease (HUS) could be categorised as seropathotype 
group HAS. Under the new scheme, the HAS group now includes the serotypes causing the majority 
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(86 %) of the deaths, 71 % of the hospitalisations, 100 % of the HUS cases and 86 % of the cases with 
bloody diarrhoea. 
By this „modified‟ approach, in cases when full serotyping has been undertaken all serotypes 
associated with severe disease are automatically categorised in the HAS group. Furthermore, as new 
information becomes available, serotypes may be reclassified and the model updated. 
A molecular approach, utilising genes encoding virulence characteristics additional to the presence of 
vtx genes, is proposed. This molecular approach must be regarded as provisional because screening 
VTEC for the presence of eae, aaiC and aggR genes is not routinely undertaken. This scheme has the 
advantage of overcoming problems associated with the lack of flagella „H‟ antigen typing. The 
performance of this proposed approach needs to be verified with well-characterised isolates from cases 
of human infection and from food-producing animals and foods.  
5. Exposure assessment 
Data on VTEC are reported annually on a mandatory basis by EU MSs to the EC and EFSA based on 
Zoonoses Directive 2003/99/EC
18
. Most MSs have provided data on their VTEC investigations in the 
past years. When interpreting these data it is important to note that data from different investigations 
are not directly comparable due to differences in sampling strategies and applied analytical methods. 
The most widely used analytical method only aims at detecting VTEC O157, whereas fewer 
investigations have been conducted with analytical methods aiming at detecting all or selected 
serotypes of VTEC. Thus the proportion of non-O157 VTEC strains may have been largely under-
reported. 
Most reported data on VTEC are from animals (mainly ruminants) and meat and milk thereof, since 
these are considered to be main sources of human infections. These data are summarised in the 
Community and EU Summary Reports on Zoonoses and Food-borne Outbreaks in 2004-2011. 
5.1. Occurrence of VTEC in ready-to-eat (RTE) food 
5.1.1. EU monitoring data 
An overview of the data during the years 2007 to 2011 (from EFSA and ECDC (2010, 2011, 2012)) on 
occurrence of VTEC in RTE food is provided in Table 15. 
In food, most information on VTEC was reported on fresh bovine meat. During 2007-2010, overall 
0.3 - 2.3 % of fresh bovine meat samples were found positive for VTEC in the reporting MSs, and 
0.1 - 0.7 % of these samples were positive for VTEC O157. The other VTEC serogroups reported in 
bovine meat were O26, O103, O111, and O145, but overall very little information on the serogroups 
was provided by MSs. The proportion of positive samples varied widely between the MSs. On fresh 
sheep meat, VTEC were detected in 0 - 8.2 % of the samples: VTEC O157 was not detected. Some 
data were reported on fresh meat from other animal species at the EU level, where VTEC were 
detected between <0.1 - 3.2 % of the samples and <0.1 % were positive for VTEC O157. 
VTEC was reported from samples of raw cow‟s milk and cheeses made from cow‟s milk. VTEC O157 
was only recovered from raw milk in 2011 in Belgium in one out of 39 batches of raw milk intended 
for direct human consumption. VTEC O22 was detected in 2008. In cheeses, VTEC O91 was 
recovered in soft and semi-soft cheeses made from raw or mild heat-treated cow‟s milk in 2010. 
Fewer VTEC data were provided from other foodstuffs. Nine MSs provided data on VTEC in fruit, 
vegetables and juices in 2007–2010. Five investigations reported VTEC in 0.5 – 6.5 % of samples and 
VTEC O157 was detected in three investigations of vegetables, with the proportion positive units at 
                                                     
18  Directive 2003/99/EC of the European Parliament and of the Council of 17 November 2003 on the monitoring of 
zoonoses and zoonotic agents, amending Council Decision 90/424/EEC and repealing Council Directive 92/117/EEC. 
OJ L 325, 12.12.2003 p. 31-40. 
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0.5 – 5.3 %. Two MSs reported data on VTEC in fishery products, and in one investigation VTEC was 
detected at 4.2 %. In 2011 more data have been provided on VTEC in seeds, sprouts and vegetables, 
likely prompted by the O104:H4 outbreak. None of the samples tested positive for VTEC O157, three 
were positive for non-O157 in sprouted RTE seeds at retail and one in a RTE dish at retail. 
As mentioned in a previous EFSA Opinion (EFSA Panel on Biological Hazards, 2012a), when 
reviewing the EU Summary Reports on Trends and Sources of Zoonoses, Zoonotic Agents and Food-
borne outbreaks in 2009 and 2010 comparison between MSs is difficult due to the differences in the 
methods, sampling schemes and reporting systems. For example detection rates of VTEC in fresh 
bovine meat are available with results based on sampling plans by either surface area or weight (i.e. 
per 400 cm
2
 or 25 g): it is not clear in this dataset to identify if the samples were of carcasses, primary 
cuts or final products. The sampling stage (i.e. before, after or during chilling) can have important 
effects on determining VTEC prevalence. In addition there are significant trends in the in prevalence 
of VTEC in fresh bovine meat which may reflect differences in methods, sampling schemes and 
reporting systems among MSs. For example the reported percentage of samples where VTEC O157 
was detected in bovine fresh meat at slaughter, cutting/processing plant in Spain for 2009 was 14.9 %. 
In contrast the respective prevalence in Spain for the years 2006-2008 was less than 1.3 % whilst in 
2010 it was 0 %. For most MS no information has been provided for VTEC serogroups other than 
O157. 
5.1.2. Data from literature 
Table 16 provides an overview of the occurrence of VTEC in RTE food. Depending on the 
methodologies used, VTEC of various serogroups have been recovered from RTE foods, albeit 
relatively rarely. 
VTEC has been recovered from a range of different animal species and food categories. The most 
widely used analytical method only aims at detecting VTEC O157, whereas fewer investigations have 
been conducted on analytical methods aimed at detecting all or selected serotypes of VTEC. At the EU 
level, O157 has been recovered from fresh bovine meat, fresh sheep meat, raw cows‟ milk and dairy 
products as well as other foods, albeit at low prevalences. MSs provided data on the VTEC serogroups 
other than O157 in 2010, and have detected O26, O91, O103 and O145 from bovine meat, cheeses, 
cattle, sheep or pigs. 
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Table 15:  VTEC in fresh meat, milk and dairy products and other food in EU, 2007-2011 (EFSA and ECDC, 2010, 2011, 2012, 2013)(a) 
Animal/ food category  2011     2010     2009     2008     2007   
 No. 
MS 
n VTEC 
(%) 
VTEC 
O157 
(%) 
 No. 
MS 
n VTEC 
(%) 
VTEC 
O157 
(%) 
 No. 
MS 
n VTEC 
(%) 
VTEC 
O157 
(%) 
 No. 
MS 
n VTEC 
(%) 
VTEC 
O157 
(%) 
 No. 
MS 
n VTEC 
(%) 
VTEC 
O157 
(%) 
Fresh bovine meat(b) 8 4 347 1.4 0.3  12 8 566 0.5 0.1  13 9 285 2.3 0.7  14 14 810 0.3 0.1  13 14 115 0.3 0.1 
Fresh sheep meat 2 220 0 0  3 394 7.4 0  4 248 3.2 0  1 61 8.2 0  4 290 1.7 0 
Fresh meat from other 
animal species(c) 
3 1 459 <0.1 <0.1  9 5 800 0.6 <0.1  11 248 3.2 0  8 6 660 0.7 <0.1  9 6 374 0.4 0.1 
Raw cows‟ milk(d) 4 499 1.6 0.2  4 1 683 3.3 0  3 998 1.2 0.1  4 1 439 1.7 <0.1  5 1 079 0.5 0 
Milk and dairy products 
excl. raw cows‟ milk(e) 
3 1 546 1.8 <0.1  5 2 704 0.3 0  7 5 602 0.4 <0.1  4 1 138 1.1 0  7 2 289 0.9 0 
Other food(f) 8 4 727 0.1 0  4 2 806 1.6 <0.1  5 340 0.9 0.9  4 1 119 0.4 0.4  5 3 459 <0.1 0 
(a): Only investigations with ≥ 25 samples included; n = number of samples; No. MSs = Number of Member States reporting data. 
(b): In 2011, Belgium reported on carcasses at slaughterhouses the serotypes VTEC O26 (4), VTEC O103 (3) , and VTEC O111 (5) O103 and VTEC O111 (1) and VTEC O145 (2). In 2010, 
France reported in chilled minced bovine meat the serotypes VTEC O26:H11 (4) and VTEC O145:H28 (1). 
(c): Includes meat from pig, broilers, turkey and wild or farmed game - land animals. In 2009 Austria reported in meat from wild or farmed game - land mammal the serotype VTEC O146:H21 
(1). In 2008 Germany reported in meat from wild or farmed game - land mammals the serotypes VTEC O146 (2) and VTEC O91 (1). In 2007 Germany reported in meat from wild or 
farmed game - land mammals the serotypes VTEC O128 (1), VTEC O146 (1), VTEC O8 (1) and VTEC O113 (1). 
(d): No additional information on serogroups was provided by MSs except for one investigation from Germany in 2008 in which 3 positive samples were VTEC O22. 
(e): In 2010 Germany reported the serotype VTEC O91 (1) in soft and semi-soft cheeses made from raw or low heat treated cow's milk. 
(f): Includes fruits and vegetables, juice, fishery products and other processed fruit products and prepared dishes. 
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Table 16:  Occurrence of pathogenic E. coli in ready-to-eat (RTE) food 
Reference Commodity Number of 
samples analysed 
Positive 
samples 
Other information 
Althaus et al. (2012) RTE lettuce 142 12 (VTEC), 11 
(EPEC) 
The VTEC strain was eae negative; non 
O-157. Screened with multiplex PCR 
for the vtx and eae genes 
Fresh-cut fruits 64 0 Screened with multiplex PCR for the vtx 
and eae genes 
Sprouts 27 0 Screened with multiplex PCR for the vtx 
and eae genes 
Castro-Rosas et al. (2012) RTE-salads (mixed salads with raw vegetables) 
(restaurants) 
130 8 (positive for 
diarrhoegenic 
E. coli) 
Generic E. coli tested for virulence 
factors. Non-O157 VTEC (3 samples), 
EIEC (2 samples), ETEC (1 sample), 
non-O157 VTEC and EIEC (2 samples) 
Gomez-Govea et al. (2012) Green onions, parsley, tomatoes, Serrano peppers, 
jalapeño peppers, cantaloupe (supermarkets) 
300 0 Screened for E. coli O157:H7 by 
VIDAS
(a)
 
Santos et al. (2012) Minimally processed leafy salads: romaine lettuce, 
spinach; mixed salads (with three or four different 
ingredients such as endive, radicchio, canonigo, green 
lettuce, purple lettuce, arugula, carrot, corn, cabbage, 
chicory and nuts) (retail) 
151 0 Screened for E. coli O157:H7 by 
VIDAS
(a)
 
Koseki et al. (2011) Iceberg lettuce (retail stores) 419 0 Screening with PCR 
De Giusti et al. (2010) RTE salads 699 0 Screened for E. coli O157:H7 by PCR 
Oliveira et al. (2010) Conventional and organic lettuce (farms) 72 × 2 (144) 0 Generic E. coli tested for several 
virulence genes 
Bohaychuk et al. (2009) Lettuce, spinach, tomatoes, carrots, green onions and 
strawberries (farmers‟ markets) 
673 0  
Microbial Data Program, 
Progress Update and 2009 
Data Summary 
(www.asm.usda.gov/mdp)  
Cantaloupe, cilantro, green onions, hot peppers, 
conventional and organic lettuce, spinach, alfalfa sprouts, 
round and Roma tomatoes (distribution centres and 
terminal (wholesale) markets) 
15354 51 (presumptive 
positive by 
PCR), isolate 
obtained from 
24 samples 
13 isolates were characterised as VTEC 
and 11 as ETEC. None of the VTEC 
isolates contained eae genes and did not 
belong to the most common serotypes. 
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Reference Commodity Number of 
samples analysed 
Positive 
samples 
Other information 
Microbial Data Program, 
Progress Update and 2008 
Data Summary 
(www.asm.usda.gov/mdp)  
Cantaloupe, bagged lettuce, spinach, alfalfa sprouts, 
tomatoes (distribution centres and terminal (wholesale) 
markets) 
10 330 35 (presumptive 
positive by 
PCR), isolate 
obtained from 
11 samples 
7 isolates were characterised as VTEC 
and 4 as ETEC. None of the VTEC 
isolates contained eae genes and did not 
belong to the most common serotypes 
Abadias et al. (2008) Fresh, minimally processed fruit, vegetables and sprouts 
(retail) 
300 0 Generic E. coli analysed for E. coli 
O157:H7 
Arthur et al. (2007) Muskmelon, scallions and green onions, organic and 
conventional leaf lettuce, head lettuce, parsley, cilantro, 
tomatoes 
1 183 0 Enrichment cultures positive for E. coli 
were assessed for verotoxigenicity 
Mora et al. (2007) Fresh vegetables (markets) 101 4 (positive for 
E. coli O157) 
 
Johnston et al. (2006) Leafy greens, herbs, melons, vegetables (packing sheds) 466 0 Screened for E. coli O157:H7. 
Johnston et al. (2005) Leafy greens, herbs, and cantaloupe 398 0 Screened for E. coli O157:H7 
Loncarevic et al. (2005) Lettuce (farms) 179 0 Screening for E. coli O157 by IMS
(b)
 
Sagoo et al. (2003b) Bagged prepared RTE salads (mostly mixed salads and 
also single type of salad) at retail 
3 820 0 Screened for E. coli O157 
Sagoo et al. (2003a) Open, RTE prepared salads from catering and retail 2 950 0 Screened for E. coli O157 
Johannessen et al. (2002) Lettuce, pre-cut salad, growing herbs, parsley/dill, 
strawberries (distributors/wholesalers) 
703 0 Screened for E. coli O157:H7 by IMS
(b)
 
Sagoo et al. (2001) RTE organic vegetables (grown in close proximity or in 
contact with soil (e.g. broccoli, cabbage, carrot, 
cauliflower, celeriac, celery, cress, lettuce, mushrooms, 
radish, spring onions, watercress), and other salad 
vegetables, such as cucumber, pepper and tomato) at 
retail 
3 200 0  
Gillespie et al. (2000) Cold, RTE slided meat from hotels, public houses, 
restaurants, cafés and residential care homes 
3 349 0 Screened for E. coli O157 by IMS
b
 
Little and de Louvois (1998) Cooked sliced meats from manufacturing butchers‟ 
premises 
1 491 0 Screened for E. coli O157:H7 by plating 
RTE pies/pasties from manufacturing butchers‟ premises 637 0 Screened for E. coli O157:H7 by plating 
Other cooked meat products from manufacturing 
butchers‟ premises 
55 0 Screened for E. coli O157:H7 by plating 
(a): Vitek Immunodiagnostic Assay System. 
(b): Immuno-magnetic separation. 
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5.2. Occurrence of VTEC in food animals 
5.2.1. EU monitoring data 
An overview of the data reported during 2007 to 2011 (from EFSA and ECDC (2010, 2011, 2012)) on 
occurrence of VTEC in food animals is provided in Table 17. In cattle, during the years 2007-2011 
VTEC was reported in 2.1 - 13.5 % of animals at the EU level, and VTEC O157 was found in 0.2 -
 2.3 % of these. The prevalence of VTEC in cattle varied between the MSs from 0 to 53.8 %. The 
prevalence at herd or holding level ranged between 6.1 to 12.6 % and 1.5 to 13.7 % for VTEC and 
VTEC O157, respectively. For slaughter batches, the prevalence ranged between 13.0 to 20.2 % for all 
VTEC, and 5.5 to 20.2 % for VTEC O157. The serogroup of the majority of the VTEC organisms 
were not specified, except for Austria, which reported a complete list. A wide range of serogroups was 
identified in those countries where serogrouping was undertaken. 
In sheep VTEC was detected in 0.9 - 20.1 % of the animal sampled by the reporting MSs during 2007-
2011, and 0 - 4.8 % of these samples were VTEC O157. The specimens taken from animals varied 
between the MSs and included faeces, ear, hide and fleece samples. Most of the VTEC serotypes were 
not specified, except for Austria, which reported a complete list. Data from goats were reported only 
in 2007, 2010 and 2011. The prevalence of VTEC in goats varied between 0 and 11.8 % and for 
VTEC O157, between 0  and 1.3 %. 
In conclusion, among food animals, most reported data on VTEC were from cattle and sheep, in which 
the reported VTEC and VTEC O157 prevalence varied widely between the MSs. In addition, other 
serogroups were reported from cattle.  
5.2.2. Data from literature 
Although the most common serogroups associated with human infection (i.e. VTEC O157) have been 
widely recovered from ruminants, a considerable number of non-O157 serogroups have also been 
identified. For example, in study of bovine faecal samples and soil samples collected from farms 
throughout Ireland over a 12-month period from 2007-2008. 107 VTEC isolates were recovered, 
representing 17 serogroups. O26:H11 and O145:H28 were detected, with O113:H4 being the most 
frequently isolated. Additionally, serogroups O2:H27, O13/O15:H2, and ONT:H27 carrying vtx1 
and/or vtx2 and eae genes were recovered (Monaghan et al., 2011).  
In a further study VTEC was detected by PCR- and culture-based methods in 67 % of 450 beef animal 
hides and 27 % of a similar number of carcasses screened for over a 12 month period. Forty isolates 
representing 12 VTEC serotypes (O5:H-, O13:H2, O26:H11, O33:H11, O55:H11, O113:H4, 
O128:H8, O136:H12, O138:H48, O150:H2, O168:H8 and ONT:H11) and 15 serotype/virulotype 
combinations were identified (Monaghan et al., 2012). 
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Table 17:  VTEC in cattle and sheep in EU, 2007-2011 (EFSA and ECDC, 2010, 2011, 2012, 2013)(a) 
Animal/ food 
category 
 2011     2010     2009     2008     2007   
 No. 
MS 
n VTEC 
(%) 
VTEC 
O157 
(%) 
 No. 
MS 
n VTEC 
(%) 
VTEC 
O157 
(%) 
 No. 
MS 
n VTEC 
(%) 
VTEC 
O157 
(%) 
 No. 
MS 
n VTEC 
(%) 
VTEC 
O157 
(%) 
 No. 
MS 
n VTEC 
(%) 
VTEC 
O157 
(%) 
Cattle 
(animal/single) 
6 2 788 3.7 0.8  9 6 800 13.5 0.2  8 5 239 6.6 2.3  8 4 937 2.1 0.3  9 4 746 2.8 2.1 
Cattle 
(herd/holding) 
2 2 617 12.6 1.5  2 2 089 10.0 4.7  3 925 6.1 3.6  1 328 16.2 13.7  2 559 8.1 6.3 
Cattle (slaughter 
batch) 
1 402 16.2 5.5  1 53 18.9 18.9  1 258 20.2 20.2  1 167 17.4 17.4  2 408 13.0 13.0 
Sheep (animals) 2 1054 12.3 4.8  5 773 17.5 0  3 324 20.1 0.3  3 671 3.1 1.6  4 533 0.9 0.4 
Goats (animals) 1 214 0 0  1 76 11.8 1.3  - - - -  - - - -  2 120 4.2 0 
(a): Only investigations with ≥25 samples included; n = number of samples; No. MSs = Number of Member States reporting data. 
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5.3. Assessment of public health risk associated with the contamination of RTE foods with 
VTEC 
For assessing public health risk as part of investigation of outbreaks or incidents of VTEC infection, 
rapid testing should be performed for the detection of verocytotoxins or genes encoding the production 
of such toxins in any suspect foods. Clinical outcomes should be used to assess the pathogenic 
potential of all strains, especially those that are newly-emerging and of „unusual‟ genotypes. 
Assessment of public health risk of foods contaminated with VTEC during outbreak investigations 
will be greatly assisted by preliminary detection or characterisation results (e.g. serogroup or vtx type) 
which identify similarities between the clinical isolates with those from food, even prior to full 
compilation of data establishing a common strain. Outbreak control responses may be strongly 
influenced by the severity of disease, setting, food type, additional microbiological data (particularly 
the presence of organisms indicative of faecal contamination) and supportive epidemiological 
evidence.  
In the absence of evidence of identification of human infection a different approach for the detection 
of VTEC in foods may be justified. Recent advances in microbiological detection methodologies allow 
the detection of vtx genes (as well as the presence of verocytotoxin) and this requires attempted 
isolation of VTEC for all samples where these targets are detected. When VTEC have been isolated, 
the application of the Karmali, „modified‟ Karmali and molecular classifications (see section 4.4.2.) 
indicate that specific groups should be regarded of high public health risk. These three classification 
systems may also be useful in assessing the public health risks of other VTEC „types‟. As already 
stated, it is not possible to fully define human pathogenic VTEC or identify factors for VTEC that 
absolutely predict the potential to cause human disease. Nevertheless, any RTE product containing one 
of the VTEC serogroups of group I (O157, O26, O103, O145, O111, O104) in combination with vtx 
and [1] eae or [2] aaiC and aggR genes should be considered as presenting a potentially high risk for 
diarrhoea and HUS. For any other serogroups in combination with the same genes, the potential risk is 
regarded as high for diarrhoea, but currently unknown for HUS. In the absence of these genes, current 
available data do not allow any inference regarding potential risks. Additional epidemiological and 
microbiological data (particularly the presence of organisms indicative of faecal contamination) is also 
important in assessing appropriate risk management options.  
5.4. Conclusions 
VTEC has been recovered from a range of different animal species and food categories. The most 
widely used analytical method only aims at detecting VTEC O157, whereas fewer investigations have 
been conducted with analytical methods aiming at detecting all or selected VTEC serotypes. 
Prevalence data on VTEC from food and animals reported at EU level are not sufficiently comparable 
to enable any conclusions to be made on trends over the years. Nevertheless VTEC, including some 
serogroups associated with cases of human infection, have been identified in a range of different 
animal species and food categories. 
On the basis of the proposed molecular classification scheme, any RTE product contaminated with an 
isolate of one of the VTEC serogroups of group I (O157, O26, O103, O145, O111, O104) in 
combination with vtx and [1] eae or [2] aaiC and aggR genes should be considered as presenting a 
potentially high risk for diarrhoea and HUS. For any other serogroups in combination with the same 
genes, the potential risk is regarded as high for diarrhoea, but currently unknown for HUS. In the 
absence of these genes, current available data do not allow any inference regarding potential risks. 
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ANSWERS TO TERMS OF REFERENCE (TORS) 
ToR 1: the „seropathotype‟ concept – the limitation to “relevant” serotypes O157, O26, O103, 
O111, O145, O121, O91, O104, O113
4
; i.e., can pathogenicity be excluded for defined VTEC 
serotypes? 
 The seropathotype classification of Karmali et al. (2003) does not define pathogenic VTEC 
nor does it provide an exhaustive list of pathogenic serotypes. Instead it classifies VTEC 
based on their reported frequency in human disease, their known association with outbreaks 
and their severity of the outcome including haemolytic uraemic syndrome (HUS) and 
haemorrhagic colitis (HC). 
 Pathogenicity can neither be excluded nor confirmed for a given VTEC serogroup or serotype 
based on the seropathotype concept or analysis of the public health surveillance data. 
 It is not possible to fully define human pathogenic VTEC or identify factors for VTEC that 
absolutely predict the potential to cause human disease. 
ToR 2: justification of the statement: „seropathotypes D and E are not HUS-associated and are 
uncommon in man or only found in non-human sources’4; 
 In the period 2007-2010, 13 545 confirmed VTEC infections and 777 HUS cases were 
reported in the EU. Isolates from 85 % of these cases were not fully serotyped and could 
therefore not be classified using the Karmali seropathotype concept. 
 The Karmali seropathotype D group was associated with 5 % of cases that were fully 
serotyped. Seropathotype E group, defined by Karmali et al. (2003) as non-human only, 
included 14 confirmed cases (0.7 %) of human infection. Furthermore approximately 27 % of 
strains from human cases could not be assigned to a seropathotype group as these were not 
listed by Karmali et al. (2003). 
 There were no HUS cases reported for the serotypes included in seropathotype groups D and 
E, but there were 17 HUS cases reported that could not be assigned to a seropathotype group. 
 Using a modification of the Karmali approach based on the health outcome of reported 
confirmed human VTEC cases in the EU during 2007-2010, in cases when full serotyping has 
been undertaken all serotypes associated with severe disease (HUS) could be categorised as 
seropathotype group „haemolytic uraemic syndrome (HUS)-associated serotype(s)‟ or HAS. 
Under the new scheme, the HAS group now includes the serotypes causing the majority 
(86 %) of the deaths, 71 % of the hospitalisations, 100 % of the HUS cases and 86 % of the 
cases with bloody diarrhoea. 
 By this „modified‟ approach, in cases when full serotyping of isolates has been undertaken, all 
serotypes associated with severe disease are automatically categorised in the HAS group. 
Furthermore, as new information becomes available, serotypes may be reclassified and the 
model updated. 
ToR 3: an alternative concept based on detection of verocytotoxins or genes encoding for 
verocytotoxins in isolates; 
 The detection of verocytotoxins alone or genes encoding for such verocytotoxins is not a 
sound scientific basis for assessing the disease risk to the consumer. 
 There is no single or combination of marker(s) that defines a „pathogenic‟ VTEC. Strains 
positive for verocytotoxin 2 gene (vtx2)- and eae (intimin production)- or [aaiC (secreted 
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protein of EAEC) plus aggR (plasmid-encoded regulator)] genes are associated with a higher 
risk of more severe illness than other virulence factor combinations. Other virulence gene 
combinations and/or serotypes may also be associated with severe disease in humans, 
including HUS. 
 A molecular approach, utilising genes encoding virulence characteristics additional to the 
presence of vtx genes, is proposed. This molecular approach must be regarded as provisional 
because screening VTEC for the presence of eae, aaiC or aggR genes is not routinely 
undertaken. This scheme has the advantage of overcoming problems associated with the lack 
of flagella „H‟ antigen typing. The performance of this proposed approach needs to be verified 
with well-characterised isolates from cases of human infection and from food-producing 
animals and foods. 
ToR 4: the contribution by VTEC to diarrhoeal cases and to more severe outcomes in the EU, 
based on hazard identification and characterisation, and under-reporting in EU; 
 The health outcome has not been reported for all cases (reported for diarrhoea: 53 % of cases; 
and for HUS: 59 % of cases) of the reported confirmed VTEC cases in the EU between 2007 
and 2010. Most patients (ca. 64 %) presented with only diarrhoea. VTEC infection resulted in 
HUS in around 10 % of the cases. 
 Detection of VTEC is highly dependent on the methods applied to clinical specimens and the 
strategies for application of these methods vary between different MSs. 
 The degree of under-estimation (including under-ascertainment and under-reporting) of VTEC 
O157 infections has been estimated in seven EU MSs. Disease-multipliers differ widely 
between EU countries, ranging from 13 to 87. 
 The 2011 O104:H4 outbreak has clearly demonstrated the difficulty of predicting the 
emergence of „new‟ pathogenic VTEC types by only looking at the presence of the eae gene 
or by focusing on a restricted panel of serogroups. 
 The ISO/TS 13136:2012 standard improves the concept of detecting VTEC in food. 
ToR 5: the public health risk associated with the contamination of RTE foods with VTEC, 
considering either the seropathotype concept or the detection of verocytotoxins or genes 
encoding the production of such toxins in isolates. 
 VTEC has been recovered from a range of different animal species and food categories. The 
most widely used analytical method only aims at detecting VTEC O157, whereas fewer 
investigations have been conducted with analytical methods aiming at detecting all or selected 
serotypes of VTEC. Based on available data, the genetic diversity of VTEC strains in the food 
chain appears to be greater than from clinical cases. As a consequence, virulence potential of a 
given VTEC strain among food chain isolates cannot be accurately predicted. 
 Pathogenicity can neither be excluded nor confirmed for a given VTEC serogroup or serotype 
based on the seropathotype concept or analysis of the public health surveillance data. 
 On the basis of the proposed molecular classification scheme, any RTE product contaminated 
with an isolate of one of the VTEC serogroups of group I (O157, O26, O103, O145, O111, 
O104) in combination with vtx and [1] eae or [2] aaiC and aggR genes should be considered 
as presenting a potentially high risk for diarrhoea and HUS. For any other serogroups in 
combination with the same genes, the potential risk is regarded as high for diarrhoea, but 
currently unknown for HUS. In the absence of these genes, current available data do not allow 
any inference regarding potential risks. 
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RECOMMENDATIONS 
 The inclusion of aaiC and aggR genes in the proposed molecular approach is due to the 
O104:H4 outbreak, which was caused by a highly virulent strain. This was an exceptional 
event and future surveillance will provide data that may be used to review the inclusion of 
these virulence factors. Thus screening VTEC for the presence of aaiC and aggR genes should 
be performed on isolates from human, food and animal sources, to address this question. 
 For public health investigation of VTEC infection, clinical and/or food samples should be 
screened by PCR for the presence of the vtx genes. If positive, all efforts should be made to 
isolate and characterise the causative organism.  
 Verification and periodic revision of the proposed molecular approach in light of new 
epidemiological information. 
 In accordance with the ISO specifications, international harmonisation of nomenclature of 
VTEC and its virulence factors, using STEC instead of VTEC and stx instead of vtx or vt may 
be considered. 
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DOCUMENTATION PROVIDED TO EFSA 
1. E-mail dated 26/09/2012 from the Austrian Federal Ministry of Health providing data of the 
human VTEC cases in Austria in 2009-2012. 
2. Annex to the mandate as provided by the Austrian Federal Ministry of Health19.  
Data: EFSA, ECDC, Germany and Austria regarding the Austrian request: “Verocytotoxin 
producing E. coli (VTEC) – “seropathotype concept” and scientific criteria regarding 
pathogenicity assessment”. May 2012. Submitted by the Austrian Federal Ministry of Health. 
 
Austrian data (National Reference Laboratory for E. coli, VTEC data 2009 – 2011, human samples) 
demonstrate that the cause of the majority of human cases (41 %) are other serotypes than the types 
mentioned in the EC draft paper (Regulation (EC) No. 2073/2005 proposal 2012) based on EFSA 
“seropathotype concept”: 
 
VTEC HUS cases Austria 2009-2011 (n = 31): 
 23 % of HUS cases were caused by “other serotypes” → no isolate, no pathogenicity 
assessment possible according to the ISO method
7
 
 25 % of HUS cases were caused by eae neg. VTEC → no isolate, no pathogenicity 
assessment possible according to the ISO method
7
 
                                                     
19 The Annex is shown above in the original format. Explanatory footnotes have been added by EFSA. 
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Data, kindly provided from the German NRC for Salmonella and other enterics demonstrate, that 
in Germany the proportion of “non top five O-serotypes” in human isolates was even higher. It was 
67 % in the years 1999-2004 (n = 3 424)! The situation is approximately the same now (personal 
communication). 
 
German data: (German National Reference Center for Salmonella and other enterics, VTEC data 1999 – 2004, human 
samples (n = 3424) 
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Technical Report: “Shiga toxin/verotoxin-producing Escherichia coli in humans, food and animals in 
the EU/EEA, with special reference to the German outbreak strain STEC O104, Stockholm: ECDC; 
2011”: 
 
 
 
Total cases: 3573 minus 1008 cases (untyped/untypeable): 2565 cases (serotyped). Of these 2565 
(serotyped) cases 371 cases belong to other serotypes (O91, O113, O128, O146, “others”) than the 
serotypes mentioned in the EC draft paper (O157, O26, O103, O111, O145, O104). 
VTEC: EFSA ECDC, Zoonoses & Outbreaks 2010
20
: 
 “Others” 2010: at least about 10 % of human cases 
 Assuming “NT” VTEC are predominantly “others”: about 40 % of human cases caused by 
“others”! 
                                                     
20 EFSA Journal, 10(3):2597, 442 pp. 
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Many MS (Austria, Denmark, Germany, the Netherlands): number of reported cases caused by 
“others” greater than cases caused by VTEC O157 – × 3 in Austria and Denmark! 
Most MS: predominantly O157 → a strong indication for massive underreporting of “others”! 
 
VTEC-seropathotype and scientific criteria regarding pathogenicity assessment  
 
EFSA Journal 2013;11(4):3138 56 
Without considering the “underreporting bias”, these “others” constitute a certainly 
considerable and unacceptably high number of serotyped VTEC causing human cases and HUS 
belonging to “seropathotypes D and E ... not HUS-associated and ... uncommon in man or found 
only in non-human sources” according to the EFSA opinion 201121: 
 About 15 % – EFSA/ECDC data – Technical Report 2009 – considering serotypes discussed 
by EFSA
20
, or 301 cases (comprises of 244 cases “others”, 47 cases O146 and 26 cases O128) 
 41 % – Austrian data, 25 % of HUS cases 
 67 % – data Germany 
 10 % - 40 % according to EFSA ECDC data 201020 
ECDC – European Centre for Disease Control: 10 VTEC strains were selected for an external 
quality assurance programme 2010, results published in 2012: 
10 different VTEC were selected, the “most commonly reported strains”, there were no statements 
regarding restrictions (five strains ISO 13136, six strains in the proposal amending Reg. (EC) No. 
2073/2005) concerning pathogenicity.  
Relevance of the “seropathotype concept” and ISO 13136: using this concept and in consequence ISO 
13136 accredited food laboratories would fail to identify relevant strains distributed by ECDC for 
quality assurance purposes: 
 
 
 
                                                     
21 EFSA Journal, 9(11):2424, 101 pp. 
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Austrian data regarding “underreporting bias” 
Following a food-borne outbreak in an Austrian province (Tirol) caused by VTEC the local health 
insurance agreed to paying for VTEC tests in clinical microbiology. 
Result: provinces – e.g. Niederösterreich, Oberösterreich, twice the population compared to 
Tirol, report about half the cases: 
Table: preliminary data – reported infectious diseases in Austria. “E” (Erkrankungsfälle) stands for 
“illness”, “T” (Todesfälle) for “deaths“. 
Link:http://bmg.gv.at/cms/home/attachments/2/9/6/CH1258/CMS1314254664782/ja_2011_vorlaeufig
.pdf (Austrian Ministry for Health  - website) 
 
 
 
Statistik Austria: Austrian population, provinces, since 1961: 
http://www.statistik.at/web_de/statistiken/bevoelkerung/bevoelkerungsstand_und_veraenderung/bevoe
lkerung_im_jahresdurchschnitt/index.html 
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APPENDICES 
A.  CLINICAL OUTCOME OF CONFIRMED HUMAN VTEC CASES DURING 2007-2010 BY SEROTYPE 
Table 1:  Clinical outcome of confirmed VTEC cases in humans in the EU(a) by serotype. TESSy data, 2007-2010 as provided by the European Centre for 
Disease Prevention and Control (ECDC) 
Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
  O157 6 658 1 361 7 5 290 394 616 5 648 384 2 121 4 153 1 623 1 696 167 3 172 
NFT NFT O157:HNT 5 610 960 2 4 648 348 584 4 678 288 1 628 3 694 1 337 1 460 140 2 673 
A HAS (A/B/C) O157:H7 774 200 4 570 26 14 734 69 280 425 172 158 20 424 
A HAS (A/B/C) O157:H- 273 200 1 72 20 18 235 27 213 33 114 78 7 74 
NLK D O157:H11 1 1     1   1    1 
  ONT 4 035 3 093 7 935 30 20 3 985 191 2 941 903 312 1 535 60 2 128 
NFT NFT ONT:HNT 3 904 3 010 7 887 24 19 3 861 185 2 852 867 305 1 464 54 2 081 
NFT NFT ONT:H- 36 31  5 1  35  32 4 2 28 1 5 
NFT NFT ONT:H7 14 4  10   14  3 11 1 2  11 
NFT NFT ONT:H2 12 8  4   12 4 8   5 1 6 
NFT NFT ONT:H19 10 3  7 1 1 8 1 3 6  3  7 
NFT NFT ONT:H18 7 5  2   7  6 1 2 4  1 
NFT NFT ONT:H28 6 4  2   6  4 2  4  2 
NFT NFT ONT:H21 6 3  3 1  5  4 2  4  2 
NFT NFT ONT:H25 5   5   5 1 1 3  2  3 
NFT NFT ONT:H16 4 4     4  4  1 3   
NFT NFT ONT:H6 4 1  3   4  1 3    4 
NFT NFT ONT:H10 4 4     4  3 1  3  1 
NFT NFT ONT:H9 3 1  2   3  1 2  1  2 
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
NFT NFT ONT:H45 2 1  1   2  1 1  1  1 
NFT NFT ONT:H8 2   2 1  1  2   1 1  
NFT NFT ONT:H14 2 1  1 1  1  2    1 1 
NFT NFT ONT:H1 2 2     2  2    1 1 
NFT NFT ONT:H4 2 1  1 1  1  2   1 1  
NFT NFT ONT:H30 2 2     2  2  1 1   
NFT NFT ONT:H20 1 1     1  1   1   
NFT NFT ONT:H29 1 1     1  1   1   
NFT NFT ONT:H12 1 1     1  1   1   
NFT NFT ONT:H49 1 1     1  1   1   
NFT NFT ONT:H23 1 1     1  1   1   
NFT NFT ONT:H5 1 1     1  1   1   
NFT NFT ONT:H39 1 1     1  1   1   
NFT NFT ONT:H26 1 1     1  1   1   
  O26 780 514 1 265 39 77 664 100 514 166 94 336 45 305 
NFT NFT O26:HNT 650 402 1 247 33 66 551 95 404 151 78 254 41 277 
B HAS (A/B/C) O26:H11 107 98  9 4 8 95 5 93 9 11 70 4 22 
NLK D O26:H- 20 11  9 2 3 15  14 6 3 11  6 
NLK D O26:H7 2 2     2  2  2    
NLK D O26:H34 1 1     1  1   1   
  O103 370 306   64 14 21 335 7 302 61 31 198 11 130 
NFT NFT O103:HNT 230 180  50 4 6 220 7 176 47 19 95 6 110 
B D O103:H2 131 121  10 10 15 106  121 10 11 99 5 16 
NLK D O103:H- 6 3  3   6  3 3  3  3 
NLK D O103:H7 1   1   1   1    1 
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
NLK D O103:H11 1 1     1  1   1   
D D O103:H25 1 1     1  1  1    
  O145 220 147   73 10 24 186 23 141 56 25 78 13 104 
NFT NFT O145:HNT 147 95  52 8 10 129 19 89 39 18 38 7 84 
B HAS (A/B/C) O145:H- 33 24  9 2 1 30 2 20 11 6 16  11 
NLK HAS (A/B/C) O145:H28 19 7  12  13 6 2 11 6  5 6 8 
NLK D O145:H34 18 18     18  18   18   
NLK D O145:H7 2 2     2  2  1 1   
NLK D O145:H20 1 1     1  1     1 
  O91 202 169   33 1 2 199 1 175 26 7 106 3 86 
NFT NFT O91:HNT 139 119  20 1  138  124 15 3 63  73 
NLK D O91:H- 44 37  7  2 42  37 7 3 32 2 7 
NLK D O91:H14 11 7  4   11  9 2  7 1 3 
NLK D O91:H7 3 3     3  1 2 1   2 
NLK HAS (A/B/C) O91:H10 2 1  1   2 1 1   1  1 
C D O91:H21 2 1  1   2  2   2   
NLK D O91:H26 1 1     1  1   1   
  O111 134 94 1 39 4 4 126 22 89 23 15 63 2 54 
NFT NFT O111:HNT 97 65 1 31 4 3 90 18 62 17 11 37 2 47 
B HAS (A/B/C) O111:H- 29 26  3  1 28 3 24 2 2 24  3 
NLK HAS (A/B/C) O111:H8 6 3  3   6 1 3 2 2 2  2 
NLK D O111:H2 1   1   1   1    1 
NLK D O111:H4 1   1   1   1    1 
  O128 108 83   25 1 3 104 5 88 15 5 58 5 40 
NFT NFT O128:HNT 65 43  22 1 1 63 4 49 12 3 25 1 36 
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
NLK HAS (A/B/C) O128:H2 30 28  2  2 28 1 28 1 1 24 2 3 
NLK D O128:H- 13 12  1   13  11 2 1 9 2 1 
  O146 102 81   21 2 2 98   82 20 4 62 7 29 
NFT NFT O146:HNT 45 29  16  1 44  32 13 1 20 2 22 
D D O146:H21 27 23  4 2  25  25 2 2 21 2 2 
NLK D O146:H28 18 17  1   18  14 4  13 2 3 
NLK D O146:H- 9 9    1 8  9  1 7 1  
NLK D O146:H5 1 1     1  1     1 
NLK D O146:H10 1 1     1   1    1 
NLK D O146:H31 1 1     1  1   1   
  O117 76 48   28   4 72   58 18 1 49 1 25 
D D O117:H7 55 36  19  1 54  41 14  34 1 20 
NFT NFT O117:HNT 13 6  7  3 10  10 3  9  4 
NLK D O117:H- 6 5  1   6  5 1  5  1 
NLK D O117:H11 1   1   1  1  1    
NLK D O117:H8 1 1     1  1   1   
  O113 61 43   18 3   58 2 43 16 3 26 3 29 
NFT NFT O113:HNT 28 17  11   28 2 16 10 1 6  21 
D D O113:H4 16 15  1 1  15  16  2 11 1 2 
C D O113:H21 9 4  5 1  8  5 4  3 1 5 
NLK D O113:H6 5 5     5  5   5   
E D O113:H- 3 2  1 1  2  1 2  1 1 1 
  O121 56 19   37 2 5 49 11 19 26 1 17 2 36 
NFT NFT O121:HNT 29 3  26 1 1 27 2 2 25  2  27 
B HAS (A/B/C) O121:H19 23 14  9 1 4 18 8 15  1 13 2 7 
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
C D O121:H- 2 2     2  2   2   
NLK D O121:H7 1   1   1   1    1 
NLK HAS (A/B/C) O121:H2 1   1   1 1      1 
  O63 55 38   17 2   53 1 43 11 9 30 2 14 
NLK D O63:H6 31 17  14 2  29  23 8 1 18 2 10 
NFT NFT O63:HNT 19 16  3   19 1 15 3 5 10  4 
NLK D O63:H7 3 3     3  3  2 1   
NLK D O63:H19 1 1     1  1  1    
NLK D O63:H10 1 1     1  1   1   
  O76 34 20   14     34 1 19 14 1 14 1 18 
NFT NFT O76:HNT 17 6  11   17  6 11 1 3  13 
NLK HAS (A/B/C) O76:H19 15 13  2   15 1 13 1  11 1 3 
E D O76:H7 2 1  1   2   2    2 
  O156 34 21   13     34   21 13 3 16   15 
NLK D O156:H7 14 3  11   14  3 11 1 2  11 
NFT NFT O156:HNT 9 8  1   9  8 1 1 5  3 
E D O156:H- 5 5     5  5   5   
NLK D O156:H25 4 3  1   4  3 1 1 2  1 
NLK D O156:H34 2 2     2  2   2   
  O174 32 27   5 3   29 4 25 3 3 13 1 15 
NFT NFT O174:HNT 12 10  2   12  10 2 1 1  10 
NLK HAS (A/B/C) O174:H21 11 9  2   11 1 9 1 1 8 1 1 
NLK HAS (A/B/C) O174:H2 5 4  1 3  2 3 2  1   4 
D D O174:H8 3 3     3  3   3   
NLK D O174:H28 1 1     1  1   1   
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
  O55 31 27   4     31 3 27 1 5 16 3 7 
NFT NFT O55:HNT 22 20  2   22 3 19  4 9 2 7 
NLK D O55:H12 6 4  2   6  5 1  5 1  
NLK D O55:H7 3 3     3  3  1 2   
  O5 25 18   7 4   21 1 20 4 1 16 1 7 
NFT NFT O5:HNT 15 9  6 4  11 1 11 3 1 7 1 6 
C D O5:H- 8 7  1   8  7 1  7  1 
NLK D O5:H19 1 1     1  1   1   
NLK D O5:H16 1 1     1  1   1   
  O8 20 9   11     20   12 8 2 8 1 9 
NFT NFT O8:HNT 14 6  8   14  8 6 2 4 1 7 
NLK D O8:H9 2 1  1   2  1 1  1  1 
NLK D O8:H8 1 1     1  1   1   
NLK D O8:H12 1 1     1  1   1   
NLK D O8:H- 1   1   1  1   1   
NLK D O8:H25 1   1   1   1    1 
  O78 20 19   1 1   19 1 18 1 1 15   4 
NFT NFT O78:HNT 14 13  1 1  13 1 13   10  4 
NLK D O78:H- 6 6     6  5 1 1 5   
  O177 19 15   4   1 18   14 5   9 1 9 
NFT NFT O177:HNT 12 10  2   12  9 3  5  7 
NLK D O177:H- 5 3  2  1 4  3 2  2 1 2 
NLK D O177:H45 1 1     1  1   1   
NLK D O177:H11 1 1     1  1   1   
  O118 19 13   6     19   14 5 3 7   9 
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
NFT NFT O118:HNT 14 10  4   14  12 2 3 5  6 
NLK D O118:H16 3 1  2   3  1 2  1  2 
NLK D O118:H12 1 1     1  1   1   
NLK D O118:H4 1 1     1   1    1 
  O125 18 17   1     18   17 1 2 10 2 4 
NFT NFT O125:HNT 12 11  1   12  11 1 1 6 1 4 
NLK D O125:H6 6 6     6  6  1 4 1  
  O2 17 13   4     17   16 1 1 12   4 
NFT NFT O2:HNT 8 6  2   8  7 1  4  4 
NLK D O2:H6 6 4  2   6  6   6   
NLK D O2:H14 1 1     1  1   1   
NLK D O2:H20 1 1     1  1   1   
NLK D O2:H29 1 1     1  1  1    
  O153 16 4   12     16   6 10   4 1 11 
NFT NFT O153:HNT 14 3  11   14  5 9  3 1 10 
NLK D O153:H2 1 1     1  1   1   
NLK D O153:H25 1   1   1   1    1 
  O166 15 11   4   1 14   12 3 1 9   5 
NFT NFT O166:HNT 8 5  3   8  5 3 1 2  5 
NLK D O166:H28 5 4  1  1 4  5   5   
NLK D O166:H15 1 1     1  1   1   
NLK D O166:H30 1 1     1  1   1   
  O84 13 5   8   1 12   8 5 1 5   7 
NFT NFT O84:HNT 7 1  6  1 6  2 5    7 
E D O84:H- 2 2     2  2  1 1   
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
NLK D O84:H28 2   2   2  2   2   
NLK D O84:H1 1 1     1  1   1   
NLK D O84:H2 1 1     1  1   1   
  O6 13 11   2   1 12 1 9 3 2 5 2 4 
NFT NFT O6:HNT 6 5  1  1 5 1 4 1 2 1 1 2 
NLK D O6:H- 4 3  1   4  3 1  3  1 
NLK D O6:H25 1 1     1  1   1   
NLK D O6:H10 1 1     1   1    1 
NLK D O6:H19 1 1     1  1    1  
  O1 13 13     1   12 2 11     4   9 
NFT NFT O1:HNT 11 11     11 1 10   3  8 
NLK D O1:H20 1 1     1  1   1   
NLK HAS (A/B/C) O1:H42 1 1   1   1      1 
  O86 12 11   1     12 1 10 1   6   6 
NFT NFT O86:HNT 10 10     10  10   6  4 
NLK D O86:H- 1 1     1   1    1 
NLK HAS (A/B/C) O86:H27 1   1   1 1      1 
  O114 12 10   2     12 2 9 1 1 8   3 
NFT NFT O114:HNT 11 9  2   11 2 8 1 1 7  3 
NLK D O114:H41 1 1     1  1   1   
  O181 12 12     1   11   11 1   8   4 
NLK D O181:H49 7 7   1  6  6 1  3  4 
NLK D O181:H16 4 4     4  4   4   
NFT NFT O181:HNT 1 1     1  1   1   
  O142 11 7   4     11   7 4   5   6 
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
NFT NFT O142:HNT 8 7  1   8  7 1  5  3 
NLK D O142:H34 1   1   1   1    1 
NLK D O142:H- 1   1   1   1    1 
NLK D O142:H33 1   1   1   1    1 
  O80 11 7   4     11 2 8 1 1 7   3 
NFT NFT O80:HNT 6 4  2   6 1 5  1 4  1 
NLK HAS (A/B/C) O80:H2 4 2  2   4 1 3   2  2 
NLK D O80:H- 1 1     1   1  1   
  O43 10 7   3     10   8 2 1 6   3 
NFT NFT O43:HNT 6 4  2   6  5 1 1 4  1 
NLK D O43:H2 4 3  1   4  3 1  2  2 
  O123 9 2   7     9 1 4 4 1 1   7 
NFT NFT O123:HNT 6 2  4   6  3 3 1 1  4 
NLK HAS (A/B/C) O123:H2 2   2   2 1 1     2 
NLK D O123:H19 1   1   1   1    1 
  O44 9 9         9   9     5   4 
NFT NFT O44:HNT 9 9     9  9   5  4 
  O20 8 6   2 1   7 1 6 1 1 4 1 2 
NLK D O20:H45 2 1  1 1  1  2   2   
NLK D O20:H49 1 1     1  1   1   
NLK D O20:H12 1 1     1  1  1    
NLK D O20:H16 1 1     1   1    1 
NFT NFT O20:HNT 1 1     1 1      1 
NLK D O20:H25 1 1     1  1    1  
NLK D O20:H4 1   1   1  1   1   
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
  O104 8 3   5 1 3 4 1 6 1   4 2 2 
NFT NFT O104:HNT 4 1  3  2 2  3 1  3  1 
NLK D O104:H2 2 1  1   2  2   1 1  
NLK D O104:H- 1   1  1   1    1  
C HAS (A/B/C) O104:H21 1 1   1   1      1 
  O100 8 8         8   8     2   6 
NFT NFT O100:HNT 7 7     7  7   2  5 
NLK D O100:H- 1 1     1  1     1 
  ONON-O157 7     7 1   6   1 6     1 6 
NFT NFT ONON-O157:HNT 7   7 1  6  1 6   1 6 
  O178 7 7       1 6   7   1 5   1 
NFT NFT O178:HNT 3 3    1 2  3   2  1 
NLK D O178:H7 3 3     3  3  1 2   
NLK D O178:H19 1 1     1  1   1   
  O126 7 6   1     7 2 5   1 1   5 
NFT NFT O126:HNT 6 5  1   6 2 4  1 1  4 
NLK D O126:H- 1 1     1  1     1 
  O119 6 5   1     6   5 1   3   3 
NFT NFT O119:HNT 4 3  1   4  4   2  2 
NLK D O119:H- 1 1     1  1   1   
NLK D O119:H4 1 1     1   1    1 
  O25 6 5   1     6   6     1   5 
NFT NFT O25:HNT 6 5  1   6  6   1  5 
  O165 6 5   1 1   5   5 1 1 3   2 
NLK D O165:H- 2 2     2  2   2   
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
NFT NFT O165:HNT 2 2   1  1  2  1   1 
C D O165:H25 2 1  1   2  1 1  1  1 
  O130 5 4   1     5   4 1 1 1   3 
NFT NFT O130:HNT 3 3     3  3  1 1  1 
NLK D O130:H11 2 1  1   2  1 1    2 
  O18 5 5         5   4 1   1   4 
NFT NFT O18:HNT 4 4     4  4   1  3 
NLK D O18:H16 1 1     1   1    1 
  O127 5 5         5 1 4   1 1   3 
NFT NFT O127:HNT 5 5     5 1 4  1 1  3 
  O101 5 3   2     5   3 2 1 2   2 
NFT NFT O101:HNT 2 1  1   2  1 1 1   1 
NLK D O101:H9 1 1     1  1   1   
NLK D O101:H- 1   1   1   1    1 
NLK D O101:H7 1 1     1  1   1   
  O38 5 2   3     5   2 3   1   4 
NFT NFT O38:HNT 4 1  3   4  1 3    4 
NLK D O38:H26 1 1     1  1   1   
  O112 5 5         5   5     5     
NLK D O112:H8 2 2     2  2   2   
NFT NFT O112:HNT 1 1     1  1   1   
NLK D O112:H18 1 1     1  1   1   
NLK D O112:H2 1 1     1  1   1   
  O132 5 5         5   5   1 3   1 
NLK D O132:H34 2 2     2  2  1 1   
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
NFT NFT O132:HNT 1 1     1  1     1 
NLK D O132:H10 1 1     1  1   1   
NLK D O132:H21 1 1     1  1   1   
  O105 5   1 4 1 3 1 1 4     1 3 1 
NFT NFT O105:HNT 3   3  3   3    3  
NLK HAS (A/B/C) O105:H18 2  1 1 1  1 1 1   1  1 
  O27 5 3   2 1 1 3   3 2   1 1 3 
NLK D O27:H30 3 3   1  2  3   1 1 1 
NFT NFT O27:HNT 2   2  1 1   2    2 
  O21 4 3   1     4   3 1   2   2 
NFT NFT O21:HNT 3 2  1   3  2 1  1  2 
NLK D O21:H21 1 1     1  1   1   
  O15 4 2   2 1   3   4   1 2 1   
NFT NFT O15:HNT 1 1     1  1   1   
NLK D O15:H27 1   1 1    1    1  
NLK D O15:H- 1   1   1  1  1    
NLK D O15:H2 1 1     1  1   1   
  O163 4 3   1     4   2 2   1   3 
NFT NFT O163:HNT 3 2  1   3  2 1    3 
NLK D O163:H19 1 1     1   1  1   
  O88 4 4         4   4     4     
E D O88:H25 2 2     2  2   2   
NLK D O88:H- 2 2     2  2   2   
  O11 4 4         4 1 3   1 1   2 
NFT NFT O11:HNT 2 2     2 1 1  1   1 
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
NLK D O11:H4 2 2     2  2   1  1 
  O158 4 4         4   4   1 1   2 
NFT NFT O158:HNT 4 4     4  4  1 1  2 
  O71 4 1   3     4   2 2   1   3 
NFT NFT O71:HNT 3   3   3  1 2    3 
NLK D O71:H- 1 1     1  1   1   
  O4 4 3   1   1 3   4     1 1 2 
NFT NFT O4:HNT 3 2  1  1 2  3    1 2 
NLK D O4:H- 1 1     1  1   1   
  O75 4 4         4   4     3 1   
NLK D O75:H8 2 2     2  2   2   
NFT NFT O75:HNT 1 1     1  1    1  
NLK D O75:H- 1 1     1  1   1   
  O176 4 3   1     4   4     3   1 
NLK D O176:H- 3 3     3  3   3   
NFT NFT O176:HNT 1   1   1  1     1 
  O17 3 2 1       3   2 1   2   1 
NLK D O17:H41 2 1 1    2  1 1  1  1 
NLK D O17:H18 1 1     1  1   1   
  O115 3 3         3   3     2   1 
NFT NFT O115:HNT 2 2     2  2   1  1 
NLK D O115:H- 1 1     1  1   1   
  O53 3 2   1     3 1 1 1 1 1   1 
NFT NFT O53:HNT 2 2     2 1 1  1 1   
NLK D O53:H7 1   1   1   1    1 
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
  O182 3 3         3   3     3     
NLK D O182:H25 3 3     3  3   3   
  O7 3 1   2     3 1 1 1   1   2 
NFT NFT O7:HNT 2 1  1   2  1 1  1  1 
NLK HAS (A/B/C) O7:H6 1   1   1 1      1 
  O186 3 3         3   3     3     
NLK D O186:H2 2 2     2  2   2   
NLK D O186:H- 1 1     1  1   1   
  O98 3     3     3   3   1 2     
NFT NFT O98:HNT 2   2   2  2  1 1   
NLK D O98:H- 1   1   1  1   1   
  O12 3 1   2     3   1 2   2   1 
NFT NFT O12:HNT 2   2   2   2  1  1 
NLK D O12:H- 1 1     1  1   1   
  O54 3 3         3   3   1 1   1 
NLK D O54:H21 2 2     2  2  1 1   
NFT NFT O54:HNT 1 1     1  1     1 
  O3 3 1   2   1 2   2 1 1   1 1 
NFT NFT O3:HNT 3 1  2  1 2  2 1 1  1 1 
  O102 3 3         3   3     2 1   
NLK D O102:H6 2 2     2  2   1 1  
NLK D O102:H- 1 1     1  1   1   
  O35 3 2   1     3   2 1 2     1 
NFT NFT O35:HNT 2 1  1   2  1 1 1   1 
NLK D O35:H19 1 1     1  1  1    
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
  O168 3 2   1     3   3     3     
NLK D O168:H8 2 1  1   2  2   2   
NLK D O168:H28 1 1     1  1   1   
  O39 3 3         3   3   1 2     
NLK D O39:H- 1 1     1  1   1   
NLK D O39:H48 1 1     1  1  1    
NLK D O39:H21 1 1     1  1   1   
  O89 3 3         3   3     3     
NLK D O89:H- 1 1     1  1   1   
NLK D O89:H8 1 1     1  1   1   
NLK D O89:H4 1 1     1  1   1   
  O40 3 3         3   3     3     
NLK D O40:H8 2 2     2  2   2   
NLK D O40:H7 1 1     1  1   1   
  O45 3 1   2 1   2   3     1 1 1 
NFT NFT O45:HNT 2   2 1  1  2    1 1 
NLK D O45:H2 1 1     1  1   1   
  O74 2 2         2   2         2 
NFT NFT O74:HNT 2 2     2  2     2 
  O51 2     2     2     2       2 
NFT NFT O51:HNT 1   1   1   1    1 
NLK D O51:H- 1   1   1   1    1 
  O107 2 2         2   2     2     
NLK D O107:H21 1 1     1  1   1   
NLK D O107:H- 1 1     1  1   1   
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
  O137 2 2         2   1 1   1   1 
NFT NFT O137:HNT 2 2     2  1 1  1  1 
  O141 2 2         2   2     1   1 
NFT NFT O141:HNT 1 1     1  1     1 
NLK D O141:H25 1 1     1  1   1   
  O22 2 2         2 1 1     1   1 
NFT NFT O22:HNT 2 2     2 1 1   1  1 
  O92 2 2         2   2   1 1     
NLK D O92:H18 1 1     1  1   1   
NLK D O92:H- 1 1     1  1  1    
  O57 2 2         2 1 1     1   1 
NFT NFT O57:HNT 2 2     2 1 1   1  1 
  O87 2 2         2   2     1 1   
NLK D O87:H16 2 2     2  2   1 1  
  O24 2 1   1 1   1   2     1 1   
NLK D O24:H18 1 1     1  1   1   
NLK D O24:H10 1   1 1    1    1  
  O9 2 2         2   2     2     
NLK D O9:H- 2 2     2  2   2   
  O109 2 1   1     2   1 1   1   1 
NLK D O109:H5 1 1     1  1     1 
NLK D O109:H25 1   1   1   1  1   
  O70 2 2         2   2     1   1 
NLK D O70:H7 1 1     1  1     1 
NLK D O70:H- 1 1     1  1   1   
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
  O175 2 1   1     2   1 1 1     1 
NLK D O175:H21 1   1   1   1    1 
NLK D O175:H16 1 1     1  1  1    
  O136 2 1   1     2   2   1 1     
NLK D O136:H20 2 1  1   2  2  1 1   
  O139 1 1         1   1     1     
NLK D O139:H- 1 1     1  1   1   
  O124 1 1         1   1     1     
NFT NFT O124:HNT 1 1     1  1   1   
  O106 1 1         1   1         1 
NFT NFT O106:HNT 1 1     1  1     1 
  O49 1 1         1   1     1     
NLK D O49:H- 1 1     1  1   1   
  O41 1 1         1   1         1 
NFT NFT O41:HNT 1 1     1  1     1 
  O154 1 1         1   1     1     
NLK D O154:H31 1 1     1  1   1   
  O131 1     1     1     1       1 
NFT NFT O131:HNT 1   1   1   1    1 
  O108 1 1         1   1     1     
NFT NFT O108:HNT 1 1     1  1   1   
  O14 1 1         1   1     1     
NLK D O14:H28 1 1     1  1   1   
  O147 1     1     1     1       1 
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
NLK D O147:H7 1   1   1   1    1 
  O138 1 1         1   1     1     
NLK D O138:H48 1 1     1  1   1   
  O28 1 1         1   1     1     
NFT NFT O28:HNT 1 1     1  1   1   
  O172 1 1         1   1     1     
D D O172:H- 1 1     1  1   1   
  O29 1 1         1   1         1 
NFT NFT O29:HNT 1 1     1  1     1 
  O19 1 1         1   1     1     
NFT NFT O19:HNT 1 1     1  1   1   
  O140 1 1         1   1     1     
NFT NFT O140:HNT 1 1     1  1   1   
  O77 1     1     1     1       1 
NLK D O77:H18 1   1   1   1    1 
  O116 1 1         1   1     1     
NFT NFT O116:HNT 1 1     1  1   1   
  O79 1     1     1   1     1     
NLK D O79:H14 1   1   1  1   1   
  O34 1     1     1     1       1 
NLK D O34:H- 1   1   1   1    1 
  O169 1 1         1   1     1     
NLK D O169:H18 1 1     1  1   1   
  O65 1 1         1   1     1     
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
NLK D O65:H2 1 1     1  1   1   
  O170 1 1         1   1   1       
NLK D O170:H7 1 1     1  1  1    
  O180 1 1         1   1     1     
NFT NFT O180:HNT 1 1     1  1   1   
  O171 1 1         1   1         1 
D D O171:H2 1 1     1  1     1 
  O36 1 1         1   1       1   
NLK D O36:H- 1 1     1  1    1  
  O150 1 1     1       1         1 
NFT NFT O150:HNT 1 1   1    1     1 
  O16 1 1       1     1       1   
NFT NFT O16:HNT 1 1    1   1    1  
  O23 1 1         1   1         1 
NFT NFT O23:HNT 1 1     1  1     1 
  O73 1 1         1   1     1     
NLK D O73:H18 1 1     1  1   1   
  O134 1 1         1   1     1     
NLK D O134:H38 1 1     1  1   1   
  O148 1 1         1   1     1     
NFT NFT O148:HNT 1 1     1  1   1   
  O110 1 1         1   1     1     
NLK D O110:H8 1 1     1  1   1   
  O48 1 1         1   1     1     
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Classification based 
on original Karmali 
seropathotype 
approach(b) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(b) 
Serogroup/serotype(c) All cases Outcome Hospitalisation HUS(d) Clinical manifestation 
    Alive Dead NR(e) Yes No NR(e) Yes No NR(e) BD(f) D(g) Asy(h) NR(e) 
NLK D O48:H7 1 1     1  1   1   
  Grand Total 13 545 6 501 18 7 026 522 793 12 230 777 7 143 5 625 2 182 4 587 352 6 424 
(a): Confirmed cases are laboratory confirmed and may or may not fulfil the clinical criteria as described in the case definition.  
(b): NFT = strains that were not fully serotyped. NLK = serotypes that were fully serotyped but were not listed by Karmali et al. (2003). HAS = HUS-associated serotypes. Includes the 
serotypes that have been associated with reported confirmed HUS cases of human VTEC in EU in 2007-2010. 
(c): ONT = the „O‟ antigen was untyped/untypeable or reported as unknown. HNT = the „H‟ antigen was untyped/untypeable or reported as unknown. 
(d): Haemolytic uraemic syndrome. 
(e): NR = non reported. 
(f): BD = bloody diarrhoea. 
(g): D = diarrhoea. 
(h): Asy = asymptomatic. 
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B.  DATA REPORTED IN THE ZOONOSES DATABASE ON OCCURRENCE OF STRONG EVIDENCE FOOD-BORNE OUTBREAKS WHERE THE CAUSATIVE AGENT 
WAS PATHOGENIC ESCHERICHIA COLI (2007-2011) 
Table 1:  Reported strong evidence food-borne outbreaks where the causative agent was pathogenic Escherichia coli in the reporting countries in 
accordance with Directive 2003/99/EC
22
, 2007-2011(a) 
Zoonotic agent species Serotype Year Country Food vehicle: more food vehicle 
information 
Type of evidence Human 
cases 
Hospita
-lisation 
Deaths 
Verotoxigenic E. coli (VTEC) O104:H4 2011 Denmark Vegetables and juices and other 
products thereof: fenugreek 
sprouts 
Analytical epidemiological evidence 26 20 0 
Verotoxigenic E. coli (VTEC) O27:H30 2011 Denmark Vegetables and juices and other 
products thereof: sugar peas 
imported 
Analytical epidemiological evidence; 
descriptive epidemiological evidence 
87 0 0 
Verotoxigenic E. coli (VTEC) O104:H4 2011 Netherlands Vegetables and juices and other 
products thereof: fenugreek 
Analytical epidemiological evidence 11 8 0 
Verotoxigenic E. coli (VTEC) O104:H4(b) 2011 France Vegetables and juices and other 
products thereof(c) 
Detection of causative agent in food vehicle 
or its component - symptoms and onset of 
illness in outbreak cases 
15 15 0 
Verotoxigenic E. coli (VTEC) O104:H4(b) 2011 Germany Vegetables and juices and other 
products thereof: sprouted 
fenugreek seeds 
Analytical epidemiological evidence 3 793 2 353 53 
Verotoxigenic E. coli (VTEC) O157 2011 Netherlands Bovine meat and products 
thereof: filet americain 
Detection of causative agent in food vehicle 
or its component - detection of 
indistinguishable causative agent in humans 
3 - - 
Verotoxigenic E. coli (VTEC) O157 2011 UK Vegetables and juices and other 
products thereof: mixed salad 
Descriptive epidemiological evidence 7 2 0 
Verotoxigenic E. coli (VTEC) O157 2011 UK Crustaceans, shellfish, molluscs 
and products thereof: crab meat 
Analytical epidemiological evidence 9 1 0 
Verotoxigenic E. coli (VTEC) O157 2011 UK Vegetables and juices and other 
products thereof: handling raw 
leeks, handling raw potatoes 
Analytical epidemiological evidence 250 79 1 
Verotoxigenic E. coli (VTEC) O157 2011 UK Bovine meat and products 
thereof: beef curry 
Descriptive epidemiological evidence 4 0 0 
Verotoxigenic E. coli (VTEC) O157 2011 UK Other foods: sandwiches Descriptive epidemiological evidence 6 3 0 
Verotoxigenic E. coli (VTEC) O157 2011 UK Other foods: kebabs Descriptive epidemiological evidence 12 1 0 
                                                     
22  Directive 2003/99/EC of the European Parliament and of the Council of 17 November 2003 on the monitoring of zoonoses and zoonotic agents, amending Council Decision 90/424/EEC and 
repealing Council Directive 92/117/EEC. OJ L 325, 12.12.2003, p. 31–40  
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Zoonotic agent species Serotype Year Country Food vehicle: more food vehicle 
information 
Type of evidence Human 
cases 
Hospita
-lisation 
Deaths 
Verotoxigenic E. coli (VTEC) O157 2011 Ireland Tap water, including well water Detection of causative agent in food vehicle 
or its component - Detection of 
indistinguishable causative agent in 
humans, Descriptive epidemiological 
evidence 
2 0 - 
Verotoxigenic E. coli (VTEC) O157 2011 Ireland Tap water, including well 
water: group water scheme, 
ground water 
Detection of causative agent in food vehicle 
or its component - Detection of 
indistinguishable causative agent in 
humans, Descriptive epidemiological 
evidence 
20 7 0 
Verotoxigenic E. coli (VTEC) O157 2011 Ireland Tap water, including well water Detection of causative agent in food vehicle 
or its component - Detection of 
indistinguishable causative agent in 
humans, Descriptive epidemiological 
evidence 
3 - - 
Verotoxigenic E. coli (VTEC) O26 2010 Germany Cheese: different types of cheese, 
predominantly raw milk cheeses, 
inclusive semi-hard cheese 
Detection of causative agent in food vehicle 
or its component - Detection of 
indistinguishable causative agent in humans 
4 2 0 
Verotoxigenic E. coli (VTEC) NR 2008 Belgium Bovine meat and products 
thereof: minced raw beef meat 
also mixed with raw pork meat 
Analytical epidemiological evidence 
Laboratory characterisation of food and 
human isolates 
Laboratory detection in human cases 
Laboratory detection in implicated food 
6 4 0 
Verotoxigenic E. coli (VTEC) O157:H7 2008 Germany Milk: raw milk Analytical epidemiological evidence 
Laboratory characterisation of food and 
human isolates 
Laboratory detection in human cases 
23 2 0 
Verotoxigenic E. coli (VTEC) NR 2008 Portugal Fish and fish products: tuna fish 
paté 
Laboratory detection in implicated food 5 - 0 
Verotoxigenic E. coli (VTEC) NR 2007 Belgium Dairy products (other than 
cheeses): ice-cream bought on 
farm 
Laboratory detection in human cases 13 5 0 
Verotoxigenic E. coli (VTEC) O157 2007 Ireland Tap water, including well 
water: well water 
Laboratory detection in human cases 6 2 0 
Verotoxigenic E. coli (VTEC) O76 2007 Sweden Cheese Laboratory detection in human cases 5 0 0 
Enterotoxigenic E. coli (ETEC) NR 2007 Denmark Unknown Laboratory detection in human cases 8 0 0 
Enterotoxigenic E. coli (ETEC) O26:H- 2007 Denmark Bovine meat and products 
thereof: organic sausage 
Analytical epidemiological evidence 18 0 0 
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Zoonotic agent species Serotype Year Country Food vehicle: more food vehicle 
information 
Type of evidence Human 
cases 
Hospita
-lisation 
Deaths 
Enterotoxigenic E. coli (ETEC) NR 2007 Sweden Mixed or buffet meals: 
sandwich layer-cake 
Laboratory detection in human cases 40 0 0 
Enteropathogenic E. coli 
(EPEC) 
NR 2011 Spain Crustaceans, shellfish, molluscs 
and products thereof  
Detection in a food vehicle or its 
component in combination with compatible 
clinical symptoms and onset of illness in 
outbreak cases 
14 0 0 
Enteropathogenic E. coli 
(EPEC) 
NR 2007 Poland Other foods Analytical epidemiological evidence 3 3 0 
Enteropathogenic E. coli 
(EPEC) 
NR 2007 Slovenia Other foods: French salad Laboratory characterisation of isolates 92 0 0 
Enteropathogenic E. coli 
(EPEC) 
NR 2007 Spain Cheese Not specified 6 0 0 
E. coli, pathogenic, unspecified NR 2010 Spain Crustaceans, shellfish, molluscs 
and products thereof  
Detection in a food vehicle or its 
component in combination with compatible 
clinical symptoms and onset of illness in 
outbreak cases 
54 0 0 
E. coli, pathogenic, unspecified NR 2009 France Bovine meat and products 
thereof 
Analytical epidemiological evidence; 
Laboratory detection in implicated food 
5 1 0 
E. coli, pathogenic, unspecified NR 2009 France Pig meat and products thereof Analytical epidemiological evidence; 
Laboratory detection in human cases 
30 0 0 
E. coli, pathogenic, unspecified NR 2009 France Mixed or buffet meals Analytical epidemiological evidence; 
Laboratory detection in human cases 
13 0 0 
E. coli, pathogenic, unspecified NR 2009 France Sheep meat and products 
thereof 
Analytical epidemiological evidence; 
Laboratory detection in implicated food 
4 0 0 
E. coli, pathogenic, unspecified NR 2009 France Bovine meat and products 
thereof 
Analytical epidemiological evidence; 
Laboratory detection in implicated food 
2 2 0 
E. coli, pathogenic, unspecified NR 2009 France Unknown Analytical epidemiological evidence; 
Laboratory detection in human cases 
5 1 0 
E. coli, pathogenic, unspecified NR 2009 France Other foods Analytical epidemiological evidence; 
Laboratory detection in human cases 
19 0 0 
E. coli, pathogenic, unspecified NR 2009 France Pig meat and products thereof Analytical epidemiological evidence 
Laboratory detection in human cases 
12 0 0 
E. coli, pathogenic, unspecified NR 2009 France Mixed or buffet meals Analytical epidemiological evidence 
Laboratory detection in human cases 
32 0 0 
E. coli, pathogenic, unspecified NR 2009 France Unknown Analytical epidemiological evidence 
Laboratory detection in human cases 
3 0 0 
VTEC-seropathotype and scientific criteria regarding pathogenicity assessment  
 
EFSA Journal 2013;11(4):3138 89 
Zoonotic agent species Serotype Year Country Food vehicle: more food vehicle 
information 
Type of evidence Human 
cases 
Hospita
-lisation 
Deaths 
E. coli, pathogenic, unspecified NR 2009 France Bovine meat and products 
thereof 
Analytical epidemiological evidence 
Laboratory detection in human cases 
6 1 0 
E. coli, pathogenic, unspecified NR 2009 Romania Dairy products (other than 
cheeses) 
Laboratory detection in human cases 
Laboratory detection in implicated food 
3 3 0 
E. coli, pathogenic, unspecified NR 2009 Romania Cheese Analytical epidemiological evidence 
Laboratory detection in human cases 
2 2 0 
E. coli, pathogenic, unspecified NR 2009 Romania Other or mixed red meat and 
products thereof 
Analytical epidemiological evidence; 
Laboratory detection in implicated food 
6 6 0 
E. coli, pathogenic, unspecified NR 2009 Romania Other or mixed red meat and 
products thereof 
Laboratory detection in human cases; 
Laboratory detection in implicated food 
72 32 0 
E. coli, pathogenic, unspecified NR 2009 Romania Cheese Laboratory detection in human cases; 
Laboratory detection in implicated food 
14 14 0 
E. coli, pathogenic, unspecified NR 2009 Sweden Tap water, including well water Laboratory detection in implicated food 4 0 0 
E. coli, pathogenic, unspecified NR 2008 France Unknown Analytical epidemiological evidence 
Laboratory detection in implicated food 
4 1 0 
E. coli, pathogenic, unspecified NR 2008 France Bovine meat and products 
thereof 
Analytical epidemiological evidence 
Laboratory detection in human cases 
8 0 0 
E. coli, pathogenic, unspecified NR 2008 France Bovine meat and products 
thereof 
Analytical epidemiological evidence 
Laboratory detection in implicated food 
3 1 0 
E. coli, pathogenic, unspecified NR 2008 Spain Cheese Epidemiological evidence* 4 0 0 
E. coli, pathogenic, unspecified NR 2008 Spain Poultry meat Epidemiological evidence* 2 0 0 
E. coli, pathogenic, unspecified NR 2008 Spain Bakery product Epidemiological evidence* 58 0 0 
E. coli, pathogenic, unspecified NR 2008 Spain Other foods Epidemiological evidence* 22 0 0 
E. coli, pathogenic, unspecified NR 2007 Denmark Cereal products including rice 
and seeds/pulses (nuts, 
almonds): boiled wheat salad 
with raw fennel and black olives 
from glass 
Laboratory detection in human cases 45 0 0 
E. coli, pathogenic, unspecified NR 2007 France Unknown Analytical epidemiological evidence 3 0 0 
E. coli, pathogenic, unspecified NR 2007 France Unknown Laboratory detection in human cases 4 0 0 
E. coli, pathogenic, unspecified NR 2007 France Crustaceans, shellfish, molluscs 
and products thereof 
Analytical epidemiological evidence 6 0 0 
VTEC-seropathotype and scientific criteria regarding pathogenicity assessment  
 
EFSA Journal 2013;11(4):3138 90 
Zoonotic agent species Serotype Year Country Food vehicle: more food vehicle 
information 
Type of evidence Human 
cases 
Hospita
-lisation 
Deaths 
E. coli, pathogenic, unspecified NR 2007 France Other or unspecified poultry 
meat and products thereof 
Laboratory detection in implicated food 6 0 0 
E. coli, pathogenic, unspecified NR 2007 France Fish and fish products Laboratory detection in human cases 7 0 0 
E. coli, pathogenic, unspecified NR 2007 France Bovine meat and products 
thereof 
Analytical epidemiological evidence 13 0 0 
E. coli, pathogenic, unspecified NR 2007 France Other foods Laboratory detection in implicated food 15 0 0 
E. coli, pathogenic, unspecified NR 2007 France Broiler meat (Gallus gallus) and 
products thereof 
Laboratory detection in implicated food 20 0 0 
E. coli, pathogenic, unspecified NR 2007 France Unknown Analytical epidemiological evidence 30 0 0 
E. coli, pathogenic, unspecified NR 2007 France Broiler meat (Gallus gallus) and 
products thereof 
Analytical epidemiological evidence 40 0 0 
E. coli, pathogenic, unspecified NR 2007 France Cheese Analytical epidemiological evidence 9 1 0 
E. coli, pathogenic, unspecified NR 2007 France Other foods Laboratory detection in implicated food 10 10 0 
E. coli, pathogenic, unspecified NR 2007 Norway Unknown Laboratory detection in human cases 2 0 0 
E. coli, pathogenic, unspecified NR 2007 Norway Unknown Laboratory detection in human cases 4 1 0 
E. coli, pathogenic, unspecified NR 2007 Poland Tap water, including well water Laboratory detection in implicated food 9 0 0 
E. coli, pathogenic, unspecified NR 2007 Poland Tap water, including well water Laboratory detection in implicated food 4 2 0 
E. coli, pathogenic, unspecified NR 2007 Slovenia Tap water, including well water Laboratory detection in human cases 43 1 0 
E. coli, pathogenic, unspecified NR 2007 Spain Other foods: meat other animal Not specified 86 0 0 
E. coli, pathogenic, unspecified NR 2007 Spain Other foods: soups, gravies Not specified    
E. coli, pathogenic, unspecified NR 2007 Spain Other foods: fish Not specified    
E. coli, pathogenic, unspecified NR 2007 Spain Other foods: other salads Not specified    
Other Bacterial agents - Other 
Bacterial agents: Escherichia 
coli 
General 2011 Romania Dairy products (other than 
cheeses): cream 
Detection of causative agent in food vehicle 
or its component - Symptoms and onset of 
illness pathognomonic to causative agent 
13 13 0 
(a): NR or - = not reported. 
(b): Enteroaggregative E. coli, vtx2-positive. 
(c): France reported 15 VTEC O104 cases in humans associated to „vegetables and juices and other products thereof‟ without any additional foodstuff information. Therefore these cases could 
not be linked to sprouted seeds. 
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C.  FLOW DIAGRAM OF THE SCREENING PROCEDURE OF THE ISO/TS 13136:2012 STANDARD7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Test portion (1 ml) of the culture, DNA purification 
and vtx ad eae genes detection 
Positive result to vtx and eae: 
Test for serogroup-associated genes. 
Isolation (see Appendix D) 
Negative result to vtx: 
Result reporting 
Test portion x g or x ml 
9 x ml mTSB+N/A or BPW 
Enrichment 18 h to 24 h 
37 °C  1 °C 
Positive result to vtx: 
Isolation (see Appendix D) 
Results reporting Results reporting Results reporting 
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D.  FLOW DIAGRAM OF THE ISOLATION PROCEDURE OF THE ISO/TS 13136:2012 STANDARD7 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a): If the sample was positive to one of the serogroups-associated genes in the scope of the method, a Serogroup-Specific 
Enrichment (SSE) may be performed in order to facilitate the isolation. 
If a colony is positive for the presence of the genes identified at the screening step go to the following 
step. If a pool is positive, incubate NA. Test individual colonies making up the positive pool as above. 
 
Identify positive colonies as E. coli and check the serogroup if the sample was positive to the 
serogroup-specific PCR (e.g. by PCR or slide agglutination) 
Enrichment broth or SSE streaked onto suitable solid media. 
Incubation for 18 h to 24 h at 37 C  1 °C 
Pick up to 50 colonies with E. coli morphology. Point-inoculate on Nutrient Agar (NA) (single colonies) 
and H2O (pools by 10 colonies each). Perform stx and eae detection on isolated colonies or pools. 
Further characterisation (optional): send the strain to a Reference Laboratory 
Results reporting 
VTEC-seropathotype and scientific criteria regarding pathogenicity assessment  
 
EFSA Journal 2013;11(4):3138 93 
E.  PRIMER’S SEQUENCE AND THE AMPLIFICATION CONDITIONS FOR VTX GENES SUBTYPING 
Table 1:  Primers developed in this study, except primers for sequencing and detection of vtx2 
(Persson et al., 2007)
(a)
 
Gene(s), 
primer use, 
and primer 
Sequence (5′–3′)(b) Position 
Amplicon 
size (bp) 
Comments 
vtx and vtx1     
Sequencing 
vtx1-seq-F1 ATGTCATTCGCTCTGCAATAGGTAC 119–143 
1 020  
vtx1-seq-R1 GAAGAAGAGACTGAAGATTCCATCTG 1 113–1 138 
 
Detection 
vtx1-det-F1 GTACGGGGATGCAGATAAATCGC 440–462 
209  
vtx1-det-R1 AGCAGTCATTACATAAGAACGYCCACT 622–648 
 
Subtyping 
vtx1a-F1 CCTTTCCAGGTACAACAGCGGTT 362–384 
478 
All 6 primers can be 
used in a triplex PCR 
for subtyping of 
vtx/vtx1
(c)
 
vtx1a-R2 GGAAACTCATCAGATGCCATTCTGG 815–839 
vtx1c-F1 CCTTTCCTGGTACAACTGCGGTT 362–384 
252 
vtx1c-R1 CAAGTGTTGTACGAAATCCCCTCTGA 588–613 
vtx1d-F1 CAGTTAATGCGATTGCTAAGGAGTTTACC 50–78 
203 
vtx1d-R2 CTCTTCCTCTGGTTCTAACCCCATGATA 225–252 
vtx2     
Sequencing and detection 
F4 GGCACTGTCTGAAACTGCTCCTGT 606–629 627 For detection, all 4 
primers can be used in 
one reaction; for 
sequencing, use F4 and 
R1 for all subtypes 
except vtx2e and vtx2f, 
which are sequenced 
with F4-f and R1-e/f 
R1 ATTAAACTGCACTTCAGCAAATCC 1 209–1 232 
 
F4-f CGCTGTCTGAGGCATCTCCGCT 606–629 625 
R1-e/f TAAACTTCACCTGGGCAAAGCC 1 209–1 230 
 
Subtyping 
vtx2a-F2 GCGATACTGRGBACTGTGGCC 754–774 
  
vtx2a-R3 CCGKCAACCTTCACTGTAAATGTG 1 079–1 102 349 
 
vtx2a-R2 GCCACCTTCACTGTGAATGTG 1 079–1 100 347 
 
vtx2b-F1 AAATATGAAGAAGATATTTGTAGCGGC 968–994 
251  
vtx2b-R1 CAGCAAATCCTGAACCTGACG 1 198–1 218 
 
vtx2c-F1 GAAAGTCACAGTTTTTATATACAACGGGTA 926–955 177 
 
vtx2c-R2 CCGGCCACYTTTACTGTGAATGTA 1 079–1 102 
  
vtx2d-F1 AAARTCACAGTCTTTATATACAACGGGTG 927–955 
  
vtx2d-R1 TTYCCGGCCACTTTTACTGTG 1 085–1 105 179
(d)
 
 
vtx2d-O55-R TCAACCGAGCACTTTGCAGTAG 1 140–1 161 235 
 
vtx2d-R2 GCCTGATGCACAGGTACTGGAC 1 184–1 206 280 
 
vtx2e-F1 CGGAGTATCGGGGAGAGGC 695–713 
411  
vtx2e-R2 CTTCCTGACACCTTCACAGTAAAGGT 1 080–1 105 
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Gene(s), 
primer use, 
and primer 
Sequence (5′–3′)(b) Position 
Amplicon 
size (bp) 
Comments 
vtx2f-F1 TGGGCGTCATTCACTGGTTG 451–475 
424  
vtx2f-R1 TAATGGCCGCCCTGTCTCC 856–874 
 
vtx2g-F1 CACCGGGTAGTTATATTTCTGTGGATATC 203–231 
573  
vtx2g-R1 GATGGCAATTCAGAATAACCGCT 771–793 
 
(a): PCR conditions are as described in the text below, except annealing temperatures, which were 56 °C for sequencing and 
detection and 64 °C to 66 °C for the subtyping of vtx/vtx1 or vtx2. Especially, the resolution of vtx2a, vtx2c, and vtx2d 
may require individual calibration of thermocyclers. A well-defined single colony is inoculated in beef broth and 
incubated overnight at 37 °C. One hundred microlitres of broth is added to 900 μl of sterile H2O, placed in a heating 
block at 100 °C for 15 min, and centrifuged at 18 000 × g for 5 min. Upon transfer to a clean tube, the supernatant is 
used directly for PCR and stored at −18 °C for further analyses. For PCR, a total volume of 20 μl contains 2.5 μl H2O, 
10 μl HotStarTaq Master Mix Kit (Qiagen), 1.25 μl of each of two primers (stock solution of primers is 5 μM) and 5 μl 
supernatant of boiled lysate (stock). The thermocycler conditions are 95 °C for 15 min followed by 35 cycles of 94 °C 
for 50 s, 56 °C for sequencing and detection, and 64 °C for subtyping for 40 s and 72 °C for 60 s, ending with 72 °C for 
3 min. PCR amplicons are stored at 4 °C. The final resolution of vtx2a, vtx2c, and vtx2d may require calibration of 
individual brands of thermocyclers by testing annealing temperatures from 64 °C to 66 °C on the test panel of reference 
strains. In our hands, an additional PCR using the vtx2d primers was run at an annealing temperature of 66 °C. False-
positive vtx2c fragments disappeared and true vtx2d-positive fragments persisted at this annealing temperature. A total 
volume (20 μl) for standard PCR contains 2.5 μl H2O [if three primers are used (vtx2a), the H2O volume is reduced to 
1.25 μl; if four primers are used (vtx2d or detection of all vtx2 variants), H2O is not added]; 10 μl Mastermix 
(HotStarTaq, Qiagen); 1.25 μl of each of two primers (stock solution of primers is 5 μM) [if three primers are used 
(vtx2a), the H2O volume is reduced to 1.25 μl; if four primers are used (vtx2d or detection of all vtx2 variants), H2O is 
not added]; and 5 μl supernatant of boiled lysate (stock). 
(b): Wobble bases are shown in bold. 
(c): For triplex PCR for subtyping of vtx1, a total volume of 25 μl contains 12 μl Mastermix (HotStarTaq, Qiagen), 1 μl of 
each of the four primers for vtx1c and vtx1d (stock solution of primers is 5 μM), 2 μl of each of two primers for vtx1a 
(stock solution of primers is 5 μM), and 5 μl supernatant of boiled lysate (stock). 
(d): All three reverse primers in the same reaction will result in amplicons of 179 bp with nine vtx2d variants, 235 bp with 
variant vtx2d-O55-5905, 280 bp with five vtx2d variants, and finally two amplicons of 179 bp and 280 bp with variant 
vtx2d-O73-C165-02. 
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F.  VIRULENCE CHARACTERISTICS OF REPORTED CONFIRMED VTEC SEROTYPES FROM CASES OF 
HUMAN INFECTION FROM 2007-2010: CONFIRMED CASES, HOSPITALISED CASES AND HUS CASES 
Table 1:  Virulence characteristics of reported confirmed VTEC serogroups from cases of human 
infection from 2007-2010 (based on TESSy data as provided by ECDC) 
Classification based 
on original Karmali 
seropathotype 
approach(a) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(a) 
Serotype(b) 
eae, 
vtx1 
eae, 
vtx2 
eae, 
vtx1, 
vtx2 
vtx1 vtx2 
vtx1, 
vtx2 
Total 
A HAS (A/B/C) O157:H7 8 403 131 1 
 
2 545 
A HAS (A/B/C) O157:H- 3 58 171 
 
2 2 236 
B D O103:H2 124 1 
    
125 
B HAS (A/B/C) O26:H11 85 11 4 2 
  
102 
B HAS (A/B/C) O111:H- 17 3 6 
  
1 27 
B HAS (A/B/C) O121:H19 
 
22 1 
   
23 
B HAS (A/B/C) O145:H- 3 20 
    
23 
C D O113:H21 
 
2 
 
1 5 
 
8 
C D O5:H- 2 
 
1 2 
 
2 7 
C D O165:H25 
 
2 
    
2 
C D O121:H- 
 
2 
    
2 
C HAS (A/B/C) O104:H21 
     
1 1 
C D O91:H21 
    
1 
 
1 
D D O117:H7 1 
 
1 47 1 
 
50 
D D O146:H21 
  
1 3 4 16 24 
D D O113:H4 
   
1 7 8 16 
D D O174:H8 
     
3 3 
D D O171:H2 
    
1 
 
1 
D D O172:H- 
 
1 
    
1 
E D O156:H- 1 
  
3 
 
1 5 
E D O113:H- 
 
1 
  
1 
 
2 
E D O84:H- 2 
     
2 
E D O76:H7 1 
     
1 
E D O88:H25 
     
1 1 
NLK HAS (A/B/C) O128:H2 
  
3 4 8 14 29 
NLK HAS (A/B/C) O145:H28 16 3 
    
19 
NLK HAS (A/B/C) O76:H19 1 
  
10 1 2 14 
NLK HAS (A/B/C) O174:H21 
    
10 1 11 
NLK HAS (A/B/C) O111:H8 5 
 
1 
   
6 
NLK HAS (A/B/C) O174:H2 
     
5 5 
NLK HAS (A/B/C) O80:H2 
 
4 
    
4 
NLK HAS (A/B/C) O105:H18 
    
1 1 2 
NLK HAS (A/B/C) O91:H10 
    
2 
 
2 
NLK HAS (A/B/C) O123:H2 
 
2 
    
2 
NLK HAS (A/B/C) O1:H42 
    
1 
 
1 
NLK HAS (A/B/C) O121:H2 
 
1 
    
1 
NLK HAS (A/B/C) O7:H6 
    
1 
 
1 
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Classification based 
on original Karmali 
seropathotype 
approach(a) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(a) 
Serotype(b) 
eae, 
vtx1 
eae, 
vtx2 
eae, 
vtx1, 
vtx2 
vtx1 vtx2 
vtx1, 
vtx2 
Total 
NLK HAS (A/B/C) O86:H27 
 
1 
    
1 
NLK D O91:H- 
   
21 1 22 44 
NLK D O63:H6 
 
25 1 
   
26 
NLK D O26:H- 11 8 
    
19 
NLK D O145:H34 
 
17 
    
17 
NLK D O146:H28 
    
14 2 16 
NLK D O91:H14 
   
9 1 
 
10 
NLK D O128:H- 1 3 
  
2 4 10 
NLK D O156:H7 
   
9 
 
1 10 
NLK D O146:H- 
    
6 3 9 
NLK D O125:H6 
 
6 
    
6 
NLK D O117:H- 
   
6 
  
6 
NLK D O55:H12 
   
6 
  
6 
NLK D O78:H- 
   
5 
 
1 6 
NLK D O181:H49 
     
6 6 
NLK D O103:H- 3 1 1 
   
5 
NLK D O2:H6 
 
2 
  
3 
 
5 
NLK D O177:H- 2 3 
    
5 
NLK D O6:H- 
   
1 
 
3 4 
NLK D O166:H28 
   
2 2 
 
4 
NLK D O43:H2 
   
1 1 2 4 
NLK D O181:H16 
   
4 
  
4 
NLK D O55:H7 3 
     
3 
NLK D O118:H16 3 
     
3 
NLK D O63:H7 
  
3 
   
3 
NLK D O178:H7 
   
2 
 
1 3 
NLK D O176:H- 
    
1 2 3 
NLK D O156:H25 3 
     
3 
NLK D O182:H25 3 
     
3 
NLK D O27:H30 
    
3 
 
3 
NLK D O132:H34 
 
2 
    
2 
NLK D O104:H2 
    
2 
 
2 
NLK D O156:H34 1 
  
1 
  
2 
NLK D O165:H- 
 
2 
    
2 
NLK D O88:H- 
    
2 
 
2 
NLK D O168:H8 
    
2 
 
2 
NLK D O17:H41 
    
2 
 
2 
NLK D O112:H8 
   
2 
  
2 
NLK D O186:H2 2 
     
2 
NLK D O87:H16 
    
2 
 
2 
NLK D O26:H7 
  
2 
   
2 
NLK D O9:H- 
    
2 
 
2 
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Classification based 
on original Karmali 
seropathotype 
approach(a) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(a) 
Serotype(b) 
eae, 
vtx1 
eae, 
vtx2 
eae, 
vtx1, 
vtx2 
vtx1 vtx2 
vtx1, 
vtx2 
Total 
NLK D O40:H8 
    
2 
 
2 
NLK D O54:H21 
    
2 
 
2 
NLK D O136:H20 
   
2 
  
2 
NLK D O11:H4 
    
1 1 2 
NLK D O145:H7 
 
2 
    
2 
NLK D O102:H6 
    
1 1 2 
NLK D O75:H8 
    
1 1 2 
NLK D O130:H11 
   
1 
 
1 2 
NLK D O84:H28 2 
     
2 
NLK D O113:H6 
 
2 
    
2 
NLK D O2:H20 
 
1 
    
1 
NLK D O145:H20 
 
1 
    
1 
NLK D O20:H45 
    
1 
 
1 
NLK D O146:H31 
    
1 
 
1 
NLK D O20:H49 
    
1 
 
1 
NLK D O21:H21 
    
1 
 
1 
NLK D O118:H12 
    
1 
 
1 
NLK D O24:H18 
   
1 
  
1 
NLK D O112:H2 
   
1 
  
1 
NLK D O109:H5 
   
1 
  
1 
NLK D O20:H25 1 
     
1 
NLK D O166:H15 
    
1 
 
1 
NLK D O92:H18 
    
1 
 
1 
NLK D O1:H20 
   
1 
  
1 
NLK D O14:H28 
     
1 1 
NLK D O36:H- 
    
1 
 
1 
NLK D O38:H26 
   
1 
  
1 
NLK D O15:H- 
     
1 1 
NLK D O39:H- 
    
1 
 
1 
NLK D O39:H21 
    
1 
 
1 
NLK D O12:H- 
    
1 
 
1 
NLK D O39:H48 
    
1 
 
1 
NLK D O40:H7 
     
1 1 
NLK D O91:H7 
  
1 
   
1 
NLK D O115:H- 
 
1 
    
1 
NLK D O107:H- 
    
1 
 
1 
NLK D O177:H45 
  
1 
   
1 
NLK D O45:H2 1 
     
1 
NLK D O107:H21 
    
1 
 
1 
NLK D O48:H7 
    
1 
 
1 
NLK D O121:H7 
   
1 
  
1 
NLK D O112:H18 
   
1 
  
1 
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Classification based 
on original Karmali 
seropathotype 
approach(a) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(a) 
Serotype(b) 
eae, 
vtx1 
eae, 
vtx2 
eae, 
vtx1, 
vtx2 
vtx1 vtx2 
vtx1, 
vtx2 
Total 
NLK D O5:H16 
    
1 
 
1 
NLK D O119:H- 
   
1 
  
1 
NLK D O5:H19 
     
1 1 
NLK D O114:H41 
   
1 
  
1 
NLK D O53:H7 
   
1 
  
1 
NLK D O166:H30 
   
1 
  
1 
NLK D O168:H28 
    
1 
 
1 
NLK D O153:H2 
     
1 1 
NLK D O100:H- 
    
1 
 
1 
NLK D O153:H25 
 
1 
    
1 
NLK D O110:H8 
    
1 
 
1 
NLK D O126:H- 
 
1 
    
1 
NLK D O2:H29 
    
1 
 
1 
NLK D O6:H19 
   
1 
  
1 
NLK D O6:H25 
  
1 
   
1 
NLK D O169:H18 
     
1 1 
NLK D O134:H38 
    
1 
 
1 
NLK D O17:H18 
    
1 
 
1 
NLK D O91:H26 
     
1 1 
NLK D O111:H2 
  
1 
   
1 
NLK D O92:H- 
   
1 
  
1 
NLK D O65:H2 
   
1 
  
1 
NLK D O98:H- 1 
     
1 
NLK D O177:H11 
  
1 
   
1 
NLK D O70:H- 1 
     
1 
NLK D O138:H48 
    
1 
 
1 
NLK D O70:H7 
    
1 
 
1 
NLK D O139:H- 
    
1 
 
1 
NLK D O71:H- 
   
1 
  
1 
NLK D O178:H19 
    
1 
 
1 
NLK D O75:H- 
    
1 
 
1 
NLK D O101:H9 
    
1 
 
1 
NLK D O101:H- 
    
1 
 
1 
NLK D O111:H4 
 
1 
    
1 
NLK D O142:H- 
 
1 
    
1 
NLK D O142:H33 
 
1 
    
1 
NLK D O77:H18 
    
1 
 
1 
NLK D O103:H7 
  
1 
   
1 
NLK D O103:H11 1 
     
1 
NLK D O79:H14 
   
1 
  
1 
NLK D O8:H- 
     
1 1 
NLK D O109:H25 1 
     
1 
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Classification based 
on original Karmali 
seropathotype 
approach(a) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(a) 
Serotype(b) 
eae, 
vtx1 
eae, 
vtx2 
eae, 
vtx1, 
vtx2 
vtx1 vtx2 
vtx1, 
vtx2 
Total 
NLK D O8:H25 
  
1 
   
1 
NLK D O186:H- 1 
     
1 
NLK D O8:H8 
    
1 
 
1 
NLK D O8:H9 
    
1 
 
1 
NLK D O104:H- 
   
1 
  
1 
NLK D O132:H10 
    
1 
 
1 
NLK D O80:H- 
 
1 
    
1 
NLK D O132:H21 
     
1 1 
NLK D O146:H5 
    
1 
 
1 
NLK D O15:H2 
 
1 
    
1 
NLK D O84:H1 1 
     
1 
NLK D O84:H2 1 
     
1 
NLK D O2:H14 
    
1 
 
1 
NLK D O117:H11 
   
1 
  
1 
NLK D O174:H28 
    
1 
 
1 
NLK D O154:H31 
   
1 
  
1 
NLK D O89:H- 
    
1 
 
1 
NLK D O89:H4 
    
1 
 
1 
NLK D O20:H12 
  
1 
   
1 
NLK D O89:H8 
    
1 
 
1 
NLK D O163:H19 
    
1 
 
1 
NLK D O175:H16 
    
1 
 
1 
NLK D O20:H4 
   
1 
  
1 
NLK D O117:H8 
   
1 
  
1 
NLK D O8:H12 
    
1 
 
1 
NLK D O102:H- 
    
1 
 
1 
NLK D O35:H19 
 
1 
    
1 
NFT NFT O157:HNT 20 3 372 1 228 
 
11 
 
4 631 
NFT NFT ONT:HNT 82 103 38 53 56 29 361 
NFT NFT O26:HNT 109 44 24 7 2 
 
186 
NFT NFT O145:HNT 6 38 1 
 
1 
 
46 
NFT NFT O103:HNT 40 2 
 
1 1 
 
44 
NFT NFT O111:HNT 15 9 5 1 2 
 
32 
NFT NFT ONT:H- 1 3 
 
11 2 13 30 
NFT NFT O121:HNT 1 20 
  
1 
 
22 
NFT NFT O128:HNT 
 
4 2 3 9 4 22 
NFT NFT ONT:H2 1 2 
  
7 2 12 
NFT NFT O146:HNT 
 
1 
  
4 6 11 
NFT NFT ONT:H7 
  
2 6 3 
 
11 
NFT NFT O91:HNT 
 
1 
 
5 
 
4 10 
NFT NFT O153:HNT 
 
6 
 
1 2 
 
9 
NFT NFT O5:HNT 7 
  
2 
  
9 
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Classification based 
on original Karmali 
seropathotype 
approach(a) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(a) 
Serotype(b) 
eae, 
vtx1 
eae, 
vtx2 
eae, 
vtx1, 
vtx2 
vtx1 vtx2 
vtx1, 
vtx2 
Total 
NFT NFT O113:HNT 
    
5 2 7 
NFT NFT ONT:H18 
    
4 3 7 
NFT NFT O76:HNT 
   
5 
 
1 6 
NFT NFT O117:HNT 1 
  
5 
  
6 
NFT NFT ONT:H19 
  
1 2 3 
 
6 
NFT NFT O8:HNT 
 
2 
  
4 
 
6 
NFT NFT O55:HNT 
 
4 
 
1 
  
5 
NFT NFT O104:HNT 
 
2 
 
2 
  
4 
NFT NFT ONT:H25 2 2 
    
4 
NFT NFT O1:HNT 2 1 1 
   
4 
NFT NFT O123:HNT 2 1 1 
   
4 
NFT NFT ONT:H21 
   
2 
 
2 4 
NFT NFT ONT:H28 
   
2 2 
 
4 
NFT NFT O84:HNT 2 
   
2 
 
4 
NFT NFT ONT:H10 
   
2 1 
 
3 
NFT NFT O114:HNT 
 
2 1 
   
3 
NFT NFT O118:HNT 1 1 
  
1 
 
3 
NFT NFT ONT:H16 
   
3 
  
3 
NFT NFT O174:HNT 
   
1 1 1 3 
NFT NFT O71:HNT 1 
 
2 
   
3 
NFT NFT ONT:H14 1 1 
    
2 
NFT NFT ONT:H8 
    
2 
 
2 
NFT NFT ONT:H4 
   
1 1 
 
2 
NFT NFT ONT:H9 1 
   
1 
 
2 
NFT NFT ONT:H30 
    
2 
 
2 
NFT NFT ONT:H6 
 
1 
 
1 
  
2 
NFT NFT O126:HNT 1 
   
1 
 
2 
NFT NFT O80:HNT 
 
2 
    
2 
NFT NFT O6:HNT 
   
1 1 
 
2 
NFT NFT O12:HNT 
 
2 
    
2 
NFT NFT O27:HNT 
 
1 
  
1 
 
2 
NFT NFT ONON-O157:HNT 
 
1 
  
1 
 
2 
NFT NFT ONT:H1 
    
1 
 
1 
NFT NFT ONT:H49 
    
1 
 
1 
NFT NFT ONT:H29 
    
1 
 
1 
NFT NFT ONT:H45 
    
1 
 
1 
NFT NFT ONT:H39 
   
1 
  
1 
NFT NFT ONT:H12 
   
1 
  
1 
NFT NFT ONT:H26 
   
1 
  
1 
NFT NFT ONT:H20 
   
1 
  
1 
NFT NFT ONT:H5 
    
1 
 
1 
NFT NFT ONT:H23 
   
1 
  
1 
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Classification based 
on original Karmali 
seropathotype 
approach(a) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(a) 
Serotype(b) 
eae, 
vtx1 
eae, 
vtx2 
eae, 
vtx1, 
vtx2 
vtx1 vtx2 
vtx1, 
vtx2 
Total 
NFT NFT O23:HNT 
     
1 1 
NFT NFT O78:HNT 
   
1 
  
1 
NFT NFT O25:HNT 1 
     
1 
NFT NFT O127:HNT 
 
1 
    
1 
NFT NFT O3:HNT 
   
1 
  
1 
NFT NFT O45:HNT 
 
1 
    
1 
NFT NFT O98:HNT 1 
     
1 
NFT NFT O163:HNT 
    
1 
 
1 
NFT NFT O177:HNT 
 
1 
    
1 
NFT NFT O7:HNT 
  
1 
   
1 
NFT NFT O51:HNT 
 
1 
    
1 
NFT NFT O176:HNT 
   
1 
  
1 
NFT NFT O2:HNT 
    
1 
 
1 
NFT NFT O38:HNT 
   
1 
  
1 
NFT NFT O142:HNT 
    
1 
 
1 
NFT NFT O166:HNT 1 
     
1 
NFT NFT O156:HNT 1 
     
1 
NFT NFT O116:HNT 
    
1 
 
1 
NFT NFT O150:HNT 
   
1 
  
1 
NFT NFT O43:HNT 
    
1 
 
1 
NFT NFT O165:HNT 
 
1 
    
1 
NFT NFT O148:HNT 
    
1 
 
1 
  Total 612 4 254 1 642 295 287 188 7 278 
(a): NFT = strains that were not fully serotyped. NLK = serotypes that were fully serotyped but were not listed by Karmali et 
al. (2003). HAS = HUS-associated serotypes. Includes the serotypes that have been associated with reported confirmed 
HUS cases of human VTEC in EU in 2007-2010. 
(b): ONT = the „O‟ antigen was untyped/untypeable or reported as unknown. HNT = the „H‟ antigen was 
untyped/untypeable or reported as unknown. 
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Table 2:  Virulence characteristics of reported confirmed VTEC serogroups from hospitalised cases 
of human infection from 2007-2010 (based on TESSy data as provided by ECDC) 
Classification based 
on original Karmali 
seropathotype 
approach(a) 
Classification based 
on „modified‟ 
Karmali 
seropathotype 
approach(a) 
Serotype(b) 
eae, 
vtx1 
eae, 
vtx2 
eae, 
vtx1, 
vtx2 
vtx1 vtx2 
vtx1, 
vtx2 
Total 
A HAS (A/B/C) O157:H- 
 
12 6 
 
1 
 
19 
A HAS (A/B/C) O157:H7 
 
2 
    
2 
B D O103:H2 10 
     
10 
B HAS (A/B/C) O26:H11 1 3 
    
4 
B HAS (A/B/C) O145:H- 1 1 
    
2 
B HAS (A/B/C) O121:H19 
 
1 
    
1 
C HAS (A/B/C) O104:H21 
     
1 1 
D D O113:H4 
    
1 
 
1 
E D O113:H- 
    
1 
 
1 
NLK HAS (A/B/C) O174:H2 
     
3 3 
NLK HAS (A/B/C) O1:H42 
    
1 
 
1 
NLK HAS (A/B/C) O105:H18 
    
1 
 
1 
NLK D O26:H- 2 
     
2 
NLK D O63:H6 
 
1 
    
1 
NLK D O181:H49 
     
1 1 
NLK D O27:H30 
    
1 
 
1 
NFT NFT O157:HNT 
 
151 73 
   
224 
NFT NFT ONT:HNT 2 4 1 2 2 1 12 
NFT NFT O26:HNT 
 
2 4 
   
6 
NFT NFT O145:HNT 
 
4 
    
4 
NFT NFT O103:HNT 3 
     
3 
NFT NFT O111:HNT 
 
1 1 
   
2 
NFT NFT O5:HNT 2 
     
2 
NFT NFT ONT:H19 
    
1 
 
1 
NFT NFT ONT:H- 1 
     
1 
NFT NFT ONT:H14 
 
1 
    
1 
NFT NFT ONT:H4 
   
1 
  
1 
NFT NFT ONT:H21 
     
1 1 
NFT NFT ONON-O157:HNT 
    
1 
 
1 
NFT NFT O150:HNT 
   
1 
  
1 
NFT NFT O121:HNT 
 
1 
    
1 
NFT NFT O165:HNT 
 
1 
    
1 
  Total 22 185 85 4 10 7 313 
(a): NFT = strains that were not fully serotyped. NLK = serotypes that were fully serotyped but were not listed by Karmali et 
al. (2003). HAS = HUS-associated serotypes. Includes the serotypes that have been associated with reported confirmed 
HUS cases of human VTEC in EU in 2007-2010. 
(b): ONT = the „O‟ antigen was untyped/untypeable or reported as unknown. HNT = the „H‟ antigen was 
untyped/untypeable or reported as unknown. 
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Table 3:  Virulence characteristics of reported confirmed VTEC serogroups from HUS cases of 
human infection from 2007-2010 (based on TESSy data as provided by ECDC) 
Classification based on 
original Karmali 
seropathotype 
approach(a) 
Classification based on 
„modified‟ Karmali 
seropathotype 
approach(a) 
Serotype(b) 
eae, 
vtx1 
eae, 
vtx2 
eae, 
vtx1, 
vtx2 
vtx1 vtx2 
vtx1, 
vtx2 
Total 
A HAS (A/B/C) O157:H7 
 
49 3 
   
52 
A HAS (A/B/C) O157:H- 
 
20 4 
 
1 
 
25 
B HAS (A/B/C) O121:H19 
 
8 
    
8 
B HAS (A/B/C) O26:H11 1 3 
    
4 
B HAS (A/B/C) O111:H- 
 
1 2 
   
3 
B HAS (A/B/C) O145:H- 
 
2 
    
2 
C HAS (A/B/C) O104:H21 
     
1 1 
NLK HAS (A/B/C) O174:H2 
     
3 3 
NLK HAS (A/B/C) O145:H28 
 
2 
    
2 
NLK HAS (A/B/C) O128:H2 
  
1 
   
1 
NLK HAS (A/B/C) O91:H10 
    
1 
 
1 
NLK HAS (A/B/C) O174:H21 
    
1 
 
1 
NLK HAS (A/B/C) O105:H18 
    
1 
 
1 
NLK HAS (A/B/C) O86:H27 
 
1 
    
1 
NLK HAS (A/B/C) O123:H2 
 
1 
    
1 
NLK HAS (A/B/C) O1:H42 
    
1 
 
1 
NLK HAS (A/B/C) O121:H2 
 
1 
    
1 
NLK HAS (A/B/C) O80:H2 
 
1 
    
1 
NLK HAS (A/B/C) O111:H8 1 
     
1 
NLK HAS (A/B/C) O7:H6 
    
1 
 
1 
NLK HAS (A/B/C) O76:H19 
    
1 
 
1 
NFT NFT O157:HNT 
 
125 14 
 
2 
 
141 
NFT NFT ONT:HNT 1 35 4 
 
10 
 
50 
NFT NFT O26:HNT 6 24 8 
   
38 
NFT NFT O145:HNT 
 
4 
  
1 
 
5 
NFT NFT O111:HNT 
 
3 1 
   
4 
NFT NFT ONT:H2 
 
2 
  
2 
 
4 
NFT NFT O128:HNT 
 
1 
 
2 
  
3 
NFT NFT O114:HNT 
 
2 
    
2 
NFT NFT O126:HNT 1 
   
1 
 
2 
NFT NFT O121:HNT 
 
2 
    
2 
NFT NFT O55:HNT 
 
2 
    
2 
NFT NFT ONT:H25 
 
1 
    
1 
NFT NFT ONT:H19 
    
1 
 
1 
NFT NFT O127:HNT 
 
1 
    
1 
NFT NFT O1:HNT 
 
1 
    
1 
NFT NFT O80:HNT 
 
1 
    
1 
NFT NFT O103:HNT 
 
1 
    
1 
  Total 10 294 37 2 24 4 371 
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(a): NFT = strains that were not fully serotyped. NLK = serotypes that were fully serotyped but were not listed by Karmali et 
al. (2003). HAS = HUS-associated serotypes. Includes the serotypes that have been associated with reported confirmed 
HUS cases of human VTEC in EU in 2007-2010. 
(b): ONT = the „O‟ antigen was untyped/untypeable or reported as unknown. HNT = the „H‟ antigen was 
untyped/untypeable or reported as unknown. 
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GLOSSARY, ABBREVIATIONS AND DEFINITIONS 
aaiC Chromosomally-encoded gene encoding secreted protein of enteroaggregative 
Escherichia coli (EAEC) 
aggR Plasmid-encoded regulator gene 
AAF Aggregative adherence fimbriae 
A/E lesions Attaching/Effacing lesions 
astA Gene responsible for production of heat-stable enterotoxin (EAST1) 
CDC Centers for Disease Control and Prevention (USA) 
CEN European Committee of Standardisation 
CFA Colonisation factor antigens 
CT-SMAC Sorbitol-MacConkey medium 
bfp Bundle forming pili gene 
DAEC Diffuse adherent E. coli 
DALY Disability Adjusted Life Years 
eae Intimin-coding gene 
EAEC Enteroaggregative E. coli 
EAF Enteropathogenic E. coli adherence factor 
EAST1 Enteroaggregative heat-stable toxin 
EC European Commission 
ECDC European Centre for Disease Prevention and Control 
EHEC Enterohaemorrhagic E. coli 
EIEC Enteroinvasive E. coli 
EPEC Enteropathogenic E. coli 
ETEC Enterotoxigenic E. coli 
EU European Union 
EU-RL-VTEC European Union Reference Laboratory for VTEC 
ExPEC Enteric/diarrhoegenic or extra-intestinal 
FW&E Food, water and environmental 
HAS Haemolytic uraemic syndrome (HUS)-associated serotype(s) 
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hly Gene encoding production of haemolysin 
HC Haemorrhagic colitis 
HUS Haemolytic uraemic syndrome 
IMS Immuno-magnetic separation 
Ipa Invasion plasmid antigens 
ISO International Organization for Standardization 
LEE The genetic locus of enterocyte effacement 
LPS Lipopolysaccharide 
LT Heat-labile enterotoxin 
MLVA Multi-locus variable number of tandem repeat analysis 
PAI Pathogenicity island 
PCR Polymerase chain reaction 
PFGE Pulsed-field gel electrophoresis 
RTE Ready-to-eat 
Saa STEC autoagglutinating adhesion 
Serogroup Classification of E. coli strains based on identification of „O‟ (lipopolysaccharide) 
antigen – e.g. O157, O104 
Serotype Classification of E. coli strains based on identification of „O‟ (lipopolysaccharide) 
and „H‟ (flagella) antigen – e.g. O157:H7; O104:H4 
Seropathotype Empirical classification scheme for VTEC based on disease severity and serotype 
ST Heat-stable enterotoxin 
STEC Shiga toxin-producing E. coli, also known as VTEC 
TESSy The European Surveillance System 
UPEC Uropathogenic E. coli 
vtx1 Verocytotoxin 1 gene 
vtx2 Verocytotoxin 2 gene 
Vtx Verocytotoxin, also known as Shiga toxin 
VTEC Verocytotoxin-producing E. coli, also known as verotoxigenic E. coli, 
verocytotoxigenic E. coli, verotoxin-producing E. coli and Shiga toxin-producing 
E. coli (STEC) 
WGS Whole genome sequencing 
 
